

Head and Neck Cancer ----- 14258 Cases

Report of Head and Neck Cancer Registry of Japan  
Clinical Statistics of Registered Patients, 2022

Japan Society for Head and Neck Cancer  
Cancer Registry Committee

**Contents**

<i>Total Cases(2022)</i> .....	<b>11</b>
<i>Oral Cavity(2022)</i> .....	<b>36</b>
<i>Larynx(2022)</i> .....	<b>58</b>
<i>Hypopharynx(2022)</i> .....	<b>90</b>
<i>Oropharynx(2022)</i> .....	<b>123</b>
<i>Oropharynx p16 positive(2022)</i> .....	<b>126</b>
<i>Oropharynx p16 negative and unknown (2022)</i> .....	<b>140</b>
<i>Nasopharynx(2022)</i> .....	<b>156</b>
<i>Nasal Cavity and Paranasal Sinuses (Excluding the Maxillary Sinus) (2022)</i> .....	<b>168</b>
<i>Maxillary Sinus(2022)</i> .....	<b>180</b>
<i>Major Salivary Glands(2022)</i> .....	<b>190</b>
<i>Primary Unknown(2022)</i> .....	<b>206</b>

## Preface

The Head and Neck Cancer Registry in Japan has been supported by the Japan Society for Head and Neck Cancer (JSHNC) since 2003. The annual reports have been published from 2003 to 2005 as supplements of the journal of the JSHNC. Because the Act of the Protection of Personal Information (APPI) was enforced in 2005, JSHNC had decided to discontinue this registration in 2004 and thereafter. After a seven-year interval, the JSHNC restarted the registry using the system of University hospital Medical Information Network (UMIN) Center in Japan. The online registration for patients in 2011 was initiated on May 25, 2012 after renewing the contents and methods of registration. This report is for the fourteenth year of the registration after its renewal.

The importance of cancer registration has been recognized widely in Japan since the Act of Propulsion of Cancer Registration in 2013. Moreover, the number of participating institutions has increased since the Japanese Society of Head and Neck Surgery (JSHNS) decided a revision in the regime for board-certified head and neck surgeons and training facilities in 2014.

The improved Ethical Guidelines for Medical and Health Research Involving Human Subjects have been publicly announced on Feb 28, 2017 and the revised APPI was enforced on May 30, 2017 in Japan, so that the procedure for informed consent was changed and the data traceability was taken into consideration in this registration thereafter. The Ethical Guidelines was changed on March 23, 2021 and the protocol of this project was revised into version 1.3 on August 22, 2021 accordingly. The minor refinements of the contents are being prepared for introduction of the 8th UICC TNM classification. Moreover, the clinical study support center (CSSC) of Wakayama medical university hospital has participated in this registration system from July 2017. The data collection contents have been expanded to include the information on five-year prognosis from 2017. Hence, the prognosis data about the cases registered in 2014 were also disclosed this time. These reforms and expansion according to social, medical needs are important to achieve the further development of this registry. Actually, the total number of registered cases has remarkably increased by the assistance of data center, which reached 100000 on April, 2021. We expect that this vast organ-based registry led by doctors and CSSC with an increase in the number of participating institutions, will help better understand the statistics and modes of treatment of head and neck cancer, besides the hospital-based or national cancer registry in Japan.

We would like to express our deepest appreciation to all the doctors in the participating institutions. Furthermore, we would like to express our gratitude to the JSHNS, the member of specialists for head and neck cancer, and the members of UMIN Center as well.

June 1st, 2026

Seiichi Yoshimoto, MD  
Chairperson of the Board of Directors  
Ken-ichi Nibu, MD  
Chief Director of Cancer Registry  
Daisuke Kawakita, MD  
Chairperson of Cancer Registry Committee  
Japan Society for Head and Neck Cancer

Cancer Registry Committee 2026  
Japan Society for Head and Neck Cancer

Directors Ken-ichi Nibu, Tsuyoshi Kodaira, and Narikazu Uzawa  
Supervisor Munenaga Nakamizo  
Chairperson Daisuke Kawakita  
Members Toshifumi Tomioka, Ryosuke Kamiyama, Hideaki Takahashi, Tatsuo Okui, Yoshio Ohyama,  
Souichi Yanamoto and Yuji Murakami

#### Data Collection

All the doctors who are members of the Japan Society for Head and Neck Cancer are advised to participate in the registration of cancer patients. More than one doctor from an institution could participate in this registration. A participant is provided a UMIN (University hospital Medical Information Network in Japan) ID and a password for INDICE (Internet Data and Information Center for Medical Research) from the UMIN center and registers the data of the cases in their institute to the INDICE system online. The completed registration provides information regarding the patients' age, gender, tumor pathology, TNM classification, therapies (surgery, radiation and chemotherapy), and prognosis. This year, the 14th year of registration, all the data stored in the INDICE system were reviewed by head and neck oncologists and analyzed from all aspects, including the prognosis data about cases registered in 2018.

Registration was restricted to previously untreated malignant head and neck tumor cases which had a confirmed pathological diagnosis, i.e. in the oral cavity, larynx, hypopharynx, oropharynx, nasopharynx, nasal cavity, paranasal sinuses, major salivary glands, and unknown primary. Tumors arising in the cervical esophagus and thyroid gland were excluded from the registry. These head and neck tumors were classified according the General Rules for Clinical Studies on Head and Neck Cancer (The Sixth Edition, Revised version December 2019, Japan Society for Head and Neck Cancer), which are based on the TNM Classification of Malignant Tumours (Eighth Edition, 2016) of the Union for International Cancer Control (UICC).

A total of 15182 cases (including cases other than in the year 2022 and with unknown presentation of diseases, unknown aim for therapies, previously treated) were registered from April 24, 2022 to Nov. 30, 2023. The data registered before Nov. 30, 2023, were checked and corrected after confirming with each institution, whereas, any data correction after the date by themselves were not verified. The total number of previously untreated patients was 14258 for the starting date of the initial therapy from Jan. 1 to Dec. 31, 2022, after excluding cases other than in the year 2022 and with unknown presentation of diseases and duplicated registration.

List of 215 Institutions which participate in the Registry in 2022

- 1 Department of Otorhinolaryngology, Japanese Red Cross Kitami Hospital
- 2 Department of Otorhinolaryngology, Asahikawa Medical University Hospital
- 3 Department of Otorhinolaryngology, Kushiro City General Hospital
- 4 Department of Dentistry and Oral Surgery, Hokuto Hospital
- 5 Department of Otorhinolaryngology, Obihiro Kosei Hospital
- 6 Department of Otorhinolaryngology, Keiyukai Sapporo Hospital
- 7 Department of Oral Surgery and Otorhinolaryngology, Sapporo Medical University Hospital
- 8 Department of Oral Surgery, Sapporo City General Hospital
- 9 Department of Otorhinolaryngology, Teine Keijinkai Hospital
- 10 Department of Otorhinolaryngology, KKR Sapporo Medical Center
- 12 Department of Head and Neck Surgery, Hokkaido Cancer Center
- 13 Department of Oral Surgery, Hokkaido Cancer Center
- 15 Department of Otorhinolaryngology, Hokkaido University Hospital
- 16 Department of Oral Surgery, Sapporo Teishinkai Hospital
- 17 Department of Oral Surgery, Tonan Hospital
- 18 Department of Otorhinolaryngology, Nikko Memorial Hospital
- 19 Department of Otorhinolaryngology, Hirosaki University Hospital
- 21 Department of Otorhinolaryngology, Akita University Hospital
- 22 Department of Otorhinolaryngology, Iwate Medical University
- 23 Department of Head and Neck Surgery, Miyagi Cancer Center
- 24 Department of Otorhinolaryngology, Sendai Medical Center
- 25 Department of Otorhinolaryngology, Tohoku University Hospital
- 26 Department of Otorhinolaryngology, Yamagata Prefectural Central Hospital
- 27 Department of Otorhinolaryngology, Yamagata University Hospital
- 28 Department of Otorhinolaryngology, Nihonkai General Hospital
- 29 Department of Otorhinolaryngology, Minami Tohoku Hospital
- 30 Department of Otorhinolaryngology, Fukushima Medical University Hospital
- 31 Department of Head and Neck Surgery, Niigata Cancer Center
- 32 Department of Otorhinolaryngology, Niigata University Medical & Dental Hospital
- 34 Department of Oral and Maxillofacial Surgery, Niigata University Medical & Dental Hospital
- 35 Department of Oral Surgery, Nippon Dental University Hospital
- 37 Department of Head and Neck Oncology and Otolaryngology, Tochigi Cancer Center
- 38 Department of Otorhinolaryngology, Ibaraki Prefectural Central Hospital
- 39 Department of Otorhinolaryngology, Tsukuba University Hospital
- 40 Department of Otorhinolaryngology, Saiseikai Utsunomiya Hospital
- 41 Department of Otorhinolaryngology, Jichi University Hospital
- 44 Department of Otorhinolaryngology, Gunma University Hospital
- 45 Department of Head and Neck Surgery, Saitama Medical University International Medical Center

List of 215 Institutions which participate in the Registry in 2022

- 46 Department of Oral Surgery, Saitama Cancer Center
- 47 Department of Head and Neck Surgery, Saitama Cancer Center
- 48 Department of Otorhinolaryngology, Ageo Central General Hospital
- 49 Department of Otorhinolaryngology, National Defense Medical College Hospital
- 50 Department of Otolaryngology-Head and Neck Surgery, Jichi Medical University Saitama Medical Center
- 51 Department of Otorhinolaryngology, Kameda Medical Center
- 52 Department of Otorhinolaryngology, Kimitsu Chuo Hospital
- 53 Division of Head and Neck Surgery, National Cancer Center Hospital East
- 54 Department of Otorhinolaryngology, Japanese Red Cross Narita Hospital
- 55 Department of Head and Neck Surgery, Chiba Cancer Center
- 58 Department of Otorhinolaryngology, Chiba University Hospital
- 59 Department of Otorhinolaryngology, Jikei University Kashiwa Hospital
- 60 Department of Otorhinolaryngology, Juntendo University Urayasu Hospital
- 61 Department of Otorhinolaryngology, International University of Health and Welfare, Narita Hospital
- 62 Department of Otorhinolaryngology, NTT Medical Center Tokyo
- 63 Department of Head and Neck Surgery, Cancer Institute Hospital
- 65 Department of Otorhinolaryngology, Keio University Hospital
- 66 Department of Otorhinolaryngology, Showa General Hospital
- 67 Head and Neck Oncology Center, International University of Health and Welfare, Mita Hospital
- 68 Department of Head and Neck Surgery, National Cancer Center Hospital
- 69 Department of Otorhinolaryngology, Juntendo University Hospital
- 70 Department of Otorhinolaryngology, Showa University Hospital
- 71 Department of Otorhinolaryngology, Teikyo University Hospital
- 72 Department of Otorhinolaryngology, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital
- 73 Department of Otorhinolaryngology, Head and Neck Surgery, Faculty of Medicine, Tokyo Medical and Dental University Hospital
- 74 Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Tokyo Medical and Dental University Hospital
- 77 Department of Otorhinolaryngology, Tokyo Medical University Hospital
- 78 Department of Otorhinolaryngology, Jikei University Hospital
- 79 Department of Otorhinolaryngology, The University of Tokyo Hospital
- 80 Department of Otorhinolaryngology, Tokyo Women's Medical University Hospital
- 82 Department of Otorhinolaryngology, Tokyo Metropolitan Tama Medical Center
- 83 Department of Oral Surgery, Tokyo Metropolitan Tama Medical Center
- 85 Department of Otorhinolaryngology and Oral Surgery, Tokyo Medical Center
- 86 Department of Otorhinolaryngology, Japanese Red Cross Musashino Hospital

List of 215 Institutions which participate in the Registry in 2022

- 87 Department of Otorhinolaryngology, Nihon University Hospital
- 88 Department of Otorhinolaryngology, Nippon Medical School Hospital
- 90 Department of Otorhinolaryngology, Yokosuka Kyosai Hospital
- 91 Department of Dentistry and Oral Surgery, Yokohama City University Hospital
- 92 Department of Otorhinolaryngology, Yokohama City University Hospital
- 93 Department of Otorhinolaryngology, Yokohama City University Medical Center
- 94 Department of Head and Neck Surgery, Kanagawa Cancer Center
- 95 Department of Otorhinolaryngology, St.Marianna University School of Medicine Hospital
- 96 Department of Otorhinolaryngology, Kawasaki Municipal Hospital
- 97 Department of Oral and Maxillofacial Surgery, Tsurumi University Dental Hospital
- 98 Department of Otorhinolaryngology, Tokai University Hospital
- 99 Department of Oral Surgery, Tokai University Hospital
- 100 Department of Otorhinolaryngology, Kitasato University Hospital
- 102 Department of Otorhinolaryngology, Shinshu University Hospital
- 103 Department of Otorhinolaryngology, Yamanashi University Hospital
- 105 Department of Otorhinolaryngology, Seirei Hamamatsu General Hospital
- 106 Department of Head and Neck Surgery, Shizuoka Cancer Center
- 107 Department of Oral Surgery, Shizuoka City Shizuoka Hospital
- 108 Department of Otorhinolaryngology, Hamamatsu Medical University Hospital
- 109 Department of Otorhinolaryngology, Japanese Red Cross Shizuoka Hospital
- 110 Department of Dentistry and Oral Surgery, Kouseiren Takaoka Hospital
- 111 Department of Otorhinolaryngology, Toyama University Hospital
- 112 Department of Otorhinolaryngology, Kanazawa University Hospital
- 113 Department of Otorhinolaryngology, Kanazawa Medical University Hospital
- 114 Department of Matsumoto Dental University Hospital
- 115 Department of Otorhinolaryngology, Gifu University Hospital
- 116 Department of Otorhinolaryngology, Ogaki Municipal Hospital
- 117 Department of Head and Neck Surgery, Central Japan International Medical Center
- 118 Department of Head and Neck Surgery, Aichi Cancer Center
- 119 Department of Otorhinolaryngology, Aichi Medical University Hospital
- 120 Department of Otorhinolaryngology, Toyohashi Municipal Hospital
- 121 Department of Otorhinolaryngology, Fujita Health University Hospital
- 122 Department of Otorhinolaryngology, Nagoya City University Hospital
- 123 Department of Otorhinolaryngology and Oral Surgery, Nagoya University Hospital
- 124 Department of Otorhinolaryngology, Japanese Red Cross Nagoya Daiichi Hospital
- 125 Department of Otorhinolaryngology, Fukui University Hospital
- 126 Department of Otorhinolaryngology, Shiga University of Medical Science Hospital
- 127 Department of Head and Neck Surgery, Kusatsu General Hospital

List of 215 Institutions which participate in the Registry in 2022

- 128 Department of Otorhinolaryngology, Japanese Red Cross Otsu Hospital
- 130 Department of Otorhinolaryngology, Ise Red Cross Hospital
- 131 Department of Otorhinolaryngology, Mie University Hospital
- 132 Department of Otorhinolaryngology, Kyoto Medical Center
- 133 Department of Otorhinolaryngology, Kyoto University Hospital
- 134 Department of Otorhinolaryngology, Japanese Red Cross Kyoto Daiichi Hospital
- 136 Department of Otorhinolaryngology, Kyoto Prefectural University Hospital
- 137 Department of Otorhinolaryngology, Kyoto Katsura Hospital
- 138 Department of Otorhinolaryngology, Kinki University Nara Hospital
- 139 Department of Otorhinolaryngology, Nara City Hospital
- 140 Department of Otorhinolaryngology, Tenri Hospital
- 141 Department of Otorhinolaryngology and Oral and Maxillofacial Surgery, Nara Medical University Hospital
- 142 Department of Otorhinolaryngology, Head and Neck Surgery and Oral Surgery, Nara Prefecture General Medical Center
- 143 Department of Otorhinolaryngology, Rinku General Medical Center
- 144 Department of Otorhinolaryngology, Kansai Medical University Hospital
- 145 Department of Otorhinolaryngology, Kitano Hospital
- 146 Department of Oral and Maxillofacial Surgery and Otorhinolaryngology, Kinki University Hospital
- 147 Department of Otorhinolaryngology, Kishiwada City Hospital
- 149 Department of Otorhinolaryngology, Osaka General Medical Center
- 150 Department of Otorhinolaryngology, Osaka City University Hospital
- 151 Department of Otorhinolaryngology, Osaka City General Hospital
- 152 Department of Otorhinolaryngology, Japanese Red Cross Osaka Hospital
- 153 Department of Oral Surgery, Osaka University Hospital
- 154 Department of Oral and Maxillofacial Surgery 2, Osaka University Dental Hospital
- 157 Department of Otorhinolaryngology, Yodogawa Christian Hospital
- 158 Department of Otorhinolaryngology, Osaka International Cancer Center
- 159 Department of Otorhinolaryngology, Kansai Rosai Hospital
- 160 Department of Oral Surgery and Otorhinolaryngology, Wakayama Medical University Hospital
- 161 Department of Otorhinolaryngology, Japanese Red Cross Wakayama Medical Center
- 162 Department of Otorhinolaryngology, Kobe City Medical Center General Hospital
- 163 Department of Otorhinolaryngology, Kobe University Hospital
- 165 Department of Otorhinolaryngology, Hyogo College of Medicine
- 166 Department of Otorhinolaryngology, Hyogo Cancer Center
- 167 Department of Otorhinolaryngology, Hyogo Prefectural Amagasaki General Medical Center
- 168 Department of Otorhinolaryngology, Okayama University Hospital
- 169 Department of Otorhinolaryngology, Himeji Red Cross Hospital

List of 215 Institutions which participate in the Registry in 2022

- 170 Department of Otorhinolaryngology, Tottori University Hospital
- 171 Department of Otorhinolaryngology, Kawasaki Medical School Hospital
- 172 Department of Otorhinolaryngology, Kurashiki Central Hospital
- 173 Department of Otorhinolaryngology, Shimane University Hospital
- 174 Department of Otorhinolaryngology, Fukuyama City Hospital
- 175 Department of Otorhinolaryngology, Hiroshima City Hiroshima Citizens Hospital
- 177 Department of Otorhinolaryngology, Hiroshima University Hospital
- 179 Department of Otorhinolaryngology, Yamaguchi University Hospital
- 180 Department of Otorhinolaryngology, Yamaguchi Prefectural General Medical Center
- 181 Department of Otorhinolaryngology, Ehime Prefectural Central Hospital
- 182 Department of Otorhinolaryngology, Ehime University Hospital
- 184 Department of Head and Neck Surgery, Shikoku Cancer Center
- 185 Department of Otorhinolaryngology, Kochi Medical Center
- 186 Department of Otorhinolaryngology, Kochi Medical School Hospital
- 187 Department of Otorhinolaryngology, Kagawa University Hospital
- 188 Department of Oral Surgery, Tokushima University Hospital
- 189 Department of Otorhinolaryngology, Tokushima University Hospital
- 190 Department of Otorhinolaryngology, Oita University Hospital
- 192 Department of Otorhinolaryngology, University of Occupational and Environmental Health
- 194 Department of Otorhinolaryngology, Kitakyushu General Hospital
- 195 Department of Head and Neck Surgery, Kyushu Cancer Center
- 196 Department of Otorhinolaryngology, Kyushu University Hospital
- 197 Department of Otorhinolaryngology, Kyushu Medical Center
- 198 Department of Otorhinolaryngology, Hamanomachi Hospital
- 199 Department of Oral Surgery, Fukuoka University
- 200 Department of Oral Surgery, Fukuoka Dental University
- 201 Department of Otorhinolaryngology, Kurume University Hospital
- 202 Department of Otorhinolaryngology, Saga University Hospital
- 204 Department of Otorhinolaryngology, Sasebo City General Hospital
- 205 Department of Otorhinolaryngology, Nagasaki Medical Center
- 206 Department of Otorhinolaryngology, Nagasaki University Hospital
- 207 Department of Otorhinolaryngology, Kumamoto University Hospital
- 209 Department of Otorhinolaryngology, Miyazaki Prefectural Miyazaki Hospital
- 210 Department of Otorhinolaryngology, Kagoshima Medical Center
- 211 Department of Otorhinolaryngology, Kagoshima City Hospital
- 212 Department of Otorhinolaryngology, Kagoshima University Medical and Dental Hospital
- 213 Department of Otorhinolaryngology, Imakiire General Hospital
- 214 Department of Otorhinolaryngology, Okinawa Prefectural Chubu Hospital

List of 215 Institutions which participate in the Registry in 2022

215 Department of Otorhinolaryngology, Ryukyu University Hospital

**Total Cases(2022)**

**14258 Cases**

## Primary Site

Site	Number of patients	(%)
Oral cavity	3916	(27.5)
Larynx	2220	(15.6)
Hypopharynx	3266	(22.9)
Oropharynx	2632	(18.5)
Nasopharynx	361	(2.5)
Nasal cavity, etc	472	(3.3)
Maxillary sinus	384	(2.7)
Major salivary glands	833	(5.8)
Unknown primary	174	(1.2)
<b>Total</b>	<b>14258</b>	<b>(100.0)</b>

Nasal cavity, etc.: nasal cavity and paranasal sinuses (excluding the maxillary sinus).

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	13	2	15
10 - 19	16	13	29
20 - 29	49	43	92
30 - 39	141	118	259
40 - 49	567	311	878
50 - 59	1459	490	1949
60 - 69	2972	668	3640
70 - 79	4180	888	5068
80 - 89	1567	561	2128
90 - 99	114	82	196
100 - 109	0	4	4
<b>Total</b>	<b>11078</b>	<b>3180</b>	<b>14258</b>

## Histological Distribution

Histologic type	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
S.C.C., NOS	3403	2014	2,915	2,390	226	180	279	67	169	11643
S.C.C. in situ, NOS	101	64	191	58	0	4	0	0	0	418
S.C.C., kerat., NOS	149	68	48	38	9	8	13	1	1	335
Adenoid cystic ca.	41	3	0	17	7	25	17	142	0	252
Salivary duct ca.	3	0	0	0	0	0	0	206	0	209
Mucoepidermoid ca.	30	0	0	17	2	1	2	129	0	181
Ca., NOS	12	9	12	14	18	17	13	46	0	141
S.C.C., large cell, nonkerat., NOS	7	7	35	24	37	7	5	1	0	123
Malign. melanoma, NOS	25	1	0	2	3	74	10	2	0	117
Adenocarcinoma, NOS	13	0	2	5	4	22	2	33	0	81
Ca. ex pleomorphic adenoma	0	1	0	2	0	1	0	66	0	70
Olfactory neuroblastoma	0	0	0	0	0	64	0	0	0	64
S.C.C., microinvasive	15	1	20	5	0	0	0	0	0	41
Acinar cell ca.	3	0	0	2	0	1	0	33	0	39
Lymphoepithelial ca.	0	2	2	1	24	2	0	5	1	37
Malign. lymphoma, NOS	5	0	0	12	2	3	2	8	1	33
Myoepithelial ca.	4	0	1	0	1	1	1	24	0	32
Epithelial-myoepithelial ca.	1	0	0	2	1	1	0	26	0	31
Small cell ca., NOS	6	7	5	3	1	5	4	0	0	31
Verrucous ca., NOS	28	2	0	0	0	0	1	0	0	31
Neoplasm, malign.	4	2	5	0	2	6	4	7	0	30
Ca., undiff., NOS	2	1	0	5	7	8	1	2	0	26
S.C.C., spindle cell	7	6	4	4	1	1	3	0	0	26
Papillary S.C.C.	4	4	4	3	1	4	1	0	0	21
Spindle cell ca., NOS	5	7	2	0	2	0	4	0	0	20
Adenosquamous ca.	4	3	2	3	0	2	2	1	0	17
S.C.C., small cell, nonkerat.	2	0	2	5	7	0	0	0	1	17
Basaloid S.C.C.	3	3	5	2	0	2	0	1	0	16
Malign. lymphoma, large B-cell, diffuse, NOS	1	0	0	6	3	2	0	1	0	13
Neuroendocrine ca., NOS	1	2	0	3	0	7	0	0	0	13

Head and Neck Cancer ----- 14258 Cases

Histologic type	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
S.C.C. in situ with quest. stromal invasion	3	2	5	1	0	0	0	0	0	11
Basal cell adenocarcinoma	0	0	0	0	0	2	0	7	0	9
Basal cell ca., NOS	1	0	0	0	0	5	0	3	0	9
Osteosarcoma, NOS	5	0	0	0	0	1	3	0	0	9
Carcinosarcoma, NOS	3	0	1	0	0	0	1	3	0	8
Transitional cell ca., NOS	2	0	1	2	0	1	0	1	0	7
Carcinoid tumor, NOS	0	3	0	0	0	3	0	0	0	6
Chondrosarcoma, NOS	0	4	0	0	0	1	1	0	0	6
Secretory ca.	0	0	0	0	0	0	0	6	0	6
Alveolar rhabdomyosarcoma	0	0	0	0	0	2	3	0	0	5
Clear cell ca., NOS	2	0	0	2	1	0	0	0	0	5
Cystadenoca	0	0	0	0	0	0	0	5	0	5
Hemangiosarcoma	3	0	0	0	0	0	2	0	0	5
Intraepithelial, NOS	4	0	0	1	0	0	0	0	0	5
Rhabdomyosarcoma, NOS	2	0	0	0	0	3	0	0	0	5
Plasmacytoma, NOS	1	1	0	1	1	0	0	0	0	4
Extraskelatal Ewing's sarcoma	0	0	0	0	0	0	3	0	0	3
Liposarcoma, NOS	0	0	0	1	0	0	1	0	1	3
Papillary adenocarcinoma, NOS	0	0	0	1	1	1	0	0	0	3
S.C.C. with horn formation	2	0	1	0	0	0	0	0	0	3
Adenocarcinoma, intestinal type	0	0	0	0	0	2	0	0	0	2
Fibromyxosarcoma	1	0	0	0	0	0	1	0	0	2
Leiomyosarcoma, NOS	0	1	0	0	0	1	0	0	0	2
Malig. fibrous histiocytoma	0	1	0	0	0	0	1	0	0	2
Malig. tumor, spindle cell type	1	0	0	0	0	0	1	0	0	2
Mucinous adenocarcinoma	1	1	0	0	0	0	0	0	0	2
Papillary S.C.C., non-invasive	1	0	1	0	0	0	0	0	0	2
Polymorphous low grade adenocarcinoma	0	0	0	0	0	1	0	1	0	2
Adenocarcinoma with neuroendocrine differentiation	0	0	0	0	0	1	0	0	0	1
Ewing sarcoma	0	0	0	0	0	0	0	1	0	1
Fibrosarcoma, NOS	0	0	0	0	0	0	0	1	0	1

Head and Neck Cancer ----- 14258 Cases

Histologic type	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
Giant cell sarcoma	1	0	0	0	0	0	0	0	0	1
Intraepithelial neoplasia, grade III	0	0	1	0	0	0	0	0	0	1
Large cell ca., NOS	0	0	0	0	0	0	0	1	0	1
Marginal zone B-cell lymphoma, NOS	0	0	0	0	0	0	0	1	0	1
Mixed tumor, malig., NOS	1	0	0	0	0	0	0	0	0	1
Neurilemoma, malig.	0	0	0	0	0	0	1	0	0	1
Oncocytic ca.	0	0	0	0	0	0	0	1	0	1
S.C.C., kerat.	1	0	0	0	0	0	0	0	0	1
Sarcomatoid ca.	1	0	0	0	0	0	0	0	0	1
Sebaceous ca.	0	0	0	0	0	0	0	1	0	1
Solitary fibrous tumor, malig.	1	0	0	0	0	0	0	0	0	1
Spindle cell rhabdomyosarcoma	0	0	0	0	0	0	1	0	0	1
Synovial sarcoma, spindle cell	0	0	0	0	0	0	1	0	0	1
Tubular adenocarcinoma, NOS	0	0	1	0	0	0	0	0	0	1
<b>Total</b>	<b>3916</b>	<b>2220</b>	<b>3,266</b>	<b>2632</b>	<b>361</b>	<b>472</b>	<b>384</b>	<b>833</b>	<b>174</b>	<b>14258</b>

Ca., ca.: carcinoma.

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

Malig., malig.: malignant.

undiff.: undifferentiated.

quest.: questionable.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## Histological Distribution (Male)

Histologic type	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
S.C.C., NOS	2122	1851	2668	1964	175	120	225	55	145	9325
S.C.C. in situ, NOS	50	60	172	52	0	4	0	0	0	338
S.C.C., kerat., NOS	93	62	42	30	9	8	8	1	0	253
Salivary duct ca.	2	0	0	0	0	0	0	177	0	179
Ca., NOS	8	7	11	11	14	15	8	33	0	107
S.C.C., large cell, nonkerat., NOS	5	6	33	20	30	3	5	1	0	103
Adenoid cystic ca.	13	2	0	9	4	11	9	48	0	96
Mucoepidermoid ca.	12	0	0	10	0	0	1	59	0	82
Malig. melanoma, NOS	17	1	0	1	3	31	3	2	0	58
Adenocarcinoma, NOS	6	0	1	2	1	16	2	23	0	51
Ca. ex pleomorphic adenoma	0	0	0	2	0	0	0	42	0	44
Olfactory neuroblastoma	0	0	0	0	0	44	0	0	0	44
S.C.C., microinvasive	9	1	19	4	0	0	0	0	0	33
Small cell ca., NOS	6	6	4	2	1	5	3	0	0	27
Lymphoepithelial ca.	0	2	2	1	14	0	0	2	1	22
Neoplasm, malig.	1	2	4	0	0	5	3	5	0	20
Acinar cell ca.	2	0	0	2	0	1	0	13	0	18
Papillary S.C.C.	2	4	4	3	1	3	1	0	0	18
Spindle cell ca., NOS	4	7	2	0	2	0	3	0	0	18
Myoepithelial ca.	2	0	1	0	1	1	0	12	0	17
S.C.C., spindle cell	3	5	3	2	0	1	3	0	0	17
Ca., undiff., NOS	2	1	0	2	3	5	1	1	0	15
Epithelial-myoepithelial ca.	1	0	0	0	1	1	0	12	0	15
Malig. lymphoma, NOS	2	0	0	3	1	2	1	4	1	14
S.C.C., small cell, nonkerat.	2	0	2	3	6	0	0	0	1	14
Basaloid S.C.C.	2	2	5	2	0	1	0	1	0	13
Verrucous ca., NOS	8	2	0	0	0	0	1	0	0	11
Adenosquamous ca.	1	3	1	2	0	2	1	0	0	10
Neuroendocrine ca., NOS	1	1	0	2	0	5	0	0	0	9
S.C.C. in situ with quest. stromal invasion	0	2	5	1	0	0	0	0	0	8

Head and Neck Cancer ----- 14258 Cases

Histologic type	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
Basal cell ca., NOS	1	0	0	0	0	4	0	2	0	7
Carcinosarcoma, NOS	3	0	1	0	0	0	1	2	0	7
Osteosarcoma, NOS	3	0	0	0	0	1	3	0	0	7
Basal cell adenocarcinoma	0	0	0	0	0	1	0	5	0	6
Carcinoid tumor, NOS	0	3	0	0	0	2	0	0	0	5
Chondrosarcoma, NOS	0	4	0	0	0	0	1	0	0	5
Secretory ca.	0	0	0	0	0	0	0	5	0	5
Transitional cell ca., NOS	1	0	1	1	0	1	0	1	0	5
Malig. lymphoma, large B-cell, diffuse, NOS	0	0	0	1	2	1	0	0	0	4
Cystadenocarcinoma	0	0	0	0	0	0	0	3	0	3
Intraepithelial, NOS	2	0	0	1	0	0	0	0	0	3
Liposarcoma, NOS	0	0	0	1	0	0	1	0	1	3
Plasmacytoma, NOS	1	1	0	1	0	0	0	0	0	3
Rhabdomyosarcoma, NOS	2	0	0	0	0	1	0	0	0	3
S.C.C. with horn formation	2	0	1	0	0	0	0	0	0	3
Alveolar rhabdomyosarcoma	0	0	0	0	0	1	1	0	0	2
Extraskelatal Ewing's sarcoma	0	0	0	0	0	0	2	0	0	2
Hemangiosarcoma	1	0	0	0	0	0	1	0	0	2
Leiomyosarcoma, NOS	0	1	0	0	0	1	0	0	0	2
Malig. tumor, spindle cell type	1	0	0	0	0	0	1	0	0	2
Mucinous adenocarcinoma	1	1	0	0	0	0	0	0	0	2
Papillary adenocarcinoma, NOS	0	0	0	1	0	1	0	0	0	2
Papillary S.C.C., non-invasive	1	0	1	0	0	0	0	0	0	2
Adenocarcinoma. with neuroendocrine differentiation	0	0	0	0	0	1	0	0	0	1
Adenocarcinoma, intestinal type	0	0	0	0	0	1	0	0	0	1
Ewing sarcoma	0	0	0	0	0	0	0	1	0	1
Fibromyxosarcoma	0	0	0	0	0	0	1	0	0	1
Fibrosarcoma, NOS	0	0	0	0	0	0	0	1	0	1
Giant cell sarcoma	1	0	0	0	0	0	0	0	0	1
Intraepithelial neoplasia, grade III	0	0	1	0	0	0	0	0	0	1
Malig. fibrous histiocytoma	0	0	0	0	0	0	1	0	0	1

Head and Neck Cancer ----- 14258 Cases

Histologic type	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
Mixed tumor, malig., NOS	1	0	0	0	0	0	0	0	0	1
Neurilemoma, malig.	0	0	0	0	0	0	1	0	0	1
Polymorphous low grade adenocarcinoma	0	0	0	0	0	1	0	0	0	1
Sebaceous ca.	0	0	0	0	0	0	0	1	0	1
Spindle cell rhabdomyosarcoma	0	0	0	0	0	0	1	0	0	1
Tubular adenocarcinoma, NOS	0	0	1	0	0	0	0	0	0	1
<b>Total</b>	<b>2397</b>	<b>2037</b>	<b>2985</b>	<b>2136</b>	<b>268</b>	<b>301</b>	<b>293</b>	<b>512</b>	<b>149</b>	<b>11078</b>

Ca., ca.: carcinoma.

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

Malig., malig.: malignant.

undiff.: undifferentiated.

quest.: questionable.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## Histological Distribution (Female)

Histologic type	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
S.C.C., NOS	1281	163	247	426	51	60	54	12	24	2318
Adenoid cystic ca.	28	1	0	8	3	14	8	94	0	156
Mucoepidermoid ca.	18	0	0	7	2	1	1	70	0	99
S.C.C., kerat., NOS	56	6	6	8	0	0	5	0	1	82
S.C.C. in situ, NOS	51	4	19	6	0	0	0	0	0	80
Malig. melanoma, NOS	8	0	0	1	0	43	7	0	0	59
Ca., NOS	4	2	1	3	4	2	5	13	0	34
Adenocarcinoma, NOS	7	0	1	3	3	6	0	10	0	30
Salivary duct ca.	1	0	0	0	0	0	0	29	0	30
Ca. ex pleomorphic adenoma	0	1	0	0	0	1	0	24	0	26
Acinar cell ca.	1	0	0	0	0	0	0	20	0	21
Olfactory neuroblastoma	0	0	0	0	0	20	0	0	0	20
S.C.C., large cell, nonkerat., NOS	2	1	2	4	7	4	0	0	0	20
Verrucous ca., NOS	20	0	0	0	0	0	0	0	0	20
Malig. lymphoma, NOS	3	0	0	9	1	1	1	4	0	19
Epithelial-myoepithelial ca.	0	0	0	2	0	0	0	14	0	16
Lymphoepithelial ca.	0	0	0	0	10	2	0	3	0	15
Myoepithelial ca.	2	0	0	0	0	0	1	12	0	15
Ca., undiff., NOS	0	0	0	3	4	3	0	1	0	11
Neoplasm, malig.	3	0	1	0	2	1	1	2	0	10
Malig. lymphoma, large B-cell, diffuse, NOS	1	0	0	5	1	1	0	1	0	9
S.C.C., spindle cell	4	1	1	2	1	0	0	0	0	9
S.C.C., microinvasive	6	0	1	1	0	0	0	0	0	8
Adenosquamous ca.	3	0	1	1	0	0	1	1	0	7
Clear cell ca., NOS	2	0	0	2	1	0	0	0	0	5
Neuroendocrine ca., NOS	0	1	0	1	0	2	0	0	0	4
Small cell ca., NOS	0	1	1	1	0	0	1	0	0	4
Alveolar rhabdomyosarcoma	0	0	0	0	0	1	2	0	0	3
Basal cell adenocarcinoma	0	0	0	0	0	1	0	2	0	3
Basaloid S.C.C.	1	1	0	0	0	1	0	0	0	3

Head and Neck Cancer ----- 14258 Cases

Histologic type	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
Hemangiosarcoma	2	0	0	0	0	0	1	0	0	3
Papillary S.C.C.	2	0	0	0	0	1	0	0	0	3
S.C.C. in situ with quest. stromal invasion	3	0	0	0	0	0	0	0	0	3
S.C.C., small cell, nonkerat.	0	0	0	2	1	0	0	0	0	3
Basal cell ca., NOS	0	0	0	0	0	1	0	1	0	2
Cystadenocarcinoma	0	0	0	0	0	0	0	2	0	2
Intraepithelial, NOS	2	0	0	0	0	0	0	0	0	2
Osteosarcoma, NOS	2	0	0	0	0	0	0	0	0	2
Rhabdomyosarcoma, NOS	0	0	0	0	0	2	0	0	0	2
Spindle cell ca., NOS	1	0	0	0	0	0	1	0	0	2
Transitional cell ca., NOS	1	0	0	1	0	0	0	0	0	2
Adenocarcinoma, intestinal type	0	0	0	0	0	1	0	0	0	1
Carcinoid tumor, NOS	0	0	0	0	0	1	0	0	0	1
Carcinosarcoma, NOS	0	0	0	0	0	0	0	1	0	1
Chondrosarcoma, NOS	0	0	0	0	0	1	0	0	0	1
Extraskeletal Ewing's sarcoma	0	0	0	0	0	0	1	0	0	1
Fibromyxosarcoma	1	0	0	0	0	0	0	0	0	1
Large cell ca., NOS	0	0	0	0	0	0	0	1	0	1
Malig. fibrous histiocytoma	0	1	0	0	0	0	0	0	0	1
Marginal zone B-cell lymphoma, NOS	0	0	0	0	0	0	0	1	0	1
Oncocytic ca.	0	0	0	0	0	0	0	1	0	1
Papillary adenocarcinoma, NOS	0	0	0	0	1	0	0	0	0	1
Plasmacytoma, NOS	0	0	0	0	1	0	0	0	0	1
Polymorphous low grade adenocarcinoma	0	0	0	0	0	0	0	1	0	1
S.C.C., kerat.	1	0	0	0	0	0	0	0	0	1
Sarcomatoid ca.	1	0	0	0	0	0	0	0	0	1
Secretory ca.	0	0	0	0	0	0	0	1	0	1
Solitary fibrous tumor, malig.	1	0	0	0	0	0	0	0	0	1
Synovial sarcoma, spindle cell	0	0	0	0	0	0	1	0	0	1
Total	1519	183	281	496	93	171	91	321	25	3180

ca., Ca.: carcinoma.

NOS: not otherwise specified.

Head and Neck Cancer ----- 14258 Cases

S.C.C.: squamous cell carcinoma.

Malig., malig.: malignant.

undiff.: undifferentiated.

quest.: questionable.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	30	65	6	9	36	7	9	3	58	5	0	228
T1	2020	261	31	9	60	21	35	2	58	16	0	2513
T1a	553	0	0	0	3	0	0	0	2	3	0	561
T1b	174	1	0	0	1	0	0	0	1	1	0	178
T2	2398	770	126	27	384	132	31	3	149	10	0	4030
T3	1158	401	95	20	403	197	26	5	115	4	0	2424
T4	77	133	130	1	21	6	38	0	2	0	0	408
T4a	957	308	1	25	624	349	8	6	272	11	0	2561
T4b	193	48	1	0	100	69	3	1	52	2	0	469
Tis	635	0	0	0	0	0	0	0	0	5	0	640
TX	45	7	0	0	7	1	1	1	1	96	0	159
T-	0	0	1	0	0	0	0	0	0	0	0	1
<b>Total</b>	<b>8240</b>	<b>1994</b>	<b>391</b>	<b>91</b>	<b>1639</b>	<b>782</b>	<b>151</b>	<b>21</b>	<b>710</b>	<b>153</b>	<b>0</b>	<b>14172</b>

T and N Status was not reported in 86 patients.

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

**T and N Status (M0 Cases)**

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	30	64	6	9	35	4	8	2	52	3	0	213
T1	2010	255	29	9	58	19	30	2	48	9	0	2469
T1a	551	0	0	0	3	0	0	0	2	2	0	558
T1b	174	1	0	0	1	0	0	0	1	0	0	177
T2	2382	757	119	25	368	123	26	1	134	5	0	3940
T3	1142	389	85	20	374	175	21	4	90	3	0	2,303
T4	73	125	119	0	21	5	28	0	2	0	0	373
T4a	914	292	1	24	581	294	6	4	229	4	0	2349
T4b	179	37	1	0	94	57	2	1	37	0	0	408
Tis	632	0	0	0	0	0	0	0	0	1	0	633
TX	45	7	0	0	7	1	1	1	1	6	0	69
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>8132</b>	<b>1,927</b>	<b>360</b>	<b>87</b>	<b>1542</b>	<b>678</b>	<b>122</b>	<b>15</b>	<b>596</b>	<b>33</b>	<b>0</b>	<b>13492</b>

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

**T and N Status (M1 Cases)**

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	1	0	0	1	3	1	1	5	0	0	12
T1	2	5	1	0	2	2	5	0	10	0	0	27
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	10	11	7	1	13	8	5	2	13	0	0	70
T3	12	11	9	0	26	20	5	1	22	0	0	106
T4	1	6	11	1	0	1	9	0	0	0	0	29
T4a	37	13	0	1	35	51	0	2	42	0	0	181
T4b	13	11	0	0	6	11	1	0	14	1	0	57
Tis	0	0	0	0	0	0	0	0	0	0	0	0
TX	0	0	0	0	0	0	0	0	0	1	0	1
T-	0	0	1	0	0	0	0	0	0	0	0	1
<b>Total</b>	<b>75</b>	<b>58</b>	<b>29</b>	<b>3</b>	<b>83</b>	<b>96</b>	<b>26</b>	<b>6</b>	<b>106</b>	<b>2</b>	<b>0</b>	<b>484</b>

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## T and N Status (MX & M- Cases)

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	1	2	0	3
T1	8	1	1	0	0	0	0	0	0	7	0	17
T1a	2	0	0	0	0	0	0	0	0	1	0	3
T1b	0	0	0	0	0	0	0	0	0	1	0	1
T2	6	2	0	1	3	1	0	0	2	5	0	20
T3	4	1	1	0	3	2	0	0	3	1	0	15
T4	3	2	0	0	0	0	1	0	0	0	0	6
T4a	6	3	0	0	8	4	2	0	1	7	0	31
T4b	1	0	0	0	0	1	0	0	1	1	0	4
Tis	3	0	0	0	0	0	0	0	0	4	0	7
TX	0	0	0	0	0	0	0	0	0	89	0	89
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>33</b>	<b>9</b>	<b>2</b>	<b>1</b>	<b>14</b>	<b>8</b>	<b>3</b>	<b>0</b>	<b>8</b>	<b>118</b>	<b>0</b>	<b>196</b>

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Treatment Method for the Primary Lesion by Primary Site

Treatment Method	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
<b>Surgery</b>										
without	502	1386	1612	1592	338	222	264	137	143	6196
with	3330	815	1605	1007	16	240	116	687	31	7847
unknown	84	19	49	33	7	10	4	9	0	215
<b>Radiotherapy</b>										
without	3073	756	1549	1018	39	151	95	444	114	7239
with	759	1445	1668	1581	315	311	285	380	60	6804
unknown	84	19	49	33	7	10	4	9	0	215
<b>Chemotherapy</b>										
without	3077	1685	1789	1201	79	261	138	682	127	9039
with	755	516	1428	1398	275	201	242	142	47	5004
unknown	84	19	49	33	7	10	4	9	0	215
<b>Total</b>	<b>3916</b>	<b>2220</b>	<b>3266</b>	<b>2632</b>	<b>361</b>	<b>472</b>	<b>384</b>	<b>833</b>	<b>174</b>	<b>14258</b>

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

## Treatment Method for the Cervical Lymph Nodes by Primary Site

Treatment Method	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
<b>Surgery</b>										
without	2138	1820	2404	1999	343	433	312	403	58	9910
with	1693	377	809	598	9	26	67	421	116	4116
unknown	85	23	53	35	9	13	5	9	0	232
<b>Radiotherapy</b>										
without	3196	1751	1857	1192	87	376	250	560	60	9329
with	635	446	1356	1405	265	83	129	264	114	4697
unknown	85	23	53	35	9	13	5	9	0	232
<b>Chemotherapy</b>										
without	3179	1885	1994	1315	103	372	246	709	84	9887
with	652	312	1219	1282	249	87	133	115	90	4139
unknown	85	23	53	35	9	13	5	9	0	232
<b>Total</b>	<b>3916</b>	<b>2220</b>	<b>3266</b>	<b>2632</b>	<b>361</b>	<b>472</b>	<b>384</b>	<b>833</b>	<b>174</b>	<b>14258</b>

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

## Sequence of Treatment Methods for the Primary Lesion

Sequence of treatment methods	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
No treatment	124	50	114	90	8	13	21	20	97	537
A) Surg. alone	2622	641	1,166	716	10	98	35	355	9	5652
F) (Rad.+Chem.)	93	368	719	897	164	54	124	14	22	2455
B) Rad. alone	131	892	375	286	56	71	48	53	12	1924
A)B) Surg. -> Rad.	147	74	99	80	1	71	26	240	3	741
A)F) Surg. -> (Rad.+Chem.)	186	31	119	61	1	32	15	43	12	500
C) Chem. alone	71	19	135	100	17	16	20	34	4	416
C)F) Chem. -> (Rad.+Chem.)	13	20	140	121	48	18	21	1	1	383
C)A) Chem. -> Surg.	151	24	81	65	0	9	12	1	0	343
C)B) Chem. -> Rad.	6	12	44	19	5	14	7	1	2	110
C)A)F) Chem. -> Surg. -> (Rad.+Chem.)	41	3	34	17	0	5	3	1	1	105
F)C) (Rad.+Chem.) -> Chem.	11	7	20	21	26	11	5	1	2	104
A)C) Surg. -> Chem.	39	3	8	6	0	7	1	17	0	81
C)A)B) Chem. -> Surg. -> Rad.	19	4	25	6	0	3	2	1	0	60
A)A) Surg. -> Surg.	20	8	10	6	0	1	0	6	1	52
B)C) Rad. -> Chem.	6	3	10	10	2	8	8	3	1	51
F)A) (Rad.+Chem.) -> Surg.	7	5	14	5	1	3	6	0	0	41
C)C) Chem. -> Chem.	10	3	10	9	1	2	0	5	0	40
C)F)C) Chem. -> (Rad.+Chem.) -> Chem.	7	0	11	5	3	5	3	0	0	34
B)A) Rad. -> Surg.	4	10	8	2	0	0	3	1	0	28
A)B)C) Surg. -> Rad. -> Chem.	9	0	2	3	0	4	0	6	0	24
D) (Surg.+Rad.)	4	1	2	8	1	0	2	4	2	24
A)F)C) Surg. -> (Rad.+Chem.) -> Chem.	11	1	3	0	0	0	1	5	0	21
G) Surg.+Rad.+Chem.	4	1	2	8	1	0	0	3	1	20
C)B)C) Chem. -> Rad. -> Chem.	4	0	5	5	0	2	1	0	0	17
C)A)C) Chem. -> Surg. -> Chem.	3	0	4	6	0	1	2	0	0	16
C)C)C) Chem. -> Chem. -> Chem.	2	2	6	2	0	0	2	2	0	16
Other	87	19	51	45	9	14	12	7	4	248
Unknown	84	19	49	33	7	10	4	9	0	215
<b>Total</b>	<b>3916</b>	<b>2220</b>	<b>3266</b>	<b>2632</b>	<b>361</b>	<b>472</b>	<b>384</b>	<b>833</b>	<b>174</b>	<b>14258</b>

Head and Neck Cancer ----- 14258 Cases

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Primary Site

Surgical method	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
No surgery	499	1372	1600	1589	337	221	263	136	142	6159
Partial glossectomy	1299	0	0	2	0	0	0	0	0	1301
Transoral resection	6	297	394	41	1	0	0	0	0	739
Endoscopic resection	1	70	520	18	0	3	2	0	0	614
Total pharyngolaryngectomy	0	13	387	17	0	0	0	0	0	417
Total laryngectomy	0	378	13	7	0	0	0	0	0	398
Unilateral resection of the lateral wall of the oropharynx	1	0	0	378	0	0	0	0	13	392
Segmental mandibulectomy	326	0	0	0	0	0	0	5	0	331
Partial maxillectomy	237	0	0	1	0	19	20	0	0	277
Subtotal glossectomy	234	0	0	6	0	0	0	2	0	242
Resection of the buccal mucosa	213	0	0	1	0	0	0	0	0	214
Resection of the floor of mouth	187	0	0	0	0	0	0	6	0	193
Marginal mandibulectomy	183	0	0	0	0	0	0	1	0	184
Total pharyngolaryngo-esophagectomy	0	8	172	1	0	0	0	0	0	181
Superficial parotidectomy	1	0	0	0	0	0	0	171	0	172
Resection of the oropharynx, other type	3	2	1	160	0	0	0	0	3	169
Total parotidectomy	0	0	0	0	0	0	0	165	0	165
Submandibulectomy	0	0	0	0	0	0	0	158	0	158
Hemiglossectomy	124	0	0	8	0	0	0	0	0	132
Hemiglossectomy (anterior 2/3rds)	126	0	0	0	0	0	0	1	0	127
Resection of oral cavity, NOS	109	0	0	3	0	0	0	0	0	112
Total maxillectomy	33	0	0	0	0	8	64	0	0	105
Resection of the soft palate	1	0	1	94	1	0	0	0	0	97
Maxillectomy, other type	13	0	0	0	2	67	12	0	0	94
Resection of the root of tongue	0	0	0	79	0	0	0	0	0	79
Resection of the posterior wall	0	0	1	67	0	0	0	0	0	68
Extended total parotidectomy	0	0	0	1	0	0	0	64	0	65
Subtotal glossectomy (anterior 2/3rds)	58	0	0	1	0	0	0	0	0	59
Total glossectomy	38	0	0	15	0	0	0	0	0	53

Head and Neck Cancer ----- 14258 Cases

Surgical method	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
Endoscopic skull base surgery	0	0	0	0	0	49	2	0	0	51
Partial parotidectomy	0	0	0	0	0	0	0	51	0	51
Resection of the lip	49	0	0	0	0	0	0	0	0	49
Total laryngectomy+Partial pharyngectomy	0	10	33	0	0	0	0	0	0	43
Resection of lower gingiva	38	0	0	1	0	0	0	0	0	39
Deep lobe resection of the parotid gland	0	0	0	0	0	0	0	36	0	36
Others	50	36	81	104	10	93	16	26	14	430
Unknown	1	0	1	0	0	0	0	0	1	3
<b>Total</b>	<b>3830</b>	<b>2186</b>	<b>3204</b>	<b>2594</b>	<b>351</b>	<b>460</b>	<b>379</b>	<b>822</b>	<b>173</b>	<b>13999</b>

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

Surgical Methods for the Primary Lesion was not reported in 259 patients.

NOS: not otherwise specified.

## Reconstructive Surgery by Primary Site

Reconstructive surgery	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
No reconstruction	2522	2112	2,556	2,396	350	368	308	641	168	11421
Free ALT flap	472	10	26	64	0	9	14	68	2	665
Free jejunal flap	1	26	542	23	0	0	0	0	0	592
Free RA MC flap	260	1	1	47	0	6	39	17	0	371
Free FA flap	137	0	7	19	0	1	1	9	0	174
Free fibular OC flap	138	0	0	0	0	3	7	3	0	151
PM MC flap	61	17	24	15	0	1	0	15	2	135
Others	59	2	7	6	0	28	2	7	0	111
Skin graft	77	2	1	2	0	1	4	2	0	89
Local skin flap	46	1	6	4	0	17	0	14	0	88
Mucosal flap	15	1	0	5	1	25	1	0	0	48
Free nerve graft	0	0	0	0	0	0	0	42	0	42
Free scapular OC flap	32	0	1	1	0	0	2	0	0	36
Gastric pull-up	0	2	16	2	0	0	0	0	0	20
DP flap	1	2	7	2	0	0	0	3	0	15
Unknown	4	0	1	1	0	0	0	0	0	6
<b>Total</b>	<b>3825</b>	<b>2176</b>	<b>3195</b>	<b>2587</b>	<b>351</b>	<b>459</b>	<b>378</b>	<b>821</b>	<b>172</b>	<b>13964</b>

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

Reconstructive Surgery was not reported in 294 patients.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh. FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

### Neck Dissection on the Ipsilateral Side by Primary Site

Neck dissection	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
0) No N.D.	2136	1808	2393	1986	340	430	308	397	58	9856
1) Total N.D.	538	68	173	160	4	7	10	103	48	1111
2) Selective N.D.	1,129	291	615	425	5	16	55	309	63	2908
3) Lymph node excision	9	1	3	5	0	0	1	9	4	32
8) Others	9	12	11	7	1	3	1	2	1	47
9) Unknown	8	6	7	8	0	1	0	3	0	33
<b>Total</b>	<b>3829</b>	<b>2186</b>	<b>3202</b>	<b>2591</b>	<b>350</b>	<b>457</b>	<b>375</b>	<b>823</b>	<b>174</b>	<b>13987</b>

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

Neck Dissection on the Ipsilateral Side was not reported in 271 patients.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Primary Site

Neck dissection	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
0) No N.D.	3323	1939	2594	2444	348	444	364	793	165	12414
1) Total N.D.	65	32	89	21	0	1	3	5	3	219
2) Selective N.D.	413	197	500	99	2	7	5	18	5	1246
3) Lymph node excision	3	0	1	0	0	0	1	1	0	6
8) Others	17	12	12	14	0	4	2	2	1	64
9) Unknown	8	6	7	12	0	1	0	4	0	38
<b>Total</b>	<b>3829</b>	<b>2186</b>	<b>3203</b>	<b>2590</b>	<b>350</b>	<b>457</b>	<b>375</b>	<b>823</b>	<b>174</b>	<b>13987</b>

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

Neck Dissection on the Contralateral Side was not reported in 271 patients.

N.D.: neck dissection.

### Radiotherapy by Primary Site

Type of radiotherapy	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
0) No radiotherapy	2975	731	1490	988	36	150	85	421	54	6930
1) X-ray (and/or electron beam)	802	1433	1702	1581	305	239	261	331	118	6772
2) Particle beam	14	1	9	15	13	68	31	66	0	217
3) B.T.	19	0	0	2	0	1	0	0	0	22
4) X-ray + Particle beam	2	5	1	1	0	0	0	1	0	10
5) X-ray + B.T.	2	0	0	0	0	1	0	0	0	3
8) Others	3	2	2	1	0	3	2	3	0	16
9) Unknown	6	19	4	4	0	0	0	0	0	33
<b>Total</b>	<b>3823</b>	<b>2191</b>	<b>3208</b>	<b>2592</b>	<b>354</b>	<b>462</b>	<b>379</b>	<b>822</b>	<b>172</b>	<b>14003</b>

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

Radiotherapy was not reported in 255 patients.

B.T.: brachytherapy.

### Chemotherapy by Primary site

Route of administration	Oral cavity	Larynx	Hypopharynx	Oropharynx	Nasopharynx	Nasal cavity, etc	Maxillary sinus	Major salivary glands	Unknown primary	Total
0) No chemotherapy	2998	1654	1742	1175	78	260	135	667	78	8787
1) I.V.	648	478	1414	1375	269	190	139	137	92	4742
2) I.A.	52	4	4	14	1	6	97	2	0	180
3) Oral	73	50	29	19	2	1	2	11	1	188
4) I.V.+I.A.	14	0	1	2	0	3	4	0	0	24
5) I.V.+Oral	10	3	13	7	4	2	1	0	1	41
6) I.A.+Oral	2	0	0	0	0	0	1	0	0	3
8) Others	0	0	2	2	0	0	0	0	0	4
9) Unknown	5	0	4	1	0	1	1	2	0	14
<b>Total</b>	<b>3802</b>	<b>2189</b>	<b>3209</b>	<b>2595</b>	<b>354</b>	<b>463</b>	<b>380</b>	<b>819</b>	<b>172</b>	<b>13983</b>

Nasal cavity, etc. : nasal cavity and paranasal sinuses (excluding the maxillary sinus).

Chemotherapy was not reported in 275 patients.

I.V.: intravenous. I.A.: intraarterial.

# Oral Cavity(2022)

3916 Cases

## Primary Site

Site	Number of patients	(%)
1) Lip	49	(1.3)
2) Buccal mucosa	278	(7.1)
3) Retro-molar area	68	(1.7)
4) Lower gingiva	600	(15.3)
5) Upper gingiva	373	(9.5)
6) Hard palate	121	(3.1)
7) Floor of mouth	308	(7.9)
8) Tongue	2099	(53.6)
9) Oral cavity, NOS	20	(0.5)
<b>Total</b>	<b>3916</b>	<b>(100.0)</b>

NOS: not otherwise specified

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	2	1	3
10 - 19	2	1	3
20 - 29	24	22	46
30 - 39	66	62	128
40 - 49	171	143	314
50 - 59	369	186	555
60 - 69	605	305	910
70 - 79	745	397	1,142
80 - 89	375	342	717
90 - 99	38	58	96
100 - 109	0	2	2
<b>Total</b>	<b>2397</b>	<b>1519</b>	<b>3916</b>

## Carcinoma of the Lip Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	1	0	1
50 - 59	1	0	1
60 - 69	4	4	8
70 - 79	11	2	13
80 - 89	11	11	22
90 - 99	1	3	4
100 - 109	0	0	0
<b>Total</b>	<b>29</b>	<b>20</b>	<b>49</b>

## Carcinoma of the Buccal Mucosa Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	1	2
40 - 49	5	3	8
50 - 59	19	6	25
60 - 69	45	26	71
70 - 79	50	46	96
80 - 89	35	31	66
90 - 99	4	5	9
100 - 109	0	1	1
<b>Total</b>	<b>159</b>	<b>119</b>	<b>278</b>

## Carcinoma of the Retromolar Area Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	2	1	3
40 - 49	3	1	4
50 - 59	5	2	7
60 - 69	13	4	17
70 - 79	18	3	21
80 - 89	12	3	15
90 - 99	1	0	1
100 - 109	0	0	0
<b>Total</b>	<b>54</b>	<b>14</b>	<b>68</b>

## Carcinoma of the Lower Gingiva Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	3	0	3
40 - 49	8	2	10
50 - 59	29	21	50
60 - 69	98	39	137
70 - 79	132	71	203
80 - 89	80	90	170
90 - 99	9	18	27
100 - 109	0	0	0
<b>Total</b>	<b>359</b>	<b>241</b>	<b>600</b>

## Carcinoma of the Upper Gingiva Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	2	3
40 - 49	9	3	12
50 - 59	18	13	31
60 - 69	38	30	68
70 - 79	73	59	132
80 - 89	53	60	113
90 - 99	4	10	14
100 - 109	0	0	0
<b>Total</b>	<b>196</b>	<b>177</b>	<b>373</b>

## Carcinoma of the Hard Palate Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	1	1
30 - 39	1	2	3
40 - 49	2	4	6
50 - 59	9	7	16
60 - 69	13	20	33
70 - 79	26	11	37
80 - 89	9	13	22
90 - 99	1	2	3
100 - 109	0	0	0
<b>Total</b>	<b>61</b>	<b>60</b>	<b>121</b>

## Carcinoma of the Floor of Mouth Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	1	1
30 - 39	0	1	1
40 - 49	7	8	15
50 - 59	34	19	53
60 - 69	79	23	102
70 - 79	81	17	98
80 - 89	25	12	37
90 - 99	0	1	1
100 - 109	0	0	0
<b>Total</b>	<b>226</b>	<b>82</b>	<b>308</b>

## Carcinoma of the Tongue Age Distribution by Gender

Age	Male	Female	Total
0 - 9	2	1	3
10 - 19	2	1	3
20 - 29	24	19	43
30 - 39	58	54	112
40 - 49	135	122	257
50 - 59	254	118	372
60 - 69	310	157	467
70 - 79	349	186	535
80 - 89	149	120	269
90 - 99	18	19	37
100 - 109	0	1	1
<b>Total</b>	<b>1301</b>	<b>798</b>	<b>2099</b>

## Carcinoma of the Oral Cavity, NOS Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	1	1
30 - 39	0	1	1
40 - 49	1	0	1
50 - 59	0	0	0
60 - 69	5	2	7
70 - 79	5	2	7
80 - 89	1	2	3
90 - 99	0	0	0
100 - 109	0	0	0
Total	12	8	20

NOS : Not Otherwise Specified

Oral Cavity -----3916 Cases

## Histological Distribution by Subsite

Histologic type	1) Lip	2) Buccal mucosa	3) Retro-molar area	4) Lower gingiva	5) Upper gingiva	6) Hard palate	7) Floor of mouth	8) Tongue	9) Oral cavity, NOS	Total
S.C.C., NOS	37	222	62	534	320	69	265	1,877	17	3403
S.C.C., kerat., NOS	1	15	0	24	11	0	10	88	0	149
S.C.C. in situ, NOS	0	9	1	8	5	2	11	65	0	101
Adenoid cystic ca.	2	6	1	0	2	15	8	7	0	41
Mucoepidermoid ca.	3	6	2	1	4	8	3	3	0	30
Verrucous ca., NOS	2	2	0	3	2	1	0	18	0	28
Malig. melanoma, NOS	0	0	1	1	11	9	0	2	1	25
S.C.C., microinvasive	0	4	0	0	0	0	1	10	0	15
Adenocarcinoma, NOS	1	2	0	1	1	3	4	1	0	13
Ca., NOS	1	1	0	1	4	1	1	2	1	12
S.C.C., large cell, nonkerat., NOS	1	0	0	0	1	0	1	4	0	7
S.C.C., spindle cell	0	0	0	2	3	0	0	2	0	7
Small cell ca., NOS	0	0	0	2	0	0	1	3	0	6
Malig. lymphoma, NOS	0	0	0	1	1	1	0	1	1	5
Osteosarcoma, NOS	0	0	0	4	1	0	0	0	0	5
Spindle cell ca., NOS	0	0	0	3	1	0	0	1	0	5
Adenosquamous ca.	0	0	0	0	0	2	0	2	0	4
Intraepithelial, NOS	0	1	0	0	0	0	0	3	0	4
Myoepithelial ca.	1	0	0	0	0	3	0	0	0	4
Neoplasm, malig.	0	0	0	2	1	0	0	1	0	4
Papillary S.C.C.	0	2	0	0	0	0	1	1	0	4
Acinar cell ca.	0	2	0	0	1	0	0	0	0	3
Basaloid S.C.C.	0	0	0	2	0	0	1	0	0	3
Carcinosarcoma, NOS	0	1	0	1	0	0	1	0	0	3
Hemangiosarcoma	0	0	0	1	1	0	0	1	0	3
S.C.C. in situ with quest. stromal invasion	0	0	0	1	0	0	0	2	0	3
Salivary duct ca.	0	1	0	0	0	2	0	0	0	3
Ca., undiff., NOS	0	0	0	2	0	0	0	0	0	2
Clear cell ca., NOS	0	1	0	0	0	1	0	0	0	2
Rhabdomyosarcoma, NOS	0	0	0	1	0	0	0	1	0	2

Oral Cavity -----3916 Cases

Histologic type	1) Lip	2) Buccal mucosa	3) Retro-molar area	4) Lower gingiva	5) Upper gingiva	6) Hard palate	7) Floor of mouth	8) Tongue	9) Oral cavity, NOS	Total
S.C.C. with horn formation	0	0	0	1	0	0	0	1	0	2
S.C.C., small cell, nonkerat.	0	0	0	1	1	0	0	0	0	2
Transitional cell ca., NOS	0	0	1	0	0	0	0	1	0	2
Basal cell ca., NOS	0	0	0	0	0	1	0	0	0	1
Epithelial-myoepithelial ca.	0	0	0	0	0	1	0	0	0	1
Fibromyxosarcoma	0	0	0	0	0	1	0	0	0	1
Giant cell sarcoma	0	0	0	0	1	0	0	0	0	1
Malig. lymphoma, large B-cell, diffuse, NOS	0	1	0	0	0	0	0	0	0	1
Malig. tumor, spindle cell type	0	0	0	0	0	0	0	1	0	1
Mixed tumor, malig., NOS	0	0	0	1	0	0	0	0	0	1
Mucinous adenocarcinoma	0	0	0	0	0	1	0	0	0	1
Neuroendocrine ca., NOS	0	0	0	1	0	0	0	0	0	1
Papillary S.C.C., non-invasive	0	1	0	0	0	0	0	0	0	1
Plasmacytoma, NOS	0	0	0	0	1	0	0	0	0	1
S.C.C., kerat.	0	0	0	0	0	0	0	1	0	1
Sarcomatoid ca.	0	0	0	1	0	0	0	0	0	1
Solitary fibrous tumor, malig.	0	1	0	0	0	0	0	0	0	1
<b>Total</b>	<b>49</b>	<b>278</b>	<b>68</b>	<b>600</b>	<b>373</b>	<b>121</b>	<b>308</b>	<b>2099</b>	<b>20</b>	<b>3916</b>

Ca., ca.: carcinoma.

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

Malig., malig.: malignant.

undiff.: undifferentiated.

quest.: questionable.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

### T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	7	2	0	0	0	0	0	0	3	0	0	12
T1	814	12	0	0	12	0	0	0	9	4	0	851
T2	889	99(1)	2	5	89(1)	9	0	0	17(1)	2	0	1112
T3	371(3)	112	2(1)	6	143(3)	40(3)	0	2	19	0	0	695
T4	9	6	2	1(1)	7	1	2	0	1	0	0	29
T4a	349(8)	135(1)	0	10	252(11)	111(9)	1	4(2)	54(4)	5	0	921
T4b	42(1)	18(2)	1	0	39	11	1	1	14(3)	0	0	127
Tis	117	0	0	0	0	0	0	0	0	0	0	117
TX	14	1	0	0	2	0	0	1	0	22(1)	0	40
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>2612(12)</b>	<b>385(4)</b>	<b>7(1)</b>	<b>22(1)</b>	<b>544(15)</b>	<b>172(12)</b>	<b>4</b>	<b>8(2)</b>	<b>117(8)</b>	<b>33(1)</b>	<b>0</b>	<b>3904</b>

T and N Status was not reported in 12 patients.

M1:56 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

### Carcinoma of the Lip

#### T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	10	1	0	0	0	0	0	0	0	1	0	12
T2	17	1	0	0	2	1	0	0	1	0	0	22
T3	3	1	0	0	1	1	0	0	0	0	0	6
T4	0	0	0	0	1	0	0	0	0	0	0	1
T4a	0	0	0	0	2	0	0	1	1	0	0	4
T4b	0	0	0	0	0	0	0	0	0	0	0	0
Tis	3	0	0	0	0	0	0	0	0	0	0	3
TX	1	0	0	0	0	0	0	0	0	0	0	1
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>34</b>	<b>3</b>	<b>0</b>	<b>0</b>	<b>6</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>1</b>	<b>0</b>	<b>49</b>

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Carcinoma of the Buccal mucosa T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	55	0	0	0	2	0	0	0	1	2	0	60
T2	80	7	0	1	8(1)	1	0	0	1	0	0	98
T3	24(1)	9	0	1	15	0	0	0	0	0	0	49
T4	0	0	0	0	1	0	0	0	0	0	0	1
T4a	12	10	0	0	15(1)	2	0	0	1	0	0	40
T4b	3	5	0	0	5	1	0	0	3(3)	0	0	17
Tis	9	0	0	0	0	0	0	0	0	0	0	9
TX	0	0	0	0	0	0	0	0	0	1	0	1
T-	0	0	0	0	0	0	0	0	0	0	0	0
Total	183(1)	31	0	2	46(2)	4	0	0	6(3)	3	0	275

M1:6 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Carcinoma of the Retromolar Area T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	11	0	0	0	0	0	0	0	2	0	0	13
T2	15	2	0	0	5	0	0	0	1	0	0	23
T3	3	3	0	0	3	0	0	0	1	0	0	10
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	5(1)	3	0	0	2	1	1	0	1	0	0	13
T4b	2	3(1)	0	0	3	0	0	0	1	0	0	9
Tis	0	0	0	0	0	0	0	0	0	0	0	0
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	0	0
Total	36(1)	11(1)	0	0	13	1	1	0	6	0	0	68

M1:2 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Carcinoma of the Lower Gingiva T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	1	1	0	0	0	0	0	0	1	0	0	3
T1	55	0	0	0	2	0	0	0	1	1	0	59
T2	93	7	1	1	12	1	0	0	2(1)	0	0	117
T3	25	6	0	1	4	0	0	0	1	0	0	37
T4	5	1	2	0	1	0	1	0	0	0	0	10
T4a	142(1)	52	0	4	95(3)	15	0	0	15(1)	1	0	324
T4b	5	6	0	0	14	3	0	0	4	0	0	32
Tis	9	0	0	0	0	0	0	0	0	0	0	9
TX	2	1	0	0	2	0	0	0	0	3	0	8
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>337(1)</b>	<b>74</b>	<b>3</b>	<b>6</b>	<b>130(3)</b>	<b>19</b>	<b>1</b>	<b>0</b>	<b>24(2)</b>	<b>5</b>	<b>0</b>	<b>599</b>

M1:6 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Carcinoma of the Upper Gingiva T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	2	0	0	2
T1	40	0	0	0	0	0	0	0	0	0	0	40
T2	56	6	0	0	8	2	0	0	1	0	0	73
T3	18(1)	10	0	0	2	5	0	0	1	0	0	36
T4	1	3	0	0	1	0	1	0	0	0	0	6
T4a	89(3)	20	0	3	38(2)	15(5)	0	1	4(1)	1	0	171
T4b	18	2	1	0	11	5	0	1	1	0	0	39
Tis	4	0	0	0	0	0	0	0	0	0	0	4
TX	0	0	0	0	0	0	0	0	0	1	0	1
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>226(4)</b>	<b>41</b>	<b>1</b>	<b>3</b>	<b>60(2)</b>	<b>27(5)</b>	<b>1</b>	<b>2</b>	<b>9(1)</b>	<b>2</b>	<b>0</b>	<b>372</b>

M1:13 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Carcinoma of the Hard Palate T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	23	0	0	0	1	0	0	0	0	0	0	24
T2	25	1	0	1	1	0	0	0	0	0	0	28
T3	10(1)	2	0	0	1	0	0	0	0	0	0	13
T4	1	0	0	1(1)	0	1	0	0	0	0	0	3
T4a	20(1)	7(1)	0	0	2	5	0	0	1	0	0	35
T4b	6(1)	2(1)	0	0	0	1	0	0	1	0	0	10
Tis	5	0	0	0	0	0	0	0	0	0	0	5
TX	1	0	0	0	0	0	0	0	0	1	0	2
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>91(3)</b>	<b>12(2)</b>	<b>0</b>	<b>2(1)</b>	<b>5</b>	<b>7</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>1</b>	<b>0</b>	<b>120</b>

M1:6 cases. Number in parenthesis indicates number of M1 cases  
T-: not within defined T classification or without reported T classification.  
N-: not within defined N classification or without reported N classification.

## Carcinoma of the Floor Mouth T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	2	1	0	0	0	0	0	0	0	0	0	3
T1	60	5	0	0	3	0	0	0	2	0	0	70
T2	71	4	0	1	13	2	0	0	2	2	0	95
T3	32	13	0	0	9	6	0	0	4	0	0	64
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	16(1)	7	0	1	15(2)	11	0	0	8(2)	0	0	58
T4b	3	0	0	0	0	1	0	0	1	0	0	5
Tis	10	0	0	0	0	0	0	0	0	0	0	10
TX	0	0	0	0	0	0	0	1	0	1	0	2
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>194(1)</b>	<b>30</b>	<b>0</b>	<b>2</b>	<b>40(2)</b>	<b>20</b>	<b>0</b>	<b>1</b>	<b>17(2)</b>	<b>3</b>	<b>0</b>	<b>307</b>

M1:5 cases. Number in parenthesis indicates number of M1 cases  
T-: not within defined T classification or without reported T classification.  
N-: not within defined N classification or without reported N classification.

## Carcinoma of the Tongue T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	4	0	0	0	0	0	0	0	0	0	0	4
T1	558	6	0	0	4	0	0	0	3	0	0	571
T2	532	69(1)	1	1	40	2	0	0	9	0	0	654
T3	255	68	2(1)	4	108(3)	28(3)	0	2	12	0	0	479
T4	2	2	0	0	3	0	0	0	1	0	0	8
T4a	56(1)	36	0	2	81(3)	62(4)	0	2(2)	23	3	0	265
T4b	3	0	0	0	6	0	1	0	3	0	0	13
Tis	77	0	0	0	0	0	0	0	0	0	0	77
TX	9	0	0	0	0	0	0	0	0	15(1)	0	24
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>1496(1)</b>	<b>181(1)</b>	<b>3(1)</b>	<b>7</b>	<b>242(6)</b>	<b>92(7)</b>	<b>1</b>	<b>4(2)</b>	<b>51</b>	<b>18(1)</b>	<b>0</b>	<b>2095</b>

M1:19 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Carcinoma of the Oral Cavity, NOS T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	2	0	0	0	0	0	0	0	0	0	0	2
T2	0	2	0	0	0	0	0	0	0	0	0	2
T3	1	0	0	0	0	0	0	0	0	0	0	1
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	9	0	0	0	2	0	0	0	0	0	0	11
T4b	2	0	0	0	0	0	0	0	0	0	0	2
Tis	0	0	0	0	0	0	0	0	0	0	0	0
TX	1	0	0	0	0	0	0	0	0	0	0	1
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>15</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>19</b>

NOS : Not Otherwise Specified

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

### Treatment Method for the Primary Lesion by Subsite

Treatment Method	1) Lip	2) Buccal mucosa	3) Retro-molar area	4) Lower gingiva	5) Upper gingiva	6) Hard palate	7) Floor of mouth	8) Tongue	9) Oral cavity, NOS	Total
<b>Surgery</b>										
without	7	44	12	82	98	30	46	178	5	502
with	42	224	56	512	267	90	255	1869	15	3330
unknown	0	10	0	6	8	1	7	52	0	84
<b>Radiotherapy</b>										
without	45	216	47	455	246	86	239	1725	14	3073
with	4	52	21	139	119	34	62	322	6	759
unknown	0	10	0	6	8	1	7	52	0	84
<b>Chemotherapy</b>										
without	46	217	48	458	271	98	242	1680	17	3077
with	3	51	20	136	94	22	59	367	3	755
unknown	0	10	0	6	8	1	7	52	0	84
<b>Total</b>	<b>49</b>	<b>278</b>	<b>68</b>	<b>600</b>	<b>373</b>	<b>121</b>	<b>308</b>	<b>2099</b>	<b>20</b>	<b>3916</b>

NOS: not otherwise specified.

### Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	1) Lip	2) Buccal mucosa	3) Retro-molar area	4) Lower gingiva	5) Upper gingiva	6) Hard palate	7) Floor of mouth	8) Tongue	9) Oral cavity, NOS	Total
<b>Surgery</b>										
without	37	171	31	222	237	96	159	1177	8	2138
with	12	97	37	372	128	24	142	869	12	1693
unknown	0	10	0	6	8	1	7	53	0	85
<b>Radiotherapy</b>										
without	45	224	52	484	287	106	246	1738	14	3196
with	4	44	16	110	78	14	55	308	6	635
unknown	0	10	0	6	8	1	7	53	0	85
<b>Chemotherapy</b>										
without	46	224	51	481	296	106	248	1711	16	3179
with	3	44	17	113	69	14	53	335	4	652
unknown	0	10	0	6	8	1	7	53	0	85
<b>Total</b>	<b>49</b>	<b>278</b>	<b>68</b>	<b>600</b>	<b>373</b>	<b>121</b>	<b>308</b>	<b>2099</b>	<b>20</b>	<b>3916</b>

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	1) Lip	2) Buccal mucosa	3) Retro-molar area	4) Lower gingiva	5) Upper gingiva	6) Hard palate	7) Floor of mouth	8) Tongue	9) Oral cavity, NOS	Total
No treatment	4	6	1	23	21	7	14	46	2	124
A) Surg. alone	40	183	40	367	197	69	200	1514	12	2622
A)F) Surg. -> (Rad.+Chem.)	0	8	8	30	20	2	16	101	1	186
C)A) Chem. -> Surg.	0	13	4	35	9	2	9	79	0	151
A)B) Surg. -> Rad.	0	12	1	29	21	11	16	56	1	147
B) Rad. alone	1	14	5	32	28	9	8	32	2	131
F) (Rad.+Chem.)	1	8	2	7	27	6	6	35	1	93
C) Chem. alone	0	9	1	11	13	2	10	25	0	71
C)A)F) Chem. -> Surg. -> (Rad.+Chem.)	0	4	0	10	2	1	3	21	0	41
A)C) Surg. -> Chem.	0	0	1	6	4	4	2	22	0	39
A)A) Surg. -> Surg.	0	2	0	3	0	0	2	13	0	20
C)A)B) Chem. -> Surg. -> Rad.	0	1	1	1	3	0	1	11	1	19
C)F) Chem. -> (Rad.+Chem.)	0	1	0	3	1	2	2	4	0	13
A)F)C) Surg. -> (Rad.+Chem.) -> Chem.	0	0	0	2	0	0	1	8	0	11
F)C) (Rad.+Chem.) -> Chem.	0	1	2	0	1	0	2	5	0	11
C)C) Chem. -> Chem.	1	2	0	1	0	1	1	4	0	10
A)B)C) Surg. -> Rad. -> Chem.	0	0	0	1	2	0	0	6	0	9
A)C)F) Surg. -> Chem. -> (Rad.+Chem.)	0	0	0	1	1	0	0	6	0	8
C)F)C) Chem. -> (Rad.+Chem.) -> Chem.	0	1	1	1	1	1	0	2	0	7
F)A) (Rad.+Chem.) -> Surg.	0	0	0	3	2	0	1	1	0	7
F)A)B) (Rad.+Chem.) -> Surg. -> Rad.	0	0	0	4	2	0	0	1	0	7
B)C) Rad. -> Chem.	0	0	0	3	0	1	2	0	0	6
C)B) Chem. -> Rad.	0	1	0	0	0	0	1	4	0	6
Other	2	2	1	21	10	2	4	51	0	93
Unknown	0	10	0	6	8	1	7	52	0	84
<b>Total</b>	<b>49</b>	<b>278</b>	<b>68</b>	<b>600</b>	<b>373</b>	<b>121</b>	<b>308</b>	<b>2099</b>	<b>20</b>	<b>3916</b>

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.  
 Treatment methods in parentheses were given concurrently.

Oral Cavity -----3916 Cases

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	1) Lip	2) Buccal mucosa	3) Retro-molar area	4) Lower gingiva	5) Upper gingiva	6) Hard palate	7) Floor of mouth	8) Tongue	9) Oral cavity, NOS	Total
No surgery	7	44	12	82	99	30	46	174	5	499
Partial glossectomy	0	0	0	1	2	0	0	1,296	0	1299
Segmental mandibulectomy	0	6	11	285	0	0	18	1	5	326
Partial maxillectomy	0	3	2	2	198	31	0	0	1	237
Subtotal glossectomy	0	0	0	0	0	0	10	224	0	234
Resection of the buccal mucosa	0	190	20	1	0	0	1	0	1	213
Resection of the floor of mouth	0	0	0	3	0	0	182	1	1	187
Marginal mandibulectomy	0	6	8	152	2	0	13	1	1	183
Hemiglossectomy (anterior 2/3rds)	0	0	0	0	1	0	3	122	0	126
Hemiglossectomy	0	0	1	0	0	0	4	119	0	124
Resection of oral cavity, NOS	1	6	12	4	21	48	15	0	2	109
Subtotal glossectomy (anterior 2/3rds)	0	0	0	0	0	0	4	54	0	58
Resection of the lip	40	9	0	0	0	0	0	0	0	49
Resection of lower gingiva	0	1	0	35	1	0	1	0	0	38
Total glossectomy	0	0	0	1	0	0	0	37	0	38
Total maxillectomy	1	0	0	0	29	3	0	0	0	33
Hemimandibulectomy	0	0	0	20	1	0	1	0	4	26
Others	0	3	2	8	11	8	3	15	0	50
Unknown	0	0	0	0	0	0	0	1	0	1
<b>Total</b>	<b>49</b>	<b>268</b>	<b>68</b>	<b>594</b>	<b>365</b>	<b>120</b>	<b>301</b>	<b>2045</b>	<b>20</b>	<b>3830</b>

Surgical Methods for the Primary Lesion Subsite was not reported in 86 patients.

NOS: not otherwise specified.

## Reconstructive Surgery by Subsite

Reconstructive surgery	1) Lip	2) Buccal mucosa	3) Retro-molar area	4) Lower gingiva	5) Upper gingiva	6) Hard palate	7) Floor of mouth	8) Tongue	9) Oral cavity, NOS	Total
No reconstruction	26	167	40	258	271	99	182	1469	10	2522
Free ALT flap	2	42	14	56	20	9	53	276	0	472
Free RA MC flap	0	8	4	59	28	1	25	131	4	260
Free fibular OC flap	0	2	2	118	4	3	4	1	4	138
Free FA flap	3	13	3	12	3	1	14	88	0	137
Skin graft	0	21	1	7	26	3	4	15	0	77
PM MC flap	0	2	1	23	1	1	6	27	0	61
Others	2	1	1	29	1	1	5	19	0	59
Local skin flap	15	7	0	6	6	0	5	7	0	46
Free scapular OC flap	0	1	1	24	1	0	3	0	2	32
Mucosal flap	1	4	1	1	4	2	0	2	0	15
Unknown	0	0	0	1	0	0	0	3	0	4
DP flap	0	0	0	0	0	0	0	1	0	1
Free jejunal flap	0	0	0	0	0	0	0	1	0	1
<b>Total</b>	<b>49</b>	<b>268</b>	<b>68</b>	<b>594</b>	<b>365</b>	<b>120</b>	<b>301</b>	<b>2040</b>	<b>20</b>	<b>3825</b>

Reconstructive Surgery Subsite was not reported in 91 patients.

NOS: not otherwise specified.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh. FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

### Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	1) Lip	2) Buccal mucosa	3) Retro-molar area	4) Lower gingiva	5) Upper gingiva	6) Hard palate	7) Floor of mouth	8) Tongue	9) Oral cavity, NOS	Total
0) No N.D.	37	172	32	223	236	96	158	1174	8	2136
1) Total N.D.	4	33	14	134	57	8	43	244	1	538
2) Selective N.D.	7	62	21	237	67	16	99	609	11	1129
3) Lymph node excision	0	0	1	0	1	0	0	7	0	9
8) Others	1	1	0	0	3	0	0	4	0	9
9) Unknown	0	0	0	0	1	0	1	6	0	8
<b>Total</b>	<b>49</b>	<b>268</b>	<b>68</b>	<b>594</b>	<b>365</b>	<b>120</b>	<b>301</b>	<b>2044</b>	<b>20</b>	<b>3829</b>

Neck Dissection on the Ipsilateral Side Subsite was not reported in 87 patients.

NOS: not otherwise specified.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	1) Lip	2) Buccal mucosa	3) Retro-molar area	4) Lower gingiva	5) Upper gingiva	6) Hard palate	7) Floor of mouth	8) Tongue	9) Oral cavity, NOS	Total
0) No N.D.	47	257	66	517	338	112	223	1745	18	3323
1) Total N.D.	0	1	0	11	4	3	10	36	0	65
2) Selective N.D.	2	7	2	66	19	5	64	246	2	413
3) Lymph node excision	0	1	0	0	0	0	0	2	0	3
8) Others	0	2	0	0	3	0	3	9	0	17
9) Unknown	0	0	0	0	1	0	1	6	0	8
<b>Total</b>	<b>49</b>	<b>268</b>	<b>68</b>	<b>594</b>	<b>365</b>	<b>120</b>	<b>301</b>	<b>2044</b>	<b>20</b>	<b>3829</b>

Neck Dissection on the Contralateral Side Subsite was not reported in 87 patients.

NOS: not otherwise specified.

N.D.: neck dissection.

Oral Cavity -----3916 Cases

## Radiotherapy by Subsite

Type of radiotherapy	1) Lip	2) Buccal mucosa	3) Retro-molar area	4) Lower gingiva	5) Upper gingiva	6) Hard palate	7) Floor of mouth	8) Tongue	9) Oral cavity, NOS	Total
0) No radiotherapy	41	208	45	443	240	84	234	1667	13	2975
1) X-ray (and/or electron beam)	5	56	22	144	121	30	64	353	7	802
2) Particle beam	0	0	1	2	3	5	0	3	0	14
3) B.T.	0	2	0	4	0	1	3	9	0	19
4) X-ray + Particle beam	2	0	0	0	0	0	0	0	0	2
5) X-ray + B.T.	0	1	0	0	0	0	0	1	0	2
8) Others	0	1	0	0	0	0	0	2	0	3
9) Unknown	1	0	0	1	1	0	0	3	0	6
<b>Total</b>	<b>49</b>	<b>268</b>	<b>68</b>	<b>594</b>	<b>365</b>	<b>120</b>	<b>301</b>	<b>2038</b>	<b>20</b>	<b>3823</b>

Radiotherapy Subsite was not reported in 93 patients.

NOS: not otherwise specified.

B.T.: brachytherapy.

## Chemotherapy by Subsite

Route of administration	1) Lip	2) Buccal mucosa	3) Retro-molar area	4) Lower gingiva	5) Upper gingiva	6) Hard palate	7) Floor of mouth	8) Tongue	9) Oral cavity, NOS	Total
0) No chemotherapy	44	214	48	453	261	98	235	1629	16	2998
1) I.V.	4	41	17	118	71	17	56	321	3	648
2) I.A.	0	5	0	2	21	4	1	18	1	52
3) Oral	0	6	3	14	2	1	5	42	0	73
4) I.V.+I.A.	0	1	0	0	3	0	0	10	0	14
5) I.V.+Oral	0	1	0	4	0	0	1	4	0	10
6) I.A.+Oral	0	0	0	0	1	0	0	1	0	2
9) Unknown	1	0	0	0	1	0	0	3	0	5
<b>Total</b>	<b>49</b>	<b>268</b>	<b>68</b>	<b>591</b>	<b>360</b>	<b>120</b>	<b>298</b>	<b>2028</b>	<b>20</b>	<b>3802</b>

Chemotherapy Subsite was not reported in 114 patients.

NOS: not otherwise specified.

I.V.: intravenous. I.A.: intraarterial.

# Larynx(2022)

2220 Cases

## Primary Site

Subsite	Number of patients	(%)
Glottis	1554	(70.0)
Supraglottis	550	(24.8)
Subglottis	88	(4.0)
Larynx, NOS	28	(1.3)
<b>Total</b>	<b>2220</b>	<b>(100.0)</b>

NOS: not otherwise specified

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	4	0	4
10 - 19	0	0	0
20 - 29	1	0	1
30 - 39	1	1	2
40 - 49	34	7	41
50 - 59	175	22	197
60 - 69	466	37	503
70 - 79	935	80	1,015
80 - 89	391	31	422
90 - 99	30	5	35
100 - 109	0	0	0
<b>Total</b>	<b>2,037</b>	<b>183</b>	<b>2,220</b>

## Glottis

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	3	0	3
10 - 19	0	0	0
20 - 29	1	0	1
30 - 39	1	1	2
40 - 49	24	3	27
50 - 59	123	8	131
60 - 69	332	14	346
70 - 79	646	49	695
80 - 89	302	22	324
90 - 99	22	3	25
100 - 109	0	0	0
<b>Total</b>	<b>1,454</b>	<b>100</b>	<b>1,554</b>

## Supraglottis

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	1	0	1
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	9	4	13
50 - 59	43	12	55
60 - 69	115	21	136
70 - 79	235	26	261
80 - 89	70	6	76
90 - 99	6	2	8
100 - 109	0	0	0
<b>Total</b>	<b>479</b>	<b>71</b>	<b>550</b>

## Subglottis

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	1	0	1
50 - 59	6	1	7
60 - 69	15	1	16
70 - 79	42	4	46
80 - 89	15	1	16
90 - 99	2	0	2
100 - 109	0	0	0
<b>Total</b>	<b>81</b>	<b>7</b>	<b>88</b>

## Carcinoma of the Larynx, NOS

### Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	0	0	0
50 - 59	3	1	4
60 - 69	4	1	5
70 - 79	12	1	13
80 - 89	4	2	6
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>23</b>	<b>5</b>	<b>28</b>

## Histological Distribution by Subsite

Histologic type	Glottis (C32.0)	Supraglottis (C10.1, C32.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
S.C.C., NOS	1430	483	79	22	2014
S.C.C., kerat., NOS	40	22	5	1	68
S.C.C. in situ, NOS	49	14	0	1	64
Ca., NOS	6	2	1	0	9
S.C.C., large cell, nonkerat., NOS	1	6	0	0	7
Small cell ca., NOS	3	4	0	0	7
Spindle cell ca., NOS	6	1	0	0	7
S.C.C., spindle cell	5	0	1	0	6
Chondrosarcoma, NOS	0	0	1	3	4
Papillary S.C.C.	3	1	0	0	4
Adenoid cystic ca.	0	2	1	0	3
Adenosquamous ca.	3	0	0	0	3
Basaloid S.C.C.	1	2	0	0	3
Carcinoid tumor, NOS	0	3	0	0	3
Lymphoepithelial ca.	0	2	0	0	2
Neoplasm, malig.	1	1	0	0	2
Neuroendocrine ca., NOS	0	2	0	0	2
S.C.C. in situ with quest. stromal invasion	1	0	0	1	2
Verrucous ca., NOS	2	0	0	0	2
ca. ex pleomorphic adenoma	1	0	0	0	1
ca., undiff., NOS	0	1	0	0	1
Leiomyosarcoma, NOS	0	1	0	0	1
Malig. fibrous histiocytoma	1	0	0	0	1
Malig. melanoma, NOS	0	1	0	0	1
Mucinous adenocarcinoma	0	1	0	0	1
Plasmacytoma, NOS	0	1	0	0	1
S.C.C., microinvasive	1	0	0	0	1
<b>Total</b>	<b>1554</b>	<b>550</b>	<b>88</b>	<b>28</b>	<b>2220</b>

NOS: not otherwise specified.

Ca., ca.: carcinoma.

S.C.C.: squamous cell carcinoma.

Malig., malig.: malignant.

undiff.: undifferentiated.

quest.: questionable.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	9	0	0	0	0	0	0	0	0	0	0	9
T1	177	3	1	0	7	6	0	0	4(3)	1	0	199
T1a	552	0	0	0	3	0	0	0	2	3	0	560
T1b	174	1	0	0	1	0	0	0	1	1	0	178
T2	432	29	1	1	20(1)	22(1)	0	0	14(2)	1	0	520
T3	290(1)	42(1)	0	3	41(2)	28(4)	0	0	7	0	0	411
T4	5	2	0	0	2	0	0	0	0	0	0	9
T4a	125(1)	27(3)	0	5	29	32(9)	3	0	22	2	0	245
T4b	0	0	0	0	0	0	0	0	2(1)	0	0	2
Tis	71	0	0	0	0	0	0	0	0	2	0	73
TX	4	0	0	0	0	0	0	0	0	6	0	10
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>1839(2)</b>	<b>104(4)</b>	<b>2</b>	<b>9</b>	<b>103(3)</b>	<b>88(14)</b>	<b>3</b>	<b>0</b>	<b>52(6)</b>	<b>16</b>	<b>0</b>	<b>2216</b>

T and N Status was not reported in 4 patients.

M1:29 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Glottis T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	7	0	0	0	0	0	0	0	0	0	0	7
T1	66	0	0	0	0	0	0	0	0	0	0	66
T1a	547	0	0	0	3	0	0	0	2	3	0	555
T1b	170	1	0	0	1	0	0	0	1	1	0	174
T2	317	4	0	0	1	2	0	0	1	1	0	326
T3	214	19	0	1	10(1)	1	0	0	1	0	0	246
T4	3	0	0	0	1	0	0	0	0	0	0	4
T4a	72	15(3)	0	2	11	9(4)	0	0	9	1	0	119
T4b	0	0	0	0	0	0	0	0	0	0	0	0
Tis	46	0	0	0	0	0	0	0	0	2	0	48
TX	3	0	0	0	0	0	0	0	0	5	0	8
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>1445</b>	<b>39(3)</b>	<b>0</b>	<b>3</b>	<b>27(1)</b>	<b>12(4)</b>	<b>0</b>	<b>0</b>	<b>14</b>	<b>13</b>	<b>0</b>	<b>1553</b>

T and N Status was not reported in a patient.

M1:8 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Supraglottis T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	1	0	0	0	0	0	0	0	0	0	0	1
T1	98	3	1	0	7	6	0	0	4(3)	1	0	120
T1a	2	0	0	0	0	0	0	0	0	0	0	2
T1b	4	0	0	0	0	0	0	0	0	0	0	4
T2	91	24	1	1	19(1)	19(1)	0	0	12(2)	0	0	167
T3	61(1)	22(1)	0	1	31(1)	25(3)	0	0	5	0	0	145
T4	0	1	0	0	1	0	0	0	0	0	0	2
T4a	15(1)	10	0	3	16	18(4)	3	0	13	1	0	79
T4b	0	0	0	0	0	0	0	0	2(1)	0	0	2
Tis	24	0	0	0	0	0	0	0	0	0	0	24
TX	1	0	0	0	0	0	0	0	0	1	0	2
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>297(2)</b>	<b>60(1)</b>	<b>2</b>	<b>5</b>	<b>74(2)</b>	<b>68(8)</b>	<b>3</b>	<b>0</b>	<b>36(6)</b>	<b>3</b>	<b>0</b>	<b>548</b>

T and N Status was not reported in 2 patients.

M1:19 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Subglottis T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	1	0	0	0	0	0	0	0	0	0	0	1
T1	9	0	0	0	0	0	0	0	0	0	0	9
T1a	1	0	0	0	0	0	0	0	0	0	0	1
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	19	1	0	0	0	1	0	0	0	0	0	21
T3	14	1	0	0	0	1	0	0	1	0	0	17
T4	2	0	0	0	0	0	0	0	0	0	0	2
T4a	29	2	0	0	1	4(1)	0	0	0	0	0	36
T4b	0	0	0	0	0	0	0	0	0	0	0	0
Tis	0	0	0	0	0	0	0	0	0	0	0	0
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>75</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>6(1)</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>87</b>

T and N Status was not reported in a patient.

M1:1 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Carcinoma of the Larynx, NOS

### T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	4	0	0	0	0	0	0	0	0	0	0	4
T1a	2	0	0	0	0	0	0	0	0	0	0	2
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	5	0	0	0	0	0	0	0	1	0	0	6
T3	1	0	0	1	0	1(1)	0	0	0	0	0	3
T4	0	1	0	0	0	0	0	0	0	0	0	1
T4a	9	0	0	0	1	1	0	0	0	0	0	11
T4b	0	0	0	0	0	0	0	0	0	0	0	0
Tis	1	0	0	0	0	0	0	0	0	0	0	1
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>22</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>1</b>	<b>2(1)</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>28</b>

M1:1 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Glottis (C32.0)	Supraglottis (C10.1) (C32.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
<b>Surgery</b>					
without	1030	307	38	11	1386
with	508	242	48	17	815
unknown	16	1	2	0	19
<b>Radiotherapy</b>					
without	470	227	40	19	756
with	1068	322	46	9	1445
unknown	16	1	2	0	19
<b>Chemotherapy</b>					
without	1280	324	61	20	1685
with	258	225	25	8	516
unknown	16	1	2	0	19
<b>Total</b>	1554	550	88	28	2220

NOS : Not Otherwise Specified

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Glottis (C32.0)	Supraglottis (C10.1) (C32.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
No treatment	34	12	2	2	50
B) Rad. alone	765	107	16	4	892
A) Surg. alone	413	179	35	14	641
F) (Rad.+Chem.)	210	139	17	2	368
A)B) Surg. -> Rad.	52	17	5	0	74
A)F) Surg. -> (Rad.+Chem.)	13	16	1	1	31
C)A) Chem. -> Surg.	8	12	2	2	24
C)F) Chem. -> (Rad.+Chem.)	4	14	2	0	20
C) Chem. alone	6	12	0	1	19
C)B) Chem. -> Rad.	5	6	0	1	12
B)A) Rad. -> Surg.	6	3	1	0	10
A)A) Surg. -> Surg.	6	1	1	0	8
F)C) (Rad.+Chem.) -> Chem.	1	5	0	1	7
Other	15	26	4	0	45
Unknown	16	1	2	0	19
<b>Total</b>	<b>1554</b>	<b>550</b>	<b>88</b>	<b>28</b>	<b>2220</b>

NOS : Not Otherwise Specified

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Treatment Method for the Primary Lesion by T Classification

<b>Treatment Method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
<b>Surgery</b>													
without	4	109	382	162	416	221	2	63	2	21	3	0	1385
with	5	90	175	15	102	187	7	177	0	52	5	0	815
unknown	0	0	3	1	2	3	0	5	0	0	2	0	16
<b>Radiotherapy</b>													
without	7	89	157	6	91	184	6	154	1	54	7	0	756
with	2	110	400	171	427	224	3	86	1	19	1	0	1444
unknown	0	0	3	1	2	3	0	5	0	0	2	0	16
<b>Chemotherapy</b>													
without	9	173	544	164	307	236	8	162	2	71	8	0	1684
with	0	26	13	13	211	172	1	78	0	2	0	0	516
unknown	0	0	3	1	2	3	0	5	0	0	2	0	16
<b>Total</b>	<b>9</b>	<b>199</b>	<b>560</b>	<b>178</b>	<b>520</b>	<b>411</b>	<b>9</b>	<b>245</b>	<b>2</b>	<b>73</b>	<b>10</b>	<b>0</b>	<b>2216</b>

Treatment Method for the Primary Lesion by T Classification was not reported in 4 patients.  
T-: not within defined T classification or without reported T classification

## Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	2	4	4	1	8	12	0	13	1	3	2	0	50
B) Rad. alone	2	83	367	149	208	54	1	9	1	16	1	0	891
A) Surg. alone	5	78	149	5	70	156	6	117	0	50	5	0	641
F) (Rad.+Chem.)	0	17	9	12	178	132	1	18	0	1	0	0	368
A)B) Surg. -> Rad.	0	6	20	7	13	8	1	17	0	2	0	0	74
A)F) Surg. -> (Rad.+Chem.)	0	2	1	1	3	5	0	19	0	0	0	0	31
C)A) Chem. -> Surg.	0	2	0	0	4	7	0	11	0	0	0	0	24
C)F) Chem. -> (Rad.+Chem.)	0	1	0	0	6	8	0	5	0	0	0	0	20
C) Chem. alone	0	2	2	0	7	2	0	6	0	0	0	0	19
C)B) Chem. -> Rad.	0	0	0	0	5	6	0	1	0	0	0	0	12
B)A) Rad. -> Surg.	0	1	2	1	5	1	0	0	0	0	0	0	10
A)A) Surg. -> Surg.	0	1	2	0	2	2	0	1	0	0	0	0	8
F)C) (Rad.+Chem.) -> Chem.	0	0	0	0	2	2	0	3	0	0	0	0	7
Other	0	2	1	1	7	13	0	20	0	1	0	0	45
Unknown	0	0	3	1	2	3	0	5	0	0	2	0	16
<b>Total</b>	<b>9</b>	<b>199</b>	<b>560</b>	<b>178</b>	<b>520</b>	<b>411</b>	<b>9</b>	<b>245</b>	<b>2</b>	<b>73</b>	<b>10</b>	<b>0</b>	<b>2216</b>

Treatment Method for the Primary Lesion by T Classification was not reported in 4 patients.

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Glottis

### Treatment Method for the Primary Lesion by T Classification

<b>Treatment Method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
<b>Surgery</b>													
without	3	40	378	158	273	140	0	20	0	16	2	0	1030
with	4	26	174	15	51	103	4	95	0	32	4	0	508
unknown	0	0	3	1	2	3	0	4	0	0	2	0	15
<b>Radiotherapy</b>													
without	6	27	156	6	42	107	4	84	0	33	5	0	470
with	1	39	396	167	282	136	0	31	0	15	1	0	1068
unknown	0	0	3	1	2	3	0	4	0	0	2	0	15
<b>Chemotherapy</b>													
without	7	62	539	160	220	146	4	88	0	48	6	0	1280
with	0	4	13	13	104	97	0	27	0	0	0	0	258
unknown	0	0	3	1	2	3	0	4	0	0	2	0	15
<b>Total</b>	<b>7</b>	<b>66</b>	<b>555</b>	<b>174</b>	<b>326</b>	<b>246</b>	<b>4</b>	<b>119</b>	<b>0</b>	<b>48</b>	<b>8</b>	<b>0</b>	<b>1553</b>

Treatment Method for the Primary Lesion by T Classification was not reported in a patient.

T-: not within defined T classification or without reported T classification

**Glottis**  
**Sequence of Treatment Methods for the Primary Lesion**  
**by T Classification**

<b>Sequence of treatment methods</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
No treatment	2	2	4	1	7	6	0	8	0	3	1	0	34
B) Rad. alone	1	34	363	145	167	39	0	2	0	13	1	0	765
A) Surg. alone	4	24	148	5	31	96	4	67	0	30	4	0	413
F) (Rad.+Chem.)	0	4	9	12	96	86	0	3	0	0	0	0	210
A)B) Surg. -> Rad.	0	1	20	7	10	2	0	10	0	2	0	0	52
Other	0	1	8	3	13	14	0	25	0	0	0	0	64
Unknown	0	0	3	1	2	3	0	4	0	0	2	0	15
<b>Total</b>	<b>7</b>	<b>66</b>	<b>555</b>	<b>174</b>	<b>326</b>	<b>246</b>	<b>4</b>	<b>119</b>	<b>0</b>	<b>48</b>	<b>8</b>	<b>0</b>	<b>1553</b>

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in a patient.

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Supraglottis

### Treatment Method for the Primary Lesion by T Classification

<b>Treatment Method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
<b>Surgery</b>													
without	0	62	2	4	123	72	1	34	2	5	1	0	306
with	1	58	0	0	44	73	1	45	0	19	1	0	242
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Radiotherapy</b>													
without	1	57	0	0	43	67	0	36	1	20	2	0	227
with	0	63	2	4	124	78	2	43	1	4	0	0	321
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Chemotherapy</b>													
without	1	99	2	4	72	76	2	41	2	22	2	0	323
with	0	21	0	0	95	69	0	38	0	2	0	0	225
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>1</b>	<b>120</b>	<b>2</b>	<b>4</b>	<b>167</b>	<b>145</b>	<b>2</b>	<b>79</b>	<b>2</b>	<b>24</b>	<b>2</b>	<b>0</b>	<b>548</b>

Treatment Method for the Primary Lesion by T Classification was not reported in 2 patients.

T-: not within defined T classification or without reported T classification

## Supraglottis

### Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	2	0	0	1	5	0	2	1	0	1	0	12
A) Surg. alone	1	49	0	0	34	51	0	24	0	19	1	0	179
F) (Rad.+Chem.)	0	12	0	0	71	43	0	12	0	1	0	0	139
B) Rad. alone	0	43	2	4	33	12	1	7	1	3	0	0	106
A)B) Surg. -> Rad.	0	4	0	0	2	6	1	4	0	0	0	0	17
A)F) Surg. -> (Rad.+Chem.)	0	2	0	0	1	5	0	8	0	0	0	0	16
Other	0	8	0	0	25	23	0	22	0	1	0	0	79
Unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>1</b>	<b>120</b>	<b>2</b>	<b>4</b>	<b>167</b>	<b>145</b>	<b>2</b>	<b>79</b>	<b>2</b>	<b>24</b>	<b>2</b>	<b>0</b>	<b>548</b>

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in 2 patients.

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Subglottis

### Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
<b>Surgery</b>													
without	1	6	1	0	15	7	1	7	0	0	0	0	38
with	0	3	0	0	6	10	1	28	0	0	0	0	48
unknown	0	0	0	0	0	0	0	1	0	0	0	0	1
<b>Radiotherapy</b>													
without	0	2	0	0	4	8	1	25	0	0	0	0	40
with	1	7	1	0	17	9	1	10	0	0	0	0	46
unknown	0	0	0	0	0	0	0	1	0	0	0	0	1
<b>Chemotherapy</b>													
without	1	8	1	0	12	12	1	26	0	0	0	0	61
with	0	1	0	0	9	5	1	9	0	0	0	0	25
unknown	0	0	0	0	0	0	0	1	0	0	0	0	1
<b>Total</b>	1	9	1	0	21	17	2	36	0	0	0	0	87

Treatment Method for the Primary Lesion by T Classification was not reported in a patient.

T-: not within defined T classification or without reported T classification

## Subglottis

### Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	0	0	0	0	0	0	2	0	0	0	0	2
A) Surg. alone	0	2	0	0	4	8	1	20	0	0	0	0	35
F) (Rad.+Chem.)	0	1	0	0	9	3	1	3	0	0	0	0	17
B) Rad. alone	1	5	1	0	6	3	0	0	0	0	0	0	16
Other	0	1	0	0	2	3	0	10	0	0	0	0	16
Unknown	0	0	0	0	0	0	0	1	0	0	0	0	1
<b>Total</b>	<b>1</b>	<b>9</b>	<b>1</b>	<b>0</b>	<b>21</b>	<b>17</b>	<b>2</b>	<b>36</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>87</b>

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in a patient.

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Carcinoma of the Larynx, NOS Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
<b>Surgery</b>													
without	0	1	1	0	5	2	0	2	0	0	0	0	11
with	0	3	1	0	1	1	1	9	0	1	0	0	17
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Radiotherapy</b>													
without	0	3	1	0	2	2	1	9	0	1	0	0	19
with	0	1	1	0	4	1	0	2	0	0	0	0	9
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Chemotherapy</b>													
without	0	4	2	0	3	2	1	7	0	1	0	0	20
with	0	0	0	0	3	1	0	4	0	0	0	0	8
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	0	4	2	0	6	3	1	11	0	1	0	0	28

NOS : Not Otherwise Specified

T-: not within defined T classification or without reported T classification

**Carcinoma of the Larynx, NOS**  
**Sequence of Treatment Methods for the Primary Lesion**  
**by T Classification**

<b>Sequence of treatment methods</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
No treatment	0	0	0	0	0	1	0	1	0	0	0	0	2
A) Surg. alone	0	3	1	0	1	1	1	6	0	1	0	0	14
Other	0	1	1	0	5	1	0	4	0	0	0	0	12
<b>Total</b>	<b>0</b>	<b>4</b>	<b>2</b>	<b>0</b>	<b>6</b>	<b>3</b>	<b>1</b>	<b>11</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>28</b>

NOS : Not Otherwise Specified

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Glottis (C32.0)	Supraglottis (C10.1) ( C32.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
No surgery	1021	304	38	9	1372
Total laryngectomy	213	114	40	11	378
Transoral resection	225	68	1	3	297
Endoscopic resection	44	23	1	2	70
Others	26	36	6	1	69
<b>Total</b>	<b>1529</b>	<b>545</b>	<b>86</b>	<b>26</b>	<b>2186</b>

Surgical Methods for the Primary Lesion Subsite was not reported in 34 patients.  
NOS: not otherwise specified.

## Surgical Methods for the Primary Lesion by T Classification

<b>Surgical method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
No surgery	4	109	380	158	411	219	2	63	2	21	3	0	1372
Total laryngectomy	0	6	1	0	40	166	7	158	0	0	0	0	378
Transoral resection	5	61	143	12	33	3	0	1	0	35	4	0	297
Endoscopic resection	0	15	23	3	13	0	0	0	0	15	1	0	70
Partial laryngectomy	0	2	4	0	7	2	0	1	0	0	0	0	16
Others	0	6	4	0	9	16	0	16	0	2	0	0	53
<b>Total</b>	<b>9</b>	<b>199</b>	<b>555</b>	<b>173</b>	<b>513</b>	<b>406</b>	<b>9</b>	<b>239</b>	<b>2</b>	<b>73</b>	<b>8</b>	<b>0</b>	<b>2186</b>

Surgical Methods for the Primary Lesion by T Classification was not reported in 34 patients.

NOS: not otherwise specified.

T-: not within defined T classification or without reported T classification

## Glottis

### Surgical Methods for the Primary Lesion by T Classification

<b>Surgical method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
No surgery	3	40	377	154	270	139	0	20	0	16	2	0	1021
Transoral resection	4	20	142	12	17	1	0	1	0	25	3	0	225
Total laryngectomy	0	1	1	0	19	97	4	91	0	0	0	0	213
Endoscopic resection	0	4	23	3	7	0	0	0	0	6	1	0	44
Partial laryngectomy	0	0	4	0	4	1	0	0	0	0	0	0	9
Laryngectomy, other type	0	1	3	0	2	0	0	0	0	1	0	0	7
Total laryngectomy+Partial pharyngectomy	0	0	0	0	1	2	0	1	0	0	0	0	4
Total pharyngolaryngectomy	0	0	0	0	0	1	0	1	0	0	0	0	2
Subtotal laryngectomy	0	0	0	0	0	1	0	0	0	0	0	0	1
Total pharyngolaryngo-esophagectomy	0	0	0	0	0	0	0	1	0	0	0	0	1
Others	0	0	1	0	1	0	0	0	0	0	0	0	2
<b>Total</b>	<b>7</b>	<b>66</b>	<b>551</b>	<b>169</b>	<b>321</b>	<b>242</b>	<b>4</b>	<b>115</b>	<b>0</b>	<b>48</b>	<b>6</b>	<b>0</b>	<b>1529</b>

Surgical Methods for the Primary Lesion by T Classification was not reported in a patient.

T-: not within defined T classification or without reported T classification

## Supraglottis

### Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	0	62	2	4	122	71	1	34	2	5	1	0	304
Total laryngectomy	0	5	0	0	16	59	1	33	0	0	0	0	114
Transoral resection	1	39	0	0	15	2	0	0	0	10	1	0	68
Endoscopic resection	0	9	0	0	6	0	0	0	0	8	0	0	23
Total pharyngolaryngectomy	0	0	0	0	1	3	0	6	0	0	0	0	10
Total pharyngolaryngo-esophagectomy	0	1	0	0	2	3	0	0	0	0	0	0	6
Partial laryngectomy	0	1	0	0	3	1	0	0	0	0	0	0	5
Total laryngectomy+Partial pharyngectomy	0	0	0	0	0	2	0	3	0	0	0	0	5
Laryngectomy, other type	0	1	0	0	0	1	0	1	0	0	0	0	3
Resection of the oropharynx, other type	0	2	0	0	0	0	0	0	0	0	0	0	2
Hypopharyngectomy + Cervical esophagectomy	0	0	0	0	0	1	0	0	0	0	0	0	1
Resection of the base of tongue and epiglottis	0	0	0	0	0	0	0	0	0	1	0	0	1
Others	0	0	0	0	1	1	0	1	0	0	0	0	3
<b>Total</b>	<b>1</b>	<b>120</b>	<b>2</b>	<b>4</b>	<b>166</b>	<b>144</b>	<b>2</b>	<b>78</b>	<b>2</b>	<b>24</b>	<b>2</b>	<b>0</b>	<b>545</b>

Surgical Methods for the Primary Lesion by T Classification was not reported in 5 patients.

T-: not within defined T classification or without reported T classification

## Subglottis

### Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	1	6	1	0	15	7	1	7	0	0	0	0	38
Total laryngectomy	0	0	0	0	5	9	1	25	0	0	0	0	40
Partial laryngectomy	0	1	0	0	0	0	0	1	0	0	0	0	2
Endoscopic resection	0	1	0	0	0	0	0	0	0	0	0	0	1
Partial hypopharyngectomy	0	0	0	0	0	0	0	1	0	0	0	0	1
Total laryngectomy+Partial pharyngectomy	0	0	0	0	1	0	0	0	0	0	0	0	1
Total pharyngolaryngectomy	0	0	0	0	0	1	0	0	0	0	0	0	1
Total pharyngolaryngo-esophagectomy	0	0	0	0	0	0	0	1	0	0	0	0	1
Transoral resection	0	1	0	0	0	0	0	0	0	0	0	0	1
<b>Total</b>	<b>1</b>	<b>9</b>	<b>1</b>	<b>0</b>	<b>21</b>	<b>17</b>	<b>2</b>	<b>35</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>86</b>

Surgical Methods for the Primary Lesion by T Classification was not reported in 2 patients.

T-: not within defined T classification or without reported T classification

## Carcinoma of the Larynx, NOS Surgical Methods for the Primary Lesion by T Classification

<b>Surgical method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
No surgery	0	1	0	0	4	2	0	2	0	0	0	0	9
Total laryngectomy	0	0	0	0	0	1	1	9	0	0	0	0	11
Transoral resection	0	1	1	0	1	0	0	0	0	0	0	0	3
Endoscopic resection	0	1	0	0	0	0	0	0	0	1	0	0	2
Laryngectomy, other type	0	1	0	0	0	0	0	0	0	0	0	0	1
<b>Total</b>	<b>0</b>	<b>4</b>	<b>1</b>	<b>0</b>	<b>5</b>	<b>3</b>	<b>1</b>	<b>11</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>0</b>	<b>26</b>

Surgical Methods for the Primary Lesion by T Classification was not reported in 2 patients.

NOS: not otherwise specified.

T-: not within defined T classification or without reported T classification

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Glottis (C32.0)	Supraglottis (C10.1) (C32.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
<b>Surgery</b>					
without	1356	395	50	19	1820
with	179	153	36	9	377
unknown	19	2	2	0	23
<b>Radiotherapy</b>					
without	1328	336	64	23	1751
with	207	212	22	5	446
unknown	19	2	2	0	23
<b>Chemotherapy</b>					
without	1420	373	69	23	1885
with	115	175	17	5	312
unknown	19	2	2	0	23
Total	1554	550	88	28	2220

NOS: not otherwise specified.

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Glottis (C32.0)	Supraglottis (C10.1) (C32.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No N.D.	1349	392	50	17	1808
1) Total N.D.	27	35	4	2	68
2) Selective N.D.	141	112	32	6	291
3) Lymph node excision	1	0	0	0	1
8) Others	7	4	0	1	12
9) Unknown	4	2	0	0	6
<b>Total</b>	<b>1529</b>	<b>545</b>	<b>86</b>	<b>26</b>	<b>2186</b>

Neck Dissection on the Ipsilateral Side Subsite was not reported in 34 patients.

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Glottis (C32.0)	Supraglottis (C10.1) (C32.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No N.D.	1416	441	62	20	1939
1) Total N.D.	13	17	0	2	32
2) Selective N.D.	90	80	24	3	197
8) Others	6	5	0	1	12
9) Unknown	4	2	0	0	6
<b>Total</b>	<b>1529</b>	<b>545</b>	<b>86</b>	<b>26</b>	<b>2186</b>

Neck Dissection on the Contralateral Side Subsite was not reported in 34 patients.

NOS: not otherwise specified.

N.D.: neck dissection.

## Reconstructive Surgery by Subsite

Reconstructive surgery	Glottis (C32.0)	Supraglottis (C10.1) (C32.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
No reconstruction	1508	499	81	24	2112
Free jejunal flap	3	21	2	0	26
PM MC flap	3	14	0	0	17
Free ALT flap	2	6	1	1	10
DP flap	1	0	1	0	2
Gastric pull-up	0	2	0	0	2
Others	1	0	1	0	2
Skin graft	2	0	0	0	2
Free RA MC flap	0	1	0	0	1
Local skin flap	1	0	0	0	1
Mucosal flap	0	0	0	1	1
<b>Total</b>	<b>1521</b>	<b>543</b>	<b>86</b>	<b>26</b>	<b>2176</b>

Reconstructive Surgery Subsite was not reported in 44 patients.

NOS: not otherwise specified.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh.

FA: forearm.

PM: pectoralis major.

OC: osteocutaneous. DP: deltopectoral.

## Radiotherapy by Subsite

Type of radiotherapy	Glottis (C32.0)	Supraglottis (C10.1) (C32.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No radiotherapy	458	215	39	19	731
1) X-ray (and/or electron beam)	1054	324	46	9	1433
2) Particle beam	0	1	0	0	1
4) X-ray + Particle beam	1	4	0	0	5
8) Others	0	1	1	0	2
9) Unknown	17	2	0	0	19
<b>Total</b>	<b>1530</b>	<b>547</b>	<b>86</b>	<b>28</b>	<b>2191</b>

Radiotherapy Subsite was not reported in 29 patients.

NOS: not otherwise specified.

B.T.: brachytherapy.

## Chemotherapy by Subsite

Route of administration	Glottis (C32.0)	Supraglottis (C10.1) (C32.1)	Subglottis (C32.2)	Larynx, NOS (C32.9)	Total
0) No chemotherapy	1256	318	60	20	1654
1) I.V.	233	217	23	5	478
2) I.A.	2	2	0	0	4
3) Oral	36	9	3	2	50
5) I.V.+Oral	1	1	0	1	3
<b>Total</b>	<b>1528</b>	<b>547</b>	<b>86</b>	<b>28</b>	<b>2189</b>

Chemotherapy Subsite was not reported in 31 patients.

NOS: not otherwise specified.

I.V.: intravenous. I.A.: intraarterial.

# Hypopharynx(2022)

3266 Cases

## Primary Site

Subsite	Number of patients	(%)
Postcricoid	330	(10.1)
Pyramidal sinus	2281	(69.8)
Posterior wall	497	(15.2)
Hypopharynx, NOS	158	(4.8)
<b>Total</b>	<b>3266</b>	<b>(100.0)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	2	0	2
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	4	3	7
40 - 49	53	27	80
50 - 59	313	68	381
60 - 69	904	63	967
70 - 79	1308	88	1396
80 - 89	381	31	412
90 - 99	20	1	21
100 - 109	0	0	0
<b>Total</b>	<b>2985</b>	<b>281</b>	<b>3266</b>

## Postcricoid Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	1	1	2
40 - 49	9	4	13
50 - 59	28	8	36
60 - 69	92	10	102
70 - 79	114	10	124
80 - 89	42	7	49
90 - 99	3	1	4
100 - 109	0	0	0
<b>Total</b>	<b>289</b>	<b>41</b>	<b>330</b>

## Pyriform sinus Age Distribution by Gender

Age	Male	Female	Total
0 - 9	2	0	2
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	3	2	5
40 - 49	37	18	55
50 - 59	226	45	271
60 - 69	630	37	667
70 - 79	928	59	987
80 - 89	266	14	280
90 - 99	14	0	14
100 - 109	0	0	0
<b>Total</b>	<b>2106</b>	<b>175</b>	<b>2281</b>

## Posterior wall Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	5	4	9
50 - 59	44	15	59
60 - 69	135	10	145
70 - 79	204	17	221
80 - 89	55	7	62
90 - 99	1	0	1
100 - 109	0	0	0
<b>Total</b>	<b>444</b>	<b>53</b>	<b>497</b>

## Hypopharynx, NOS Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	2	1	3
50 - 59	15	0	15
60 - 69	47	6	53
70 - 79	62	2	64
80 - 89	18	3	21
90 - 99	2	0	2
100 - 109	0	0	0
<b>Total</b>	<b>146</b>	<b>12</b>	<b>158</b>

## Histological Distribution by Subsite

Histologic type	Posterior wall (C13.2)	Pyriiform sinus (C12.9) (C13.1)	Hypopharynx, NOS (C13.9)	Total	
S.C.C., NOS	300	2029	435	151	2915
S.C.C. in situ, NOS	20	127	38	6	191
S.C.C., kerat., NOS	4	37	7	0	48
S.C.C., large cell, nonkerat., NOS	1	28	6	0	35
S.C.C., microinvasive	2	13	4	1	20
Ca., NOS	1	10	1	0	12
Basaloid S.C.C.	0	5	0	0	5
Neoplasm, malig.	0	4	1	0	5
S.C.C. in situ with quest. stromal invasion	0	5	0	0	5
Small cell ca., NOS	0	5	0	0	5
Papillary S.C.C.	0	3	1	0	4
S.C.C., spindle cell	0	3	1	0	4
Adenocarcinoma, NOS	0	1	1	0	2
Adenosquamous ca.	1	1	0	0	2
Lymphoepithelial ca.	1	1	0	0	2
S.C.C., small cell, nonkerat.	0	2	0	0	2
Spindle cell ca., NOS	0	2	0	0	2
Carcinosarcoma, NOS	0	0	1	0	1
Intraepithelial neoplasia, grade III	0	1	0	0	1
Myoepithelial ca.	0	1	0	0	1
Papillary S.C.C., non- invasive	0	1	0	0	1
S.C.C. with horn formation	0	1	0	0	1
Transitional cell ca., NOS	0	0	1	0	1
Tubular adenocarcinoma, NOS	0	1	0	0	1
<b>Total</b>	<b>330</b>	<b>2281</b>	<b>497</b>	<b>158</b>	<b>3266</b>

Ca., ca.: carcinoma.

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

Malig., malig.: malignant.

undiff.: undifferentiated.

quest.: questionable.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	2	0	0	0	0	2	0	0	1	0	0	5
T1	540(1)	27	0	4	23(1)	4	1(1)	1	33(3)	6	0	639
T1a	1	0	0	0	0	0	0	0	0	0	0	1
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	509(4)	123(2)	7	10(1)	195(3)	64(5)	2	2(1)	84(4)	0	0	996
T3	151(1)	64(2)	4(1)	6	120(7)	79(6)	2(1)	2(1)	69(20)	0	0	497
T4	4	1	1	0	8	3(1)	3(1)	0	1	0	0	21
T4a	91(6)	77(4)	1	3(1)	214(8)	131(23)	3	2	134(28)	1	0	657
T4b	14	4(3)	0	0	21(1)	21(7)	1	0	23(7)	0	0	84
Tis	341	0	0	0	0	0	0	0	0	2	0	343
TX	7	0	0	0	0	0	0	0	0	7	0	14
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>1660(12)</b>	<b>296(11)</b>	<b>13(1)</b>	<b>23(2)</b>	<b>581(20)</b>	<b>304(42)</b>	<b>12(3)</b>	<b>7(2)</b>	<b>345(62)</b>	<b>16</b>	<b>0</b>	<b>3257</b>

T and N Status was not reported in 9 patients.

M1:155 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Posterioricoid T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	56	4	0	2	4	0	0	0	2	0	0	68
T1a	1	0	0	0	0	0	0	0	0	0	0	1
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	48(1)	17	0	2(1)	11	20(2)	0	0	17(1)	0	0	115
T3	24(1)	11	1	1	15(1)	12	0	0	7(2)	0	0	71
T4	0	0	0	0	1	0	0	0	0	0	0	1
T4a	7(1)	5(1)	0	0	3(1)	13(1)	2	0	8(1)	0	0	38
T4b	0	0	0	0	0	3(1)	0	0	0	0	0	3
Tis	32	0	0	0	0	0	0	0	0	0	0	32
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>168(3)</b>	<b>37(1)</b>	<b>1</b>	<b>5(1)</b>	<b>34(2)</b>	<b>48(4)</b>	<b>2</b>	<b>0</b>	<b>34(4)</b>	<b>0</b>	<b>0</b>	<b>329</b>

T and N Status was not reported in a patient.

M1:15 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Pyriiform sinus T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	2	0	0	0	0	1	0	0	1	0	0	4
T1	360	19	0	1	18(1)	4	1(1)	1	27(3)	4	0	435
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	352(3)	86(1)	4	6	163(2)	27(3)	2	1(1)	58(1)	0	0	699
T3	88	37(1)	1	4	92(5)	43(4)	2(1)	0	47(12)	0	0	314
T4	3	1	1	0	7	3(1)	3(1)	0	1	0	0	19
T4a	71(3)	57(3)	1	3(1)	188(4)	90(15)	0	2	107(20)	1	0	520
T4b	6	2(1)	0	0	16	5	1	0	14(3)	0	0	44
Tis	230	0	0	0	0	0	0	0	0	1	0	231
TX	5	0	0	0	0	0	0	0	0	5	0	10
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>1117(6)</b>	<b>202(6)</b>	<b>7</b>	<b>14(1)</b>	<b>484(12)</b>	<b>173(23)</b>	<b>9(3)</b>	<b>4(1)</b>	<b>255(39)</b>	<b>11</b>	<b>0</b>	<b>2276</b>

T and N Status was not reported in 5 patients.

M1:91 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Posterior wall T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	1	0	0	0	0	0	1
T1	100(1)	4	0	1	1	0	0	0	4	2	0	112
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	87	18(1)	1	1	16(1)	14	0	0	6(1)	0	0	143
T3	33	13	1(1)	0	8	22(2)	0	1(1)	13(4)	0	0	91
T4	1	0	0	0	0	0	0	0	0	0	0	1
T4a	9(1)	9	0	0	11(1)	20(3)	0	0	9(3)	0	0	58
T4b	4	2(2)	0	0	5(1)	12(5)	0	0	6(3)	0	0	29
Tis	56	0	0	0	0	0	0	0	0	1	0	57
TX	2	0	0	0	0	0	0	0	0	2	0	4
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>292(2)</b>	<b>46(3)</b>	<b>2(1)</b>	<b>2</b>	<b>41(3)</b>	<b>69(10)</b>	<b>0</b>	<b>1(1)</b>	<b>38(11)</b>	<b>5</b>	<b>0</b>	<b>496</b>

T and N Status was not reported in a patient.

M1:31 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Hypopharynx, NOS T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	24	0	0	0	0	0	0	0	0	0	0	24
T1a	0	0	0	0	0	0	0	0	0	0	0	0
T1b	0	0	0	0	0	0	0	0	0	0	0	0
T2	22	2	2	1	5	3	0	1	3(1)	0	0	39
T3	6	3(1)	1	1	5(1)	2	0	1	2(2)	0	0	21
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	4(1)	6	0	0	12(2)	8(4)	1	0	10(4)	0	0	41
T4b	4	0	0	0	0	1(1)	0	0	3(1)	0	0	8
Tis	23	0	0	0	0	0	0	0	0	0	0	23
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	0	0
Total	83(1)	11(1)	3	2	22(3)	14(5)	1	2	18(8)	0	0	156

T and N Status was not reported in 2 patients.

M1:31 cases. Number in parenthesis indicates number of M1 cases

NOS : Not Otherwise Specified

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Treatment Method for the Primary Lesion by Subsite

<b>Treatment Method</b>	<b>Postcricoid (C13.0)</b>	<b>Pyriiform sinus (C12.9) (C13.1)</b>	<b>Posterior wall (C13.2)</b>	<b>Hypopharynx, NOS (C13.9)</b>	<b>Total</b>
<b>Surgery</b>					
without	175	1148	212	77	1612
with	154	1094	277	80	1605
unknown	1	39	8	1	49
<b>Radiotherapy</b>					
without	151	1037	270	91	1549
with	178	1205	219	66	1668
unknown	1	39	8	1	49
<b>Chemotherapy</b>					
without	174	1234	290	91	1789
with	155	1008	199	66	1428
unknown	1	39	8	1	49
<b>Total</b>	<b>330</b>	<b>2281</b>	<b>497</b>	<b>158</b>	<b>3266</b>

NOS: not otherwise specified.

## Treatment Method for the Cervical Lymph Nodes by Subsite

<b>Treatment Method</b>	<b>Postcricoid (C13.0)</b>	<b>Pyriiform sinus (C12.9) (C13.1)</b>	<b>Posterior wall (C13.2)</b>	<b>Hypopharynx, NOS (C13.9)</b>	<b>Total</b>
<b>Surgery</b>					
without	249	1660	376	119	2404
with	80	579	112	38	809
unknown	1	42	9	1	53
<b>Radiotherapy</b>					
without	187	1241	317	112	1857
with	142	998	171	45	1356
unknown	1	42	9	1	53
<b>Chemotherapy</b>					
without	196	1364	326	108	1994
with	133	875	162	49	1219
unknown	1	42	9	1	53
<b>Total</b>	<b>330</b>	<b>2281</b>	<b>497</b>	<b>158</b>	<b>3266</b>

NOS: not otherwise specified.

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Postericoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
No treatment	9	87	10	8	114
A) Surg. alone	111	776	213	66	1166
F) (Rad.+Chem.)	82	509	97	31	719
B) Rad. alone	37	280	45	13	375
C)F) Chem. -> (Rad.+Chem.)	18	101	17	4	140
C) Chem. alone	13	80	28	14	135
A)F) Surg. -> (Rad.+Chem.)	9	89	18	3	119
A)B) Surg. -> Rad.	12	68	17	2	99
C)A) Chem. -> Surg.	9	59	11	2	81
C)B) Chem. -> Rad.	6	33	3	2	44
C)A)F) Chem. -> Surg. -> (Rad.+Chem.)	2	28	4	0	34
C)A)B) Chem. -> Surg. -> Rad.	1	21	1	2	25
F)C) (Rad.+Chem.) -> Chem.	0	14	5	1	20
F)A) (Rad.+Chem.) -> Surg.	2	9	1	2	14
C)F)C) Chem. -> (Rad.+Chem.) -> Chem.	1	8	0	2	11
A)A) Surg. -> Surg.	1	8	1	0	10
B)C) Rad. -> Chem.	2	5	1	2	10
C)C) Chem. -> Chem.	1	8	1	0	10
A)C) Surg. -> Chem.	1	6	1	0	8
B)A) Rad. -> Surg.	1	5	1	1	8
C)F)A) Chem. -> (Rad.+Chem.) -> Surg.	1	3	2	1	7
C)C)C) Chem. -> Chem. -> Chem.	2	2	2	0	6
Other	8	43	10	1	62
Unknown	1	39	8	1	49
<b>Total</b>	<b>330</b>	<b>2281</b>	<b>497</b>	<b>158</b>	<b>3266</b>

NOS: not otherwise specified.

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Treatment Method for the Primary Lesion by T Classification

<b>Treatment Method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
<b>Surgery</b>													
without	2	209	0	0	673	309	11	298	78	26	5	0	1611
with	3	421	1	0	306	181	10	350	6	317	9	1	1605
unknown	0	11	0	0	17	7	0	9	0	0	0	0	44
<b>Radiotherapy</b>													
without	3	432	1	0	288	169	13	283	24	325	10	1	1549
with	2	198	0	0	691	321	8	365	60	18	4	0	1667
unknown	0	11	0	0	17	7	0	9	0	0	0	0	44
<b>Chemotherapy</b>													
without	4	512	1	0	415	199	10	280	26	328	12	1	1788
with	1	118	0	0	564	291	11	368	58	15	2	0	1428
unknown	0	11	0	0	17	7	0	9	0	0	0	0	44
<b>Total</b>	<b>5</b>	<b>641</b>	<b>1</b>	<b>0</b>	<b>996</b>	<b>497</b>	<b>21</b>	<b>657</b>	<b>84</b>	<b>343</b>	<b>14</b>	<b>1</b>	<b>3260</b>

Treatment Method for the Primary Lesion by T Classification was not reported in 6 patients.

T-: not within defined T classification or without reported T classification

## Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	12	0	0	19	22	2	44	11	4	0	0	114
A) Surg. alone	3	389	1	0	205	96	6	144	2	310	9	1	1166
F) (Rad.+Chem.)	1	66	0	0	396	140	3	85	22	5	1	0	719
B) Rad. alone	1	96	0	0	155	59	1	38	11	10	3	0	374
C)F) Chem. -> (Rad.+Chem.)	0	11	0	0	43	30	0	43	12	1	0	0	140
C) Chem. alone	0	15	0	0	31	32	3	39	9	5	1	0	135
A)F) Surg. -> (Rad.+Chem.)	0	7	0	0	25	28	1	58	0	0	0	0	119
A)B) Surg. -> Rad.	0	7	0	0	25	19	0	46	1	1	0	0	99
C)A) Chem. -> Surg.	0	5	0	0	23	11	1	38	1	2	0	0	81
C)B) Chem. -> Rad.	0	2	0	0	14	8	1	14	5	0	0	0	44
C)A)F) Chem. -> Surg. -> (Rad.+Chem.)	0	2	0	0	6	5	1	18	2	0	0	0	34
C)A)B) Chem. -> Surg. -> Rad.	0	0	0	0	3	4	0	18	0	0	0	0	25
F)C) (Rad.+Chem.) -> Chem.	0	0	0	0	5	6	1	6	2	0	0	0	20
F)A) (Rad.+Chem.) -> Surg.	0	1	0	0	3	3	0	7	0	0	0	0	14
C)F)C) Chem. -> (Rad.+Chem.) -> Chem.	0	1	0	0	0	3	0	5	2	0	0	0	11
A)A) Surg. -> Surg.	0	4	0	0	2	1	0	0	0	3	0	0	10
B)C) Rad. -> Chem.	0	0	0	0	0	4	0	5	1	0	0	0	10
C)C) Chem. -> Chem.	0	1	0	0	1	0	0	7	0	1	0	0	10
A)C) Surg. -> Chem.	0	2	0	0	1	3	0	2	0	0	0	0	8
B)A) Rad. -> Surg.	0	1	0	0	4	1	0	2	0	0	0	0	8

Hypopharynx -----3266Cases

<b>Sequence of treatment methods</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
C)F)A) Chem. -> (Rad.+Chem.) -> Surg.	0	0	0	0	4	2	0	1	0	0	0	0	7
C)C)C) Chem. -> Chem. -> Chem.	0	1	0	0	1	1	0	2	1	0	0	0	6
Other	0	7	0	0	13	12	1	26	2	1	0	0	62
Unknown	0	11	0	0	17	7	0	9	0	0	0	0	44
<b>Total</b>	<b>5</b>	<b>641</b>	<b>1</b>	<b>0</b>	<b>996</b>	<b>497</b>	<b>21</b>	<b>657</b>	<b>84</b>	<b>343</b>	<b>14</b>	<b>1</b>	<b>3260</b>

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in 6 patients.

T-: not within defined T classification or without reported T classification

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Postcricoid

### Treatment Method for the Primary Lesion by T Classification

Treatment Method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
<b>Surgery</b>													
without	0	22	0	0	88	43	1	16	3	2	0	0	175
with	0	46	1	0	27	28	0	22	0	30	0	0	154
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Radiotherapy</b>													
without	0	47	1	0	24	29	1	19	0	30	0	0	151
with	0	21	0	0	91	42	0	19	3	2	0	0	178
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Chemotherapy</b>													
without	0	53	1	0	42	32	1	14	0	31	0	0	174
with	0	15	0	0	73	39	0	24	3	1	0	0	155
unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>0</b>	<b>68</b>	<b>1</b>	<b>0</b>	<b>115</b>	<b>71</b>	<b>1</b>	<b>38</b>	<b>3</b>	<b>32</b>	<b>0</b>	<b>0</b>	<b>329</b>

Treatment Method for the Primary Lesion by T Classification was not reported in a patient.

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Postcricoid

### Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	0	0	0	2	3	1	3	0	0	0	0	9
A) Surg. alone	0	45	1	0	14	16	0	7	0	28	0	0	111
F) (Rad.+Chem.)	0	11	0	0	50	18	0	3	0	0	0	0	82
B) Rad. alone	0	7	0	0	18	9	0	1	0	2	0	0	37
C)F) Chem. -> (Rad.+Chem.)	0	2	0	0	6	5	0	4	1	0	0	0	18
Other	0	3	0	0	25	20	0	20	2	2	0	0	72
Unknown	0	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>0</b>	<b>68</b>	<b>1</b>	<b>0</b>	<b>115</b>	<b>71</b>	<b>1</b>	<b>38</b>	<b>3</b>	<b>32</b>	<b>0</b>	<b>0</b>	<b>329</b>

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in a patient.

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Pyriiform sinus

### Treatment Method for the Primary Lesion by T Classification

<b>Treatment Method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
<b>Surgery</b>													
without	1	156	0	0	487	194	10	234	40	22	3	0	1147
with	3	270	0	0	197	115	9	280	4	209	7	0	1094
unknown	0	10	0	0	15	5	0	6	0	0	0	0	36
<b>Radiotherapy</b>													
without	3	278	0	0	186	110	11	211	13	218	7	0	1037
with	1	148	0	0	498	199	8	303	31	13	3	0	1204
unknown	0	10	0	0	15	5	0	6	0	0	0	0	36
<b>Chemotherapy</b>													
without	4	343	0	0	283	134	8	219	15	218	9	0	1233
with	0	83	0	0	401	175	11	295	29	13	1	0	1008
unknown	0	10	0	0	15	5	0	6	0	0	0	0	36
<b>Total</b>	<b>4</b>	<b>436</b>	<b>0</b>	<b>0</b>	<b>699</b>	<b>314</b>	<b>19</b>	<b>520</b>	<b>44</b>	<b>231</b>	<b>10</b>	<b>0</b>	<b>2277</b>

Treatment Method for the Primary Lesion by T Classification was not reported in 4 patients.

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Pyriform sinus

### Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	11	0	0	13	16	1	34	8	4	0	0	87
A) Surg. alone	3	245	0	0	136	63	5	110	2	205	7	0	776
F) (Rad.+Chem.)	0	45	0	0	289	84	3	70	12	5	1	0	509
B) Rad. alone	1	75	0	0	116	41	1	32	5	6	2	0	279
C)F) Chem. -> (Rad.+Chem.)	0	7	0	0	35	18	0	35	5	1	0	0	101
A)F) Surg. -> (Rad.+Chem.)	0	4	0	0	17	18	1	49	0	0	0	0	89
C) Chem. alone	0	10	0	0	17	18	3	24	3	5	0	0	80
A)B) Surg. -> Rad.	0	6	0	0	12	12	0	37	0	1	0	0	68
C)A) Chem. -> Surg.	0	5	0	0	15	8	1	29	0	1	0	0	59
C)B) Chem. -> Rad.	0	2	0	0	8	6	1	12	4	0	0	0	33
C)A)F) Chem. -> Surg. -> (Rad.+Chem.)	0	2	0	0	5	2	1	16	2	0	0	0	28
C)A)B) Chem. -> Surg. -> Rad.	0	0	0	0	2	2	0	17	0	0	0	0	21
Other	0	14	0	0	19	21	2	49	3	3	0	0	111
Unknown	0	10	0	0	15	5	0	6	0	0	0	0	36
<b>Total</b>	<b>4</b>	<b>436</b>	<b>0</b>	<b>0</b>	<b>699</b>	<b>314</b>	<b>19</b>	<b>520</b>	<b>44</b>	<b>231</b>	<b>10</b>	<b>0</b>	<b>2277</b>

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in 4 patients.

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

**Posterior wall**  
**Treatment Method for the Primary Lesion by T Classification**

<b>Treatment Method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
<b>Surgery</b>													
without	1	23	0	0	75	57	0	26	27	1	2	0	212
with	0	88	0	0	66	33	1	29	2	56	2	0	277
unknown	0	1	0	0	2	1	0	3	0	0	0	0	7
<b>Radiotherapy</b>													
without	0	88	0	0	63	23	1	28	9	55	3	0	270
with	1	23	0	0	78	67	0	27	20	2	1	0	219
unknown	0	1	0	0	2	1	0	3	0	0	0	0	7
<b>Chemotherapy</b>													
without	0	94	0	0	76	25	1	26	9	56	3	0	290
with	1	17	0	0	65	65	0	29	20	1	1	0	199
unknown	0	1	0	0	2	1	0	3	0	0	0	0	7
<b>Total</b>	<b>1</b>	<b>112</b>	<b>0</b>	<b>0</b>	<b>143</b>	<b>91</b>	<b>1</b>	<b>58</b>	<b>29</b>	<b>57</b>	<b>4</b>	<b>0</b>	<b>496</b>

Treatment Method for the Primary Lesion by T Classification was not reported in a patient.

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

Posterior wall  
Sequence of Treatment  
Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	0	0	0	2	2	0	3	3	0	0	0	10
A) Surg. alone	0	82	0	0	45	13	1	15	0	55	2	0	213
F) (Rad.+Chem.)	1	8	0	0	39	33	0	8	8	0	0	0	97
B) Rad. alone	0	10	0	0	20	6	0	3	4	1	1	0	45
C) Chem. alone	0	3	0	0	10	4	0	6	4	0	1	0	28
A)F) Surg. -> (Rad.+Chem.)	0	3	0	0	5	6	0	4	0	0	0	0	18
A)B) Surg. -> Rad.	0	0	0	0	7	4	0	5	1	0	0	0	17
C)F) Chem. -> (Rad.+Chem.)	0	2	0	0	2	6	0	2	5	0	0	0	17
Other	0	3	0	0	11	16	0	9	4	1	0	0	44
Unknown	0	1	0	0	2	1	0	3	0	0	0	0	7
<b>Total</b>	<b>1</b>	<b>112</b>	<b>0</b>	<b>0</b>	<b>143</b>	<b>91</b>	<b>1</b>	<b>58</b>	<b>29</b>	<b>57</b>	<b>4</b>	<b>0</b>	<b>496</b>

Sequence of Treatment Methods for the Primary Lesion by T Classification was not reported in a patient.

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Hypopharynx, NOS

### Treatment Method for the Primary Lesion by T Classification

<b>Treatment Method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
<b>Surgery</b>													
without	0	8	0	0	23	15	0	22	8	1	0	0	77
with	0	17	0	0	16	5	0	19	0	22	0	1	80
unknown	0	0	0	0	0	1	0	0	0	0	0	0	1
<b>Radiotherapy</b>													
without	0	19	0	0	15	7	0	25	2	22	0	1	91
with	0	6	0	0	24	13	0	16	6	1	0	0	66
unknown	0	0	0	0	0	1	0	0	0	0	0	0	1
<b>Chemotherapy</b>													
without	0	22	0	0	14	8	0	21	2	23	0	1	91
with	0	3	0	0	25	12	0	20	6	0	0	0	66
unknown	0	0	0	0	0	1	0	0	0	0	0	0	1
<b>Total</b>	<b>0</b>	<b>25</b>	<b>0</b>	<b>0</b>	<b>39</b>	<b>21</b>	<b>0</b>	<b>41</b>	<b>8</b>	<b>23</b>	<b>0</b>	<b>1</b>	<b>158</b>

NOS: not otherwise specified.

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Hypopharynx, NOS

## Sequence of Treatment Methods for the Primary Lesion by T Classification

Sequence of treatment methods	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No treatment	0	1	0	0	2	1	0	4	0	0	0	0	8
A) Surg. alone	0	17	0	0	10	4	0	12	0	22	0	1	66
F) (Rad.+Chem.)	0	2	0	0	18	5	0	4	2	0	0	0	31
C) Chem. alone	0	1	0	0	2	2	0	7	2	0	0	0	14
B) Rad. alone	0	4	0	0	1	3	0	2	2	1	0	0	13
Other	0	0	0	0	6	5	0	12	2	0	0	0	25
Unknown	0	0	0	0	0	1	0	0	0	0	0	0	1
<b>Total</b>	<b>0</b>	<b>25</b>	<b>0</b>	<b>0</b>	<b>39</b>	<b>21</b>	<b>0</b>	<b>41</b>	<b>8</b>	<b>23</b>	<b>0</b>	<b>1</b>	<b>158</b>

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Posterior wall (C13.2)	Pyriform sinus (C12.9) (C13.1)	Hypopharynx, NOS (C13.9)	Total	
No surgery	175	1138	211	76	1600
Endoscopic resection	47	343	93	37	520
Transoral resection	40	261	83	10	394
Total pharyngolaryngectomy	35	292	49	11	387
Total pharyngolaryngo- esophagectomy	15	115	29	13	172
Total laryngectomy+Partial pharyngectomy	6	24	2	1	33
Partial hypopharyngectomy	1	15	10	3	29
Hypopharyngectomy + Cervical esophagectomy	3	18	3	3	27
Others	6	25	8	2	41
Unknown	0	1	0	0	1
<b>Total</b>	<b>328</b>	<b>2232</b>	<b>488</b>	<b>156</b>	<b>3204</b>

Surgical Methods for the Primary Lesion Subsite was not reported in 62 patients.

NOS: not otherwise specified.

## Surgical Methods for the Primary Lesion by T Classification

<b>Surgical method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
No surgery	2	208	0	0	664	307	11	298	77	27	5	0	1599
Endoscopic resection	0	242	0	0	92	5	0	0	0	174	6	1	520
Transoral resection	2	158	1	0	92	2	0	1	0	135	3	0	394
Total pharyngolaryngectomy	1	6	0	0	53	103	6	214	3	1	0	0	387
Total pharyngolaryngo-esophagectomy	0	1	0	0	26	51	2	89	3	0	0	0	172
Total laryngectomy+Partial pharyngectomy	0	1	0	0	7	5	0	19	0	1	0	0	33
Partial hypopharyngectomy	0	7	0	0	16	2	0	2	0	2	0	0	29
Hypopharyngectomy + Cervical esophagectomy	0	0	0	0	3	6	0	18	0	0	0	0	27
Others	0	6	0	0	17	6	2	7	0	3	0	0	41
Unknown	0	0	0	0	0	1	0	0	0	0	0	0	1
<b>Total</b>	<b>5</b>	<b>629</b>	<b>1</b>	<b>0</b>	<b>970</b>	<b>488</b>	<b>21</b>	<b>648</b>	<b>83</b>	<b>343</b>	<b>14</b>	<b>1</b>	<b>3203</b>

Surgical Methods for the Primary Lesion by T Classification was not reported in 63 patients.

T-: not within defined T classification or without reported T classification

## Postcricoid

### Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	0	22	0	0	88	43	1	16	3	2	0	0	175
Endoscopic resection	0	26	0	0	6	0	0	0	0	15	0	0	47
Transoral resection	0	18	1	0	6	1	0	0	0	14	0	0	40
Total pharyngolaryngectomy	0	1	0	0	6	14	0	14	0	0	0	0	35
Total pharyngolaryngo-esophagectomy	0	0	0	0	4	7	0	4	0	0	0	0	15
Total laryngectomy+Partial pharyngectomy	0	1	0	0	3	1	0	1	0	0	0	0	6
Total laryngectomy	0	0	0	0	1	2	0	1	0	0	0	0	4
Hypopharyngectomy + Cervical esophagectomy	0	0	0	0	0	1	0	2	0	0	0	0	3
Partial hypopharyngectomy	0	0	0	0	1	0	0	0	0	0	0	0	1
Others	0	0	0	0	0	1	0	0	0	1	0	0	2
<b>Total</b>	<b>0</b>	<b>68</b>	<b>1</b>	<b>0</b>	<b>115</b>	<b>70</b>	<b>1</b>	<b>38</b>	<b>3</b>	<b>32</b>	<b>0</b>	<b>0</b>	<b>328</b>

Surgical Methods for the Primary Lesion by T Classification was not reported in a patient.

T-: not within defined T classification or without reported T classification

## Pyriiform sinus

### Surgical Methods for the Primary Lesion by T Classification

<b>Surgical method</b>	<b>T0</b>	<b>T1</b>	<b>T1a</b>	<b>T1b</b>	<b>T2</b>	<b>T3</b>	<b>T4</b>	<b>T4a</b>	<b>T4b</b>	<b>Tis</b>	<b>TX</b>	<b>T-</b>	<b>Total</b>
No surgery	1	156	0	0	479	192	10	234	40	22	3	0	1137
Endoscopic resection	0	162	0	0	66	5	0	0	0	106	4	0	343
Total pharyngolaryngectomy	1	3	0	0	34	70	5	176	2	1	0	0	292
Transoral resection	2	97	0	0	59	1	0	1	0	98	3	0	261
Total pharyngolaryngo-esophagectomy	0	1	0	0	14	28	2	68	2	0	0	0	115
Total laryngectomy+Partial pharyngectomy	0	0	0	0	4	4	0	16	0	0	0	0	24
Hypopharyngectomy + Cervical esophagectomy	0	0	0	0	2	4	0	12	0	0	0	0	18
Partial hypopharyngectomy	0	4	0	0	7	1	0	1	0	2	0	0	15
Total laryngectomy	0	0	0	0	5	0	2	2	0	0	0	0	9
Laryngectomy, other type	0	0	0	0	1	0	0	0	0	1	0	0	2
Others	0	2	0	0	5	2	0	4	0	1	0	0	14
Unknown	0	0	0	0	0	1	0	0	0	0	0	0	1
<b>Total</b>	<b>4</b>	<b>425</b>	<b>0</b>	<b>0</b>	<b>676</b>	<b>308</b>	<b>19</b>	<b>514</b>	<b>44</b>	<b>231</b>	<b>10</b>	<b>0</b>	<b>2231</b>

Surgical Methods for the Primary Lesion by T Classification was not reported in 50 patients.

T-: not within defined T classification or without reported T classification

## Posterior wall

### Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	1	23	0	0	74	57	0	26	27	1	2	0	211
Endoscopic resection	0	42	0	0	14	0	0	0	0	35	2	0	93
Transoral resection	0	38	0	0	25	0	0	0	0	20	0	0	83
Total pharyngolaryngectomy	0	2	0	0	9	18	1	18	1	0	0	0	49
Total pharyngolaryngo-esophagectomy	0	0	0	0	7	12	0	9	1	0	0	0	29
Partial hypopharyngectomy	0	2	0	0	7	1	0	0	0	0	0	0	10
Hypopharyngectomy + Cervical esophagectomy	0	0	0	0	1	1	0	1	0	0	0	0	3
Total laryngectomy+Partial pharyngectomy	0	0	0	0	0	0	0	1	0	1	0	0	2
Laryngectomy, other type	0	1	0	0	0	0	0	0	0	0	0	0	1
Resection of the oropharynx, other type	0	0	0	0	1	0	0	0	0	0	0	0	1
Resection of the posterior wall	0	1	0	0	0	0	0	0	0	0	0	0	1
Resection of the soft palate	0	0	0	0	1	0	0	0	0	0	0	0	1
Others	0	2	0	0	1	1	0	0	0	0	0	0	4
<b>Total</b>	<b>1</b>	<b>111</b>	<b>0</b>	<b>0</b>	<b>140</b>	<b>90</b>	<b>1</b>	<b>55</b>	<b>29</b>	<b>57</b>	<b>4</b>	<b>0</b>	<b>488</b>

Surgical Methods for the Primary Lesion by T Classification was not reported in 9 patients.

T-: not within defined T classification or without reported T classification

## Hypopharynx, NOS

### Surgical Methods for the Primary Lesion by T Classification

Surgical method	T0	T1	T1a	T1b	T2	T3	T4	T4a	T4b	Tis	TX	T-	Total
No surgery	0	7	0	0	23	15	0	22	7	2	0	0	76
Endoscopic resection	0	12	0	0	6	0	0	0	0	18	0	1	37
Total pharyngolaryngo-esophagectomy	0	0	0	0	1	4	0	8	0	0	0	0	13
Total pharyngolaryngectomy	0	0	0	0	4	1	0	6	0	0	0	0	11
Transoral resection	0	5	0	0	2	0	0	0	0	3	0	0	10
Hypopharyngectomy + Cervical esophagectomy	0	0	0	0	0	0	0	3	0	0	0	0	3
Partial hypopharyngectomy	0	1	0	0	1	0	0	1	0	0	0	0	3
Total laryngectomy+Partial pharyngectomy	0	0	0	0	0	0	0	1	0	0	0	0	1
Others	0	0	0	0	2	0	0	0	0	0	0	0	2
<b>Total</b>	<b>0</b>	<b>25</b>	<b>0</b>	<b>0</b>	<b>39</b>	<b>20</b>	<b>0</b>	<b>41</b>	<b>7</b>	<b>23</b>	<b>0</b>	<b>1</b>	<b>156</b>

Surgical Methods for the Primary Lesion by T Classification was not reported in 2 patients.

NOS: not otherwise specified.

T-: not within defined T classification or without reported T classification

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Postericoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No N.D.	249	1652	374	118	2393
1) Total N.D.	21	120	25	7	173
2) Selective N.D.	55	448	82	30	615
3) Lymph node excision	0	3	0	0	3
8) Others	3	3	4	1	11
9) Unknown	0	5	2	0	7
<b>Total</b>	<b>328</b>	<b>2231</b>	<b>487</b>	<b>156</b>	<b>3202</b>

Neck Dissection on the Ipsilateral Side Subsite was not reported in 64 patients.

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Postericoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No N.D.	270	1,799	398	127	2594
1) Total N.D.	13	57	15	4	89
2) Selective N.D.	43	366	68	23	500
3) Lymph node excision	0	1	0	0	1
8) Others	2	4	4	2	12
9) Unknown	0	5	2	0	7
<b>Total</b>	<b>328</b>	<b>2232</b>	<b>487</b>	<b>156</b>	<b>3203</b>

Neck Dissection on the Contralateral Side Subsite was not reported in 63 patients.

N.D.: neck dissection.

## Reconstructive Surgery by Subsite

Reconstructive surgery	Postericoid (C13.0)	Pyriform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
No reconstruction	269	1769	393	125	2556
Free jejunal flap	48	387	81	26	542
Free ALT flap	1	24	1	0	26
PM MC flap	3	17	3	1	24
Gastric pull-up	3	10	2	1	16
DP flap	1	5	0	1	7
Free FA flap	0	5	2	0	7
Others	2	2	3	0	7
Local skin flap	1	2	1	2	6
Free RA MC flap	0	1	0	0	1
Free scapular OC flap	0	1	0	0	1
Skin graft	0	1	0	0	1
Unknown	0	1	0	0	1
<b>Total</b>	<b>328</b>	<b>2225</b>	<b>486</b>	<b>156</b>	<b>3195</b>

Reconstructive Surgery Subsite was not reported in 71 patients.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh. FA: forearm.

PM: pectoralis major.

OC: osteocutaneous. DP: deltopectoral.

## Radiotherapy by Subsite

Type of radiotherapy	Posterioricoid (C13.0)	Pyriiform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No radiotherapy	147	998	256	89	1490
1) X-ray (and/or electron beam)	181	1227	227	67	1702
2) Particle beam	0	6	2	1	9
4) X-ray + Particle beam	0	1	0	0	1
8) Others	0	1	1	0	2
9) Unknown	0	3	1	0	4
<b>Total</b>	<b>328</b>	<b>2236</b>	<b>487</b>	<b>157</b>	<b>3208</b>

Radiotherapy Subsite was not reported in 58 patients.

B.T.: brachytherapy.

## Chemotherapy by Subsite

Route of administration	Posterioricoid (C13.0)	Pyriiform sinus (C12.9) (C13.1)	Posterior wall (C13.2)	Hypopharynx, NOS (C13.9)	Total
0) No chemotherapy	170	1202	280	90	1742
1) I.V.	150	1000	199	65	1414
2) I.A.	1	3	0	0	4
3) Oral	5	18	4	2	29
4) I.V.+I.A.	0	1	0	0	1
5) I.V.+Oral	2	9	2	0	13
8) Others	0	1	1	0	2
9) Unknown	0	3	1	0	4
<b>Total</b>	<b>328</b>	<b>2237</b>	<b>487</b>	<b>157</b>	<b>3209</b>

Chemotherapy Subsite was not reported in 57 patients.

I.V.: intravenous. I.A.: intraarterial.

Oropharynx -----2632 Cases

Oropharynx(2022)

2632 Cases

## Primary Site

Site	Number of patients	(%)
Superior wall	239	(9.1)
Lateral wall	1527	(58.0)
Posterior wall	180	(6.8)
Anterior wall	578	(22.0)
Oropharynx, NOS	108	(4.1)
<b>Total</b>	<b>2632</b>	<b>(100.0)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	1	0	1
10 - 19	0	0	0
20 - 29	4	0	4
30 - 39	17	10	27
40 - 49	161	64	225
50 - 59	351	97	448
60 - 69	620	123	743
70 - 79	717	129	846
80 - 89	253	66	319
90 - 99	12	6	18
100 - 109	0	1	1
<b>Total</b>	<b>2136</b>	<b>496</b>	<b>2632</b>

Oropharynx -----2632 Cases

p16 status

p16 status	Total
p16 positive	1360
p16 negative	964
p16 unknown	260
not reported	48
Total	2632

Oropharynx p16 positive(2022)

1360 Cases

## Primary Site

Site	Number of patients	(%)
Superior wall	28	(2.1)
Lateral wall	1037	(76.2)
Posterior wall	20	(1.5)
Anterior wall	226	(16.6)
Oropharynx, NOS	49	(3.6)
Total	1360	(100.0)

NOS : Not Otherwise Specified

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	1	0	1
30 - 39	11	6	17
40 - 49	132	38	170
50 - 59	231	59	290
60 - 69	309	78	387
70 - 79	294	76	370
80 - 89	94	24	118
90 - 99	4	3	7
100 - 109	0	0	0
Total	1076	284	1360

## Histological Distribution by Subsite

Histologic type	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
S.C.C., NOS	27	996	16	218	46	1303
S.C.C., large cell, nonkerat., NOS	0	12	0	3	0	15
S.C.C., kerat., NOS	0	9	1	2	0	12
Ca., NOS	0	6	0	0	0	6
S.C.C. in situ, NOS	0	3	2	1	0	6
S.C.C., small cell, nonkerat.	0	5	0	0	0	5
Papillary S.C.C.	0	1	0	1	0	2
S.C.C., microinvasive	0	1	0	0	1	2
S.C.C., spindle cell	0	1	1	0	0	2
Small cell ca., NOS	0	2	0	0	0	2
Adenocarcinoma, NOS	0	0	0	0	1	1
Adenoid cystic ca.	0	0	0	1	0	1
Basaloid S.C.C.	1	0	0	0	0	1
Ca., undiff., NOS	0	0	0	0	1	1
Transitional cell ca., NOS	0	1	0	0	0	1
<b>Total</b>	<b>28</b>	<b>1037</b>	<b>20</b>	<b>226</b>	<b>49</b>	<b>1360</b>

Ca., ca.: carcinoma.

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

undiff.: undifferentiated.

nonkerat.: nonkeratinizing.

## T and N Status

T	N0	N1	N2	N2a	N2b	N3	N3a	N3b	NX	N-	Total
T0	2	13	1	0	0	1	0	1	0	0	18
T1	68	164(4)	14(1)	0	0	16	0	0	1	0	263
T2	140	399(3)	77(4)	0	0	19(3)	0	0	2	0	637
T3	28	102(3)	59(2)	0	0	9(1)	0	0	0	0	198
T4	25	98(2)	91(7)	0	0	18(3)	0	0	0	0	232
T4a	0	0	0	0	0	0	0	1	0	0	1
T4b	0	0	0	0	0	0	0	0	0	0	0
Tis	6	0	0	0	0	0	0	0	0	0	6
TX	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	1(1)	0	0	0	0	0	0	0	1
Total	269	776(12)	243(15)	0	0	63(7)	0	2	3	0	1356

T and N Status was not reported in 4 patients.

M1:34 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

NOS : Not Otherwise Specified

### Treatment Method for the Primary Lesion by Subsite

<b>Treatment Method</b>	<b>Superior wall</b>	<b>Lateral wall</b>	<b>Posterior wall</b>	<b>Anterior wall</b>	<b>Oropharynx, NOS</b>	<b>Total</b>
<b>Surgery</b>						
without	17	700	9	181	42	949
with	10	337	11	44	7	409
unknown	1	0	0	1	0	2
<b>Radiotherapy</b>						
without	11	283	10	49	11	364
with	16	754	10	176	38	994
unknown	1	0	0	1	0	2
<b>Chemotherapy</b>						
without	13	381	9	68	18	489
with	14	656	11	157	31	869
unknown	1	0	0	1	0	2
<b>Total</b>	<b>28</b>	<b>1037</b>	<b>20</b>	<b>226</b>	<b>49</b>	<b>1360</b>

NOS : Not Otherwise Specified

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
<b>Surgery</b>						
without	22	744	18	186	41	1011
with	5	292	2	39	8	346
unknown	1	1	0	1	0	3
<b>Radiotherapy</b>						
without	13	335	11	63	18	440
with	14	701	9	162	31	917
unknown	1	1	0	1	0	3
<b>Chemotherapy</b>						
without	15	412	10	72	20	529
with	12	624	10	153	29	828
unknown	1	1	0	1	0	3
<b>Total</b>	<b>28</b>	<b>1037</b>	<b>20</b>	<b>226</b>	<b>49</b>	<b>1360</b>

NOS : Not Otherwise Specified

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No treatment	0	17	0	9	5	31
F) (Rad.+Chem.)	6	476	5	112	24	623
A) Surg. alone	8	201	7	23	4	243
B) Rad. alone	4	110	1	26	8	149
C)F) Chem. -> (Rad.+Chem.)	2	55	2	17	2	78
A)B) Surg. -> Rad.	0	41	0	6	1	48
C)A) Chem. -> Surg.	0	36	1	6	0	43
A)F) Surg. -> (Rad.+Chem.)	0	29	1	4	1	35
C) Chem. alone	3	15	1	10	2	31
F)C) (Rad.+Chem.) -> Chem.	0	9	0	2	0	11
C)A)F) Chem. -> Surg. -> (Rad.+Chem.)	0	6	0	0	0	6
C)B) Chem. -> Rad.	2	4	0	0	0	6
D) (Surg.+Rad.)	0	4	0	2	0	6
A)A) Surg. -> Surg.	0	4	1	0	0	5
B)C) Rad. -> Chem.	0	3	0	2	0	5
C)A)C) Chem. -> Surg. -> Chem.	0	4	0	0	0	4
G) Surg.+Rad.+Chem.	0	3	0	0	1	4
C)A)B) Chem. -> Surg. -> Rad.	1	2	0	0	0	3
C)B)C) Chem. -> Rad. -> Chem.	0	3	0	0	0	3
C)F)C) Chem. -> (Rad.+Chem.) -> Chem.	0	1	0	1	1	3
A)B)C) Surg. -> Rad. -> Chem.	0	1	1	0	0	2
C)C)A) Chem. -> Chem. -> Surg.	0	2	0	0	0	2
C)C)F) Chem. -> Chem. -> (Rad.+Chem.)	0	2	0	0	0	2
D)C) (Surg.+Rad.) -> Chem.	0	1	0	1	0	2
A)D) Surg. -> (Surg.+Rad.)	0	0	0	1	0	1

Oropharynx p16 positive -----1360 Cases

<b>Sequence of treatment methods</b>	<b>Superior wall</b>	<b>Lateral wall</b>	<b>Posterior wall</b>	<b>Anterior wall</b>	<b>Oropharynx, NOS</b>	<b>Total</b>
A)H) Surg. -> Nonspecific Immunotherapy	0	1	0	0	0	1
B)A) Rad. -> Surg.	1	0	0	0	0	1
B)B) Rad. -> Rad.	0	1	0	0	0	1
B)I) Rad. -> Other	0	1	0	0	0	1
C)C) Chem. -> Chem.	0	1	0	0	0	1
C)C)B) Chem. -> Chem. -> Rad.	0	0	0	1	0	1
E) (Surg.+Chem)	0	1	0	0	0	1
F)A) (Rad.+Chem.) -> Surg.	0	0	0	1	0	1
F)C)C) (Rad.+Chem.) -> Chem. -> Chem.	0	1	0	0	0	1
F)F) (Rad.+Chem.) -> (Rad.+Chem.)	0	1	0	0	0	1
I)A) Other -> Surg.	0	1	0	0	0	1
I)I)I) Other -> Other -> Other	0	0	0	1	0	1
Unknown	1	0	0	1	0	2
<b>Total</b>	<b>28</b>	<b>1037</b>	<b>20</b>	<b>226</b>	<b>49</b>	<b>1360</b>

NOS : Not Otherwise Specified

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No surgery	17	699	8	181	42	947
Unilateral resection of the lateral wall of the oropharynx	0	249	1	0	0	250
Resection of the oropharynx, other type	4	48	2	10	4	68
Resection of the root of tongue	0	1	0	24	1	26
Transoral resection	0	15	0	0	1	16
Unilateral resection of the lateral wall of the oropharynx and soft palate	4	9	0	0	0	13
Resection of the posterior wall	0	0	8	0	0	8
Unilateral resection of the lateral wall of the oropharynx, soft palate and the base of tongue	0	6	0	1	0	7
Resection of the soft palate	1	4	0	0	0	5
Endoscopic resection	0	1	0	1	1	3
Resection of the base of tongue and epiglottis	0	0	0	3	0	3
Resection of the uvula	1	2	0	0	0	3
Hemiglossectomy	0	0	0	1	0	1
Resction of tongue, NOS 0	0	1	0	0	0	1
Resection of oral cavity, NOS	0	1	0	0	0	1
Total glossectomy	0	0	0	1	0	1
Others	0	0	0	2	0	2
<b>Total</b>	<b>27</b>	<b>1036</b>	<b>19</b>	<b>224</b>	<b>49</b>	<b>1355</b>

Surgical Methods for the Primary Lesion Subsite was not reported in 5 patients.

NOS: not otherwise specified.

## Reconstructive Surgery by Subsite

<b>Reconstructive surgery</b>	<b>Superior wall</b>	<b>Lateral wall</b>	<b>Posterior wall</b>	<b>Anterior wall</b>	<b>Oropharynx, NOS</b>	<b>Total</b>
No reconstruction	24	999	17	214	48	1302
Free ALT flap	1	18	1	2	1	23
Free RA MC flap	1	3	1	7	0	12
Free FA flap	0	7	0	0	0	7
PM MC flap	0	4	0	1	0	5
Local skin flap	0	2	0	0	0	2
Mucosal flap	1	0	0	0	0	1
<b>Total</b>	<b>27</b>	<b>1033</b>	<b>19</b>	<b>224</b>	<b>49</b>	<b>1352</b>

Reconstructive Surgery Subsite was not reported in 8 patients.

NOS: not otherwise specified.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh. FA: forearm.

PM: pectoralis major.

## Neck Dissection on the Ipsilateral Side by Subsite

<b>Neck dissection</b>	<b>Superior wall</b>	<b>Lateral wall</b>	<b>Posterior wall</b>	<b>Anterior wall</b>	<b>Oropharynx, NOS</b>	<b>Total</b>
0) No N.D.	22	740	17	183	41	1003
1) Total N.D.	1	69	1	10	3	84
2) Selective N.D.	4	219	1	25	5	254
3) Lymph node excision	0	3	0	2	0	5
8) Others	0	2	0	1	0	3
9) Unknown	0	3	0	3	0	6
<b>Total</b>	<b>27</b>	<b>1036</b>	<b>19</b>	<b>224</b>	<b>49</b>	<b>1355</b>

Neck Dissection on the Ipsilateral Side Subsite was not reported in 5 patients.

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No N.D.	25	1006	17	213	48	1,309
1) Total N.D.	0	1	0	0	0	1
2) Selective N.D.	2	17	2	7	0	28
8) Others	0	6	0	1	1	8
9) Unknown	0	5	0	3	0	8
<b>Total</b>	<b>27</b>	<b>1035</b>	<b>19</b>	<b>224</b>	<b>49</b>	<b>1354</b>

Neck Dissection on the Contralateral Side Subsite was not reported in 6 patients.

N.D.: neck dissection.

## Radiotherapy by Subsite

Type of radiotherapy	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No radiotherapy	11	265	10	47	11	344
1) X-ray (and/or electron beam)	16	763	10	173	38	1000
2) Particle beam	0	4	0	4	0	8
4) X-ray + Particle beam	0	1	0	0	0	1
9) Unknown	0	1	0	1	0	2
<b>Total</b>	<b>27</b>	<b>1034</b>	<b>20</b>	<b>225</b>	<b>49</b>	<b>1355</b>

Radiotherapy Subsite was not reported in 5 patients.

## Chemotherapy by Subsite

Route of administration	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No chemotherapy	13	366	10	64	18	471
1) I.V.	13	655	10	154	30	862
2) I.A.	0	1	0	4	0	5
3) Oral	1	8	0	1	1	11
5) I.V.+Oral	0	4	0	1	0	5
8) Others	0	1	0	1	0	2
<b>Total</b>	<b>27</b>	<b>1035</b>	<b>20</b>	<b>225</b>	<b>49</b>	<b>1356</b>

Chemotherapy Subsite was not reported in 4 patients.

I.V.: intravenous. I.A.: intraarterial.

# Oropharynx p16 negative and unknown (2022)

1224 Cases

## Primary Site

Site	Number of patients	(%)
Superior wall	206	(16.8)
Lateral wall	471	(38.5)
Posterior wall	153	(12.5)
Anterior wall	337	(27.5)
Oropharynx, NOS	57	(4.7)
<b>Total</b>	<b>1224</b>	<b>(100.0)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	1	0	1
10 - 19	0	0	0
20 - 29	3	0	3
30 - 39	5	4	9
40 - 49	26	24	50
50 - 59	116	37	153
60 - 69	297	43	340
70 - 79	412	51	463
80 - 89	151	42	193
90 - 99	8	3	11
100 - 109	0	1	1
<b>Total</b>	<b>1019</b>	<b>205</b>	<b>1224</b>

## Histological Distribution by Subsite

Histologic type	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
S.C.C., NOS	170	409	131	290	51	1051
S.C.C. in situ, NOS	16	10	17	5	1	49
S.C.C., kerat., NOS	4	9	3	9	0	25
Adenoid cystic ca.	2	2	0	10	0	14
Mucoepidermoid ca.	9	1	0	4	0	14
Malig. lymphoma, NOS	0	9	0	3	0	12
S.C.C., large cell, nonkerat., NOS	1	5	0	3	0	9
Ca., NOS	0	4	0	2	1	7
Malig. lymphoma, large B-cell, diffuse, NOS	0	6	0	0	0	6
Ca., undiff., NOS	0	4	0	0	0	4
Adenocarcinoma, NOS	1	0	0	2	0	3
Adenosquamous ca.	0	2	0	0	1	3
Neuroendocrine ca., NOS	0	1	0	2	0	3
Acinar cell ca.	0	1	0	1	0	2
Ca. ex pleomorphic adenoma	0	1	0	0	1	2
Clear cell ca., NOS	0	0	0	2	0	2
Epithelial-myoepithelial ca.	1	0	0	0	1	2
Malig. melanoma, NOS	1	0	1	0	0	2
S.C.C., microinvasive	0	2	0	0	0	2
S.C.C., spindle cell	0	0	0	2	0	2
Basaloid S.C.C.	0	1	0	0	0	1
Intraepithelial, NOS	0	0	1	0	0	1
Liposarcoma, NOS	1	0	0	0	0	1
Lymphoepithelial ca.	0	1	0	0	0	1
Papillary adenocarcinoma, NOS	0	1	0	0	0	1

Oropharynx p16 negative and unknown -----1224 Cases

<b>Histologic type</b>	<b>Superior wall</b>	<b>Lateral wall</b>	<b>Posterior wall</b>	<b>Anterior wall</b>	<b>Oropharynx, NOS</b>	<b>Total</b>
Papillary S.C.C.	0	1	0	0	0	1
Plasmacytoma, NOS	0	0	0	0	1	1
S.C.C. in situ with quest. stromal invasion	0	0	0	1	0	1
Small cell ca., NOS	0	1	0	0	0	1
Transitional cell ca., NOS	0	0	0	1	0	1
<b>Total</b>	<b>206</b>	<b>471</b>	<b>153</b>	<b>337</b>	<b>57</b>	<b>1224</b>

Ca., ca.: carcinoma.

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

Malig., malig.: malignant.

undiff.: undifferentiated.

quest.: questionable.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	2	2	0	0	3	0	0	1	0	0	8
T1	219(1)	10	1	4	11(1)	1(1)	0	11(4)	2	0	259
T2	161	61	4	9	50(2)	0	1(1)	29(4)	2	0	317
T3	53	29	4	4	44(4)	0	1	17	1	0	153
T4	3	2	2(1)	0	1	1(1)	0	0	0	0	9
T4a	49(1)	19(2)	0	6	45(3)	0	0	40(4)	0	0	159
T4b	8	3	0	0	11	1(1)	0	10(2)	0	0	33
Tis	93	0	0	0	0	0	0	0	1	0	94
TX	4	4	0	0	1	0	0	1	10	0	20
T-	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>592(2)</b>	<b>130(2)</b>	<b>11(1)</b>	<b>23</b>	<b>166(10)</b>	<b>3(3)</b>	<b>2(1)</b>	<b>109(14)</b>	<b>16</b>	<b>0</b>	<b>1052</b>

T and N Status was not reported in 172 patients.

M1:33 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

### Treatment Method for the Primary Lesion by Subsite

<b>Treatment Method</b>	<b>Superior wall</b>	<b>Lateral wall</b>	<b>Posterior wall</b>	<b>Anterior wall</b>	<b>Oropharynx, NOS</b>	<b>Total</b>
<b>Surgery</b>						
without	74	274	65	189	33	635
with	131	196	88	148	24	587
unknown	1	1	0	0	0	2
<b>Radiotherapy</b>						
without	138	233	96	148	25	640
with	67	237	57	189	32	582
unknown	1	1	0	0	0	2
<b>Chemotherapy</b>						
without	146	239	102	180	32	699
with	59	231	51	157	25	523
unknown	1	1	0	0	0	2
<b>Total</b>	<b>206</b>	<b>471</b>	<b>153</b>	<b>337</b>	<b>57</b>	<b>1224</b>

NOS : Not Otherwise Specified

## Treatment Method for the Cervical Lymph Nodes by Subsite

<b>Treatment Method</b>	<b>Superior wall</b>	<b>Lateral wall</b>	<b>Posterior wall</b>	<b>Anterior wall</b>	<b>Oropharynx, NOS</b>	<b>Total</b>
<b>Surgery</b>						
without	181	365	138	242	48	974
with	24	105	15	95	9	248
unknown	1	1	0	0	0	2
<b>Radiotherapy</b>						
without	147	266	110	183	31	737
with	58	204	43	154	26	485
unknown	1	1	0	0	0	2
<b>Chemotherapy</b>						
without	152	267	119	200	35	773
with	53	203	34	137	22	449
unknown	1	1	0	0	0	2
<b>Total</b>	<b>206</b>	<b>471</b>	<b>153</b>	<b>337</b>	<b>57</b>	<b>1224</b>

NOS : Not Otherwise Specified

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No treatment	6	30	4	16	2	58
A) Surg. alone	118	148	81	97	20	464
F) (Rad.+Chem.)	35	112	34	78	14	273
B) Rad. alone	16	46	15	47	10	134
C) Chem. alone	8	31	5	20	2	66
C)F) Chem. -> (Rad.+Chem.)	6	23	3	9	2	43
A)B) Surg. -> Rad.	3	11	2	16	0	32
A)F) Surg. -> (Rad.+Chem.)	3	6	0	14	2	25
C)A) Chem. -> Surg.	2	11	3	4	1	21
C)B) Chem. -> Rad.	0	11	0	2	0	13
C)A)F) Chem. -> Surg. -> (Rad.+Chem.)	0	5	0	6	0	11
F)C) (Rad.+Chem.) -> Chem.	1	2	1	5	1	10
C)C) Chem. -> Chem.	1	2	1	4	0	8
A)C) Surg. -> Chem.	0	3	2	1	0	6
B)C) Rad. -> Chem.	0	2	1	1	1	5
F)A) (Rad.+Chem.) -> Surg.	1	1	0	2	0	4
G) Surg.+Rad.+Chem.	1	1	0	2	0	4
C)A)B) Chem. -> Surg. -> Rad.	0	2	0	1	0	3
F)H) (Rad.+Chem.) -> Nonspecific Immunotherapy	0	2	0	1	0	3
C)A)C) Chem. -> Surg. -> Chem.	0	1	0	1	0	2
C)B)C) Chem. -> Rad. -> Chem.	0	1	1	0	0	2
C)C)B) Chem. -> Chem. -> Rad.	0	1	0	0	1	2
C)C)C) Chem. -> Chem. -> Chem.	0	2	0	0	0	2
C)F)C) Chem. -> (Rad.+Chem.) -> Chem.	0	1	0	1	0	2
D) (Surg.+Rad.)	0	1	0	1	0	2

Oropharynx p16 negative and unknown -----1224 Cases

Sequence of treatment methods	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
E) (Surg.+Chem)	1	0	0	1	0	2
F)A)B) (Rad.+Chem.) -> Surg. -> Rad.	0	1	0	1	0	2
A)A) Surg. -> Surg.	1	0	0	0	0	1
A)A)A) Surg. -> Surg. -> Surg.	0	0	0	1	0	1
A)A)F) Surg. -> Surg. -> (Rad.+Chem.)	0	0	0	0	1	1
A)B)A) Surg. -> Rad. -> Surg.	1	0	0	0	0	1
A)B)C) Surg. -> Rad. -> Chem.	0	1	0	0	0	1
A)C)C) Surg. -> Chem. -> Chem.	0	1	0	0	0	1
A)E) Surg. -> (Surg.+Chem)	0	1	0	0	0	1
B)A) Rad. -> Surg.	0	1	0	0	0	1
B)F) Rad. -> (Rad.+Chem.)	0	1	0	0	0	1
B)H) Rad. -> Nonspetific Immunotherapy	0	1	0	0	0	1
C)C)F) Chem. -> Chem. -> (Rad.+Chem.)	0	0	0	1	0	1
C)F)H) Chem. -> (Rad.+Chem.) -> Nonspetific Immunotherapy	0	1	0	0	0	1
C)H) Chem. -> Nonspetific Immunotherapy	0	0	0	1	0	1
F)B) (Rad.+Chem.) -> Rad.	0	0	0	1	0	1
F)F) (Rad.+Chem.) -> (Rad.+Chem.)	0	1	0	0	0	1
G)C) Surg.+Rad.+Chem. -> Chem.	0	1	0	0	0	1
H) Nonspetific Immunotherapy	0	1	0	0	0	1
H)C) Nonspetific Immunotherapy -> Chem.	0	1	0	0	0	1
H)F) Nonspetific Immunotherapy -> (Rad.+Chem.)	0	1	0	0	0	1
I)C) Other -> Chem.	0	1	0	0	0	1
Other	1	0	0	2	0	3
Unknown	1	1	0	0	0	2
<b>Total</b>	<b>206</b>	<b>471</b>	<b>153</b>	<b>337</b>	<b>57</b>	<b>1224</b>

Oropharynx p16 negative and unknown -----1224 Cases

NOS : Not Otherwise Specified

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No surgery	75	274	65	189	33	636
Unilateral resection of the lateral wall of the oropharynx	3	119	1	2	2	127
Resection of the oropharynx, other type	12	27	10	31	10	90
Resection of the soft palate	75	8	1	1	4	89
Resection of the posterior wall	0	0	57	1	1	59
Resection of the root of tongue	0	0	0	50	2	52
Resection of the uvula	23	0	0	0	3	26
Transoral resection	1	12	7	3	0	23
Total pharyngolaryngectomy	0	4	6	6	0	16
Unilateral resection of the lateral wall of the oropharynx and soft palate	7	9	0	0	0	16
Total glossectomy	0	1	0	13	0	14
Endoscopic resection	0	3	6	4	0	13
Resection of the base of tongue and epiglottis	0	1	0	12	0	13
Total laryngectomy	0	0	0	6	1	7
Hemiglossectomy	0	1	0	5	0	6
Subtotal glossectomy	0	1	0	4	1	6
Unilateral resection of the lateral wall of the oropharynx, soft palate and the base of tongue	1	3	0	0	0	4
Laryngectomy, other type	0	1	0	2	0	3
Partial glossectomy	0	1	0	1	0	2
Resection of oral cavity, NOS	2	0	0	0	0	2
Extended total parotidectomy	1	0	0	0	0	1
Hypopharyngectomy + Cervical esophagectomy	1	0	0	0	0	1
Partial maxillectomy	1	0	0	0	0	1
Resection of tongue, NOS 0	0	0	0	1	0	1
Resection of lower gingiva	0	1	0	0	0	1
Resection of the buccal mucosa	0	1	0	0	0	1

Oropharynx p16 negative and unknown -----1224 Cases

<b>Surgical method</b>	<b>Superior wall</b>	<b>Lateral wall</b>	<b>Posterior wall</b>	<b>Anterior wall</b>	<b>Oropharynx, NOS</b>	<b>Total</b>
Subtotal glossectomy (anterior 2/3rds)	0	1	0	0	0	1
Total pharyngolaryngo-esophagectomy	0	0	0	1	0	1
Others	3	2	0	5	0	10
<b>Total</b>	<b>205</b>	<b>470</b>	<b>153</b>	<b>337</b>	<b>57</b>	<b>1222</b>

Surgical Methods for the Primary Lesion Subsite was not reported in 2 patients.

NOS: not otherwise specified.

## Reconstructive Surgery by Subsite

Reconstructive surgery	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
No reconstruction	188	422	141	280	48	1,079
Free ALT flap	5	16	0	17	1	39
Free RA MC flap	3	11	0	18	3	35
Free jejunal flap	0	7	9	7	0	23
Free FA flap	2	3	1	5	1	12
PM MC flap	1	5	0	3	1	10
Others	1	1	2	2	0	6
Mucosal flap	3	0	0	0	1	4
DP flap	0	0	0	2	0	2
Gastric pull-up	0	0	0	2	0	2
Local skin flap	0	1	0	0	1	2
Skin graft	2	0	0	0	0	2
Free scapular OC flap	0	1	0	0	0	1
Unknown	0	0	0	0	1	1
<b>Total</b>	<b>205</b>	<b>467</b>	<b>153</b>	<b>336</b>	<b>57</b>	<b>1218</b>

Reconstructive Surgery Subsite was not reported in 6 patients.

NOS: not otherwise specified.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh. FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

### Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No N.D.	180	364	138	240	48	970
1) Total N.D.	8	36	5	27	0	76
2) Selective N.D.	15	68	10	65	9	167
8) Others	0	1	0	3	0	4
9) Unknown	1	0	0	1	0	2
<b>Total</b>	<b>204</b>	<b>469</b>	<b>153</b>	<b>336</b>	<b>57</b>	<b>1219</b>

Neck Dissection on the Ipsilateral Side Subsite was not reported in 5 patients.

NOS: not otherwise specified.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No N.D.	194	445	143	285	52	1,119
1) Total N.D.	2	3	4	11	0	20
2) Selective N.D.	7	17	6	36	4	70
8) Others	0	2	0	3	1	6
9) Unknown	1	2	0	1	0	4
<b>Total</b>	<b>204</b>	<b>469</b>	<b>153</b>	<b>336</b>	<b>57</b>	<b>1219</b>

Neck Dissection on the Contralateral Side Subsite was not reported in 5 patients.

NOS: not otherwise specified.

N.D.: neck dissection.

## Radiotherapy by Subsite

Type of radiotherapy	Superior wall	Lateral wall	Posterior wall	Anterior wall	Oropharynx, NOS	Total
0) No radiotherapy	136	227	96	147	25	631
1) X-ray (and/or electron beam)	68	237	55	184	32	576
2) Particle beam	1	3	0	3	0	7
3) B.T.	0	1	1	0	0	2
8) Others	0	0	0	1	0	1
9) Unknown	0	1	1	0	0	2
<b>Total</b>	<b>205</b>	<b>469</b>	<b>153</b>	<b>335</b>	<b>57</b>	<b>1219</b>

Radiotherapy Subsite was not reported in 5 patients.

NOS: not otherwise specified.

B.T.: brachytherapy.

## Chemotherapy by Subsite

<b>Route of administration</b>	<b>Superior wall</b>	<b>Lateral wall</b>	<b>Posterior wall</b>	<b>Anterior wall</b>	<b>Oropharynx, NOS</b>	<b>Total</b>
0) No chemotherapy	146	235	102	177	32	692
1) I.V.	57	224	51	150	25	507
2) I.A.	0	3	0	6	0	9
3) Oral	1	4	0	2	0	7
4) I.V.+I.A.	0	1	0	1	0	2
5) I.V.+Oral	1	1	0	0	0	2
9) Unknown	0	1	0	0	0	1
<b>Total</b>	<b>205</b>	<b>469</b>	<b>153</b>	<b>336</b>	<b>57</b>	<b>1220</b>

Chemotherapy Subsite was not reported in 4 patients.

NOS: not otherwise specified.

I.V.: intravenous. I.A.: intraarterial.

# Nasopharynx(2022)

361 Cases

## Primary Site

Site	Number of patients	(%)
Posterosuperior wall	152	(42.1)
Lateral wall	153	(42.4)
Inferior wall	2	(0.6)
Nasopharynx, NOS	54	(15.0)
<b>Total</b>	<b>361</b>	<b>(100.0)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	1	0	1
10 - 19	5	2	7
20 - 29	9	1	10
30 - 39	9	5	14
40 - 49	41	18	59
50 - 59	50	17	67
60 - 69	67	17	84
70 - 79	67	22	89
80 - 89	18	11	29
90 - 99	1	0	1
100 - 109	0	0	0
<b>Total</b>	<b>268</b>	<b>93</b>	<b>361</b>

## Histological Distribution by Subsite

Histologic type	Posteriosuperior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
S.C.C., NOS	95	102	2	27	226
S.C.C., large cell, nonkerat., NOS	16	17	0	4	37
Lymphoepithelial ca.	4	12	0	8	24
Ca., NOS	9	7	0	2	18
S.C.C., kerat., NOS	6	2	0	1	9
Adenoid cystic ca.	3	3	0	1	7
Ca., undiff., NOS	6	0	0	1	7
S.C.C., small cell, nonkerat.	4	2	0	1	7
Adenocarcinoma, NOS	1	2	0	1	4
Malig. lymphoma, large B-cell, diffuse, NOS	0	1	0	2	3
Malig. melanoma, NOS	0	1	0	2	3
Malig. lymphoma, NOS	1	0	0	1	2
Mucoepidermoid ca.	1	1	0	0	2
Neoplasm, malig.	0	2	0	0	2
Spindle cell ca., NOS	2	0	0	0	2
Clear cell ca., NOS	0	1	0	0	1
Epithelial-myoepithelial ca.	1	0	0	0	1
Myoepithelial ca.	0	0	0	1	1
Papillary adenocarcinoma, NOS	0	0	0	1	1
Papillary S.C.C.	1	0	0	0	1
Plasmacytoma, NOS	1	0	0	0	1
S.C.C., spindle cell	0	0	0	1	1
Small cell ca., NOS	1	0	0	0	1
<b>Total</b>	<b>152</b>	<b>153</b>	<b>2</b>	<b>54</b>	<b>361</b>

Ca., ca.: carcinoma.

NOS: not otherwise specified.

## Nasopharynx -----361 Cases

S.C.C.: squamous cell carcinoma.

Malig., malig.: malignant.

undiff.: undifferentiated.

quest.: questionable.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

### T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N3</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	1	0	0	0	0	1
T1	37	32	15	17(3)	1	0	103
T2	18	34(2)	33(1)	10(2)	0	0	95
T3	18	22	25(5)	15(3)	0	0	80
T4	8(1)	21(3)	28(3)	13(4)	0	0	70
Tis	0	0	0	0	0	0	0
TX	0	0	0	1	5	0	6
T-	0	0	0	0	0	0	0
<b>Total</b>	<b>83(1)</b>	<b>110(5)</b>	<b>101(9)</b>	<b>56(12)</b>	<b>6</b>	<b>0</b>	<b>354</b>

T and N Status was not reported in 7 patients.

M1:27 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Posteriosuperior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
<b>Surgery</b>					
without	143	147	1	47	338
with	4	5	1	6	16
unknown	5	1	0	1	7
<b>Radiotherapy</b>					
without	13	15	1	10	39
with	134	137	1	43	315
unknown	5	1	0	1	7
<b>Chemotherapy</b>					
without	32	34	2	11	79
with	115	118	0	42	275
unknown	5	1	0	1	7
<b>Total</b>	<b>152</b>	<b>153</b>	<b>2</b>	<b>54</b>	<b>361</b>

NOS: not otherwise specified.

## Treatment Method for the Cervical Lymph Nodes by Subsite

<b>Treatment Method</b>	<b>Posteriosuperior wall</b>	<b>Lateral wall</b>	<b>Inferior wall</b>	<b>Nasopharynx, NOS</b>	<b>Total</b>
<b>Surgery</b>					
without	143	147	2	51	343
with	2	5	0	2	9
unknown	7	1	0	1	9
<b>Radiotherapy</b>					
without	30	38	2	17	87
with	115	114	0	36	265
unknown	7	1	0	1	9
<b>Chemotherapy</b>					
without	36	46	2	19	103
with	109	106	0	34	249
unknown	7	1	0	1	9
<b>Total</b>	<b>152</b>	<b>153</b>	<b>2</b>	<b>54</b>	<b>361</b>

NOS: not otherwise specified.

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Posteriosuperior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
No treatment	5	3	0	0	8
F) (Rad.+Chem.)	69	69	0	26	164
B) Rad. alone	22	27	1	6	56
C)F) Chem. -> (Rad.+Chem.)	24	18	0	6	48
F)C) (Rad.+Chem.) -> Chem.	12	13	0	1	26
C) Chem. alone	4	7	0	6	17
A) Surg. alone	3	2	1	4	10
C)B) Chem. -> Rad.	4	1	0	0	5
C)F)C) Chem. -> (Rad.+Chem.) -> Chem.	1	2	0	0	3
B)C) Rad. -> Chem.	0	0	0	2	2
F)I) (Rad.+Chem.) -> Other	0	2	0	0	2
A)B) Surg. -> Rad.	1	0	0	0	1
A)F) Surg. -> (Rad.+Chem.)	0	1	0	0	1
C)C) Chem. -> Chem.	0	1	0	0	1
C)C)F) Chem. -> Chem. -> (Rad.+Chem.)	1	0	0	0	1
D) (Surg.+Rad.)	0	0	0	1	1
F)A) (Rad.+Chem.) -> Surg.	0	0	0	1	1
F)B) (Rad.+Chem.) -> Rad.	0	1	0	0	1
F)E) (Rad.+Chem.) -> (Surg.+Chem)	0	1	0	0	1
F)H) (Rad.+Chem.) -> Nonspetific Immunotherapy	0	1	0	0	1
G) Surg.+Rad.+Chem.	0	1	0	0	1
H) Nonspetific Immunotherapy	0	1	0	0	1
Other	1	1	0	0	2
Unknown	5	1	0	1	7
<b>Total</b>	<b>152</b>	<b>153</b>	<b>2</b>	<b>54</b>	<b>361</b>

NOS: not otherwise specified.

Nasopharynx -----361 Cases

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.  
Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Subsite

<b>Surgical method</b>	<b>Posteriosuperior wall</b>	<b>Lateral wall</b>	<b>Inferior wall</b>	<b>Nasopharynx, NOS</b>	<b>Total</b>
No surgery	141	146	1	49	337
Maxillectomy, other type	0	0	0	2	2
Resection of the soft palate	0	0	1	0	1
Transoral resection	0	0	0	1	1
Others	4	5	0	1	10
<b>Total</b>	<b>145</b>	<b>151</b>	<b>2</b>	<b>53</b>	<b>351</b>

Surgical Methods for the Primary Lesion Subsite was not reported in 10 patients.

NOS: not otherwise specified.

## Reconstructive Surgery by Subsite

<b>Reconstructive surgery</b>	<b>Posteriosuperior wall</b>	<b>Lateral wall</b>	<b>Inferior wall</b>	<b>Nasopharynx, NOS</b>	<b>Total</b>
No reconstruction	144	151	2	53	350
Mucosal flap	1	0	0	0	1
<b>Total</b>	<b>145</b>	<b>151</b>	<b>2</b>	<b>53</b>	<b>351</b>

Reconstructive Surgery Subsite was not reported in 10 patients.

NOS: not otherwise specified.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh. FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

### Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Posteriosuperior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No N.D.	141	146	2	51	340
1) Total N.D.	2	2	0	0	4
2) Selective N.D.	0	3	0	2	5
8) Others	0	1	0	0	1
<b>Total</b>	<b>143</b>	<b>152</b>	<b>2</b>	<b>53</b>	<b>350</b>

Neck Dissection on the Ipsilateral Side Subsite was not reported in 11 patients.

NOS: not otherwise specified.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Posteriosuperior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No N.D.	143	151	2	52	348
2) Selective N.D.	0	1	0	1	2
<b>Total</b>	<b>143</b>	<b>152</b>	<b>2</b>	<b>53</b>	<b>350</b>

Neck Dissection on the Contralateral Side Subsite was not reported in 11 patients.

NOS: not otherwise specified.

N.D.: neck dissection.

## Radiotherapy by Subsite

Type of radiotherapy	Posteriosuperior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No radiotherapy	12	14	1	9	36
1) X-ray (and/or electron beam)	130	133	1	41	305
2) Particle beam	5	5	0	3	13
<b>Total</b>	<b>147</b>	<b>152</b>	<b>2</b>	<b>53</b>	<b>354</b>

Radiotherapy Subsite was not reported in 7 patients.  
 NOS: not otherwise specified.  
 B.T.: brachytherapy.

## Chemotherapy by Subsite

Route of administration	Posteriosuperior wall	Lateral wall	Inferior wall	Nasopharynx, NOS	Total
0) No chemotherapy	32	34	2	10	78
1) I.V.	114	114	0	41	269
2) I.A.	0	1	0	0	1
3) Oral	1	1	0	0	2
5) I.V.+Oral	0	2	0	2	4
<b>Total</b>	<b>147</b>	<b>152</b>	<b>2</b>	<b>53</b>	<b>354</b>

Chemotherapy Subsite was not reported in 7 patients.  
 NOS: not otherwise specified.  
 I.V.: intravenous. I.A.: intraarterial.

Nasal Cavity and Paranasal Sinuses  
(Excluding the Maxillary Sinus)  
(2022)

472 Cases

## Primary Site

Site	Number of patients	(%)
Nasal cavity	265	(56.1)
Ethmoid sinus	95	(20.1)
Frontal sinus	5	(1.1)
Sphenoid sinus	11	(2.3)
Paranasal sinus, NOS	96	(20.3)
<b>Total</b>	<b>472</b>	<b>(100.0)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	1	0	1
10 - 19	1	2	3
20 - 29	1	3	4
30 - 39	11	4	15
40 - 49	41	15	56
50 - 59	59	25	84
60 - 69	71	44	115
70 - 79	73	51	124
80 - 89	39	23	62
90 - 99	4	3	7
100 - 109	0	1	1
<b>Total</b>	<b>301</b>	<b>171</b>	<b>472</b>

## Histological Distribution by Subsite

Histologic type	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
S.C.C., NOS	94	43	4	8	31	180
Malig. melanoma, NOS	52	8	0	1	13	74
Olfactory neuroblastoma	32	11	0	0	21	64
Adenoid cystic ca.	17	3	0	2	3	25
Adenocarcinoma, NOS	9	7	0	0	6	22
Ca., NOS	7	3	1	0	6	17
Ca., undiff., NOS	2	6	0	0	0	8
S.C.C., kerat., NOS	5	2	0	0	1	8
Neuroendocrine ca., NOS	3	4	0	0	0	7
S.C.C., large cell, nonkerat., NOS	6	1	0	0	0	7
Neoplasm, malig.	2	2	0	0	2	6
Basal cell ca., NOS	4	0	0	0	1	5
Small cell ca., NOS	2	0	0	0	3	5
Papillary S.C.C.	4	0	0	0	0	4
S.C.C. in situ, NOS	4	0	0	0	0	4
Carcinoid tumor, NOS	2	1	0	0	0	3
Malig. lymphoma, NOS	1	1	0	0	1	3
Rhabdomyosarcoma, NOS	1	1	0	0	1	3
Adenocarcinoma, intestinal type	2	0	0	0	0	2
Adenosquamous ca.	1	0	0	0	1	2
Alveolar rhabdomyosarcoma	1	0	0	0	1	2
Basal cell Adenocarcinoma	2	0	0	0	0	2
Basaloid S.C.C.	1	1	0	0	0	2
Lymphoepithelial ca.	0	1	0	0	1	2
Malig. lymphoma, large B-cell, diffuse, NOS	1	0	0	0	1	2

Nasal Cavity and Paranasal Sinuses -----472 Cases

Histologic type	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
Acinar cell ca.	1	0	0	0	0	1
Adenocarcinoma with neuroendocrine differentiation	1	0	0	0	0	1
Ca. ex pleomorphic adenoma	0	0	0	0	1	1
Chondrosarcoma, NOS	1	0	0	0	0	1
Epithelial-myoepithelial ca.	0	0	0	0	1	1
Leiomyosarcoma, NOS	1	0	0	0	0	1
Mucoepidermoid ca.	1	0	0	0	0	1
Myoepithelial ca.	1	0	0	0	0	1
Osteosarcoma, NOS	0	0	0	0	1	1
Papillary Adenocarcinoma, NOS	1	0	0	0	0	1
Polymorphous low grade Adenocarcinoma	1	0	0	0	0	1
S.C.C., spindle cell	1	0	0	0	0	1
Transitional cell ca., NOS	1	0	0	0	0	1
<b>Total</b>	<b>265</b>	<b>95</b>	<b>5</b>	<b>11</b>	<b>96</b>	<b>472</b>

Ca., ca.: carcinoma.

NOS: not otherwise specified.

S.C.C.: squamous cell carcinoma.

Malig., malig.: malignant.

undiff.: undifferentiated.

quest.: questionable.

kerat.: keratinizing.

nonkerat.: nonkeratinizing.

## T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	1	0	1
T1	57	3	0	0	1	0	0	1	0	1	0	63
T2	44	3(1)	0	0	2	1	0	0	0	1	0	51
T3	72(1)	3(2)	0	0	5(2)	3(1)	0	0	0	0	0	83
T4	16	1	1	0	0	0	1	0	0	0	0	19
T4a	95(2)	7	0	0	3	5(2)	0	0	3(1)	0	0	113
T4b	73(8)	11(3)	0	0	10(4)	7(1)	0	0	0	1	0	102
Tis	4	0	0	0	0	0	0	0	0	0	0	4
TX	6	0	0	0	0	0	0	0	0	12	0	18
T-	0	0	0	0	0	0	0	0	0	0	0	0
Total	367(11)	28(6)	1	0	21(6)	16(4)	1	1	3(1)	16	0	454

T and N Status was not reported in 18 patients.

M1:28 cases. Number in parentheses indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
<b>Surgery</b>						
without	106	54	4	11	47	222
with	153	39	1	0	47	240
unknown	6	2	0	0	2	10
<b>Radiotherapy</b>						
without	100	18	2	1	30	151
with	159	75	3	10	64	311
unknown	6	2	0	0	2	10
<b>Chemotherapy</b>						
without	170	32	2	6	51	261
with	89	61	3	5	43	201
unknown	6	2	0	0	2	10
<b>Total</b>	<b>265</b>	<b>95</b>	<b>5</b>	<b>11</b>	<b>96</b>	<b>472</b>

NOS: not otherwise specified.

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
<b>Surgery</b>						
without	240	89	5	11	88	433
with	19	3	0	0	4	26
unknown	6	3	0	0	4	13
<b>Radiotherapy</b>						
without	223	66	5	8	74	376
with	36	26	0	3	18	83
unknown	6	3	0	0	4	13
<b>Chemotherapy</b>						
without	222	64	5	7	74	372
with	37	28	0	4	18	87
unknown	6	3	0	0	4	13
<b>Total</b>	<b>265</b>	<b>95</b>	<b>5</b>	<b>11</b>	<b>96</b>	<b>472</b>

NOS: not otherwise specified.

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
No treatment	5	1	1	0	6	13
A) Surg. alone	72	10	1	0	15	98
A)B) Surg. -> Rad.	47	10	0	0	14	71
B) Rad. alone	40	11	0	6	14	71
F) (Rad.+Chem.)	22	19	1	1	11	54
A)F) Surg. -> (Rad.+Chem.)	14	9	0	0	9	32
C)F) Chem. -> (Rad.+Chem.)	7	6	0	2	3	18
C) Chem. alone	9	3	0	1	3	16
C)B) Chem. -> Rad.	6	4	1	0	3	14
F)C) (Rad.+Chem.) -> Chem.	6	2	0	1	2	11
C)A) Chem. -> Surg.	6	3	0	0	0	9
B)C) Rad. -> Chem.	3	4	0	0	1	8
A)C) Surg. -> Chem.	4	0	0	0	3	7
C)A)F) Chem. -> Surg. -> (Rad.+Chem.)	1	4	0	0	0	5
C)F)C) Chem. -> (Rad.+Chem.) -> Chem.	1	2	1	0	1	5
A)B)C) Surg. -> Rad. -> Chem.	3	0	0	0	1	4
C)A)B) Chem. -> Surg. -> Rad.	2	1	0	0	0	3
F)A) (Rad.+Chem.) -> Surg.	1	1	0	0	1	3
C)B)C) Chem. -> Rad. -> Chem.	1	1	0	0	0	2
C)C) Chem. -> Chem.	1	1	0	0	0	2
H) Nonspecific Immunotherapy	2	0	0	0	0	2
A)A) Surg. -> Surg.	1	0	0	0	0	1
A)A)B) Surg. -> Surg. -> Rad.	1	0	0	0	0	1
A)B)H) Surg. -> Rad. -> Nonspecific Immunotherapy	1	0	0	0	0	1

Nasal Cavity and Paranasal Sinuses -----472 Cases

Sequence of treatment methods	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
A)C)B) Surg. -> Chem. -> Rad.	0	0	0	0	1	1
A)H) Surg. -> Nonspecific Immunotherapy	0	0	0	0	1	1
B)B)C) Rad. -> Rad. -> Chem.	0	0	0	0	1	1
B)C)C) Rad. -> Chem. -> Chem.	1	0	0	0	0	1
B)H) Rad. -> Nonspecific Immunotherapy	1	0	0	0	0	1
C)A)C) Chem. -> Surg. -> Chem.	0	0	0	0	1	1
C)C)B) Chem. -> Chem. -> Rad.	0	0	0	0	1	1
C)D)C) Chem. -> (Surg.+Rad.) -> Chem.	0	0	0	0	1	1
C)F)A) Chem. -> (Rad.+Chem.) -> Surg.	0	1	0	0	0	1
I)F) Other -> (Rad.+Chem.)	1	0	0	0	0	1
Other	0	0	0	0	1	1
Unknown	6	2	0	0	2	10
<b>Total</b>	<b>265</b>	<b>95</b>	<b>5</b>	<b>11</b>	<b>96</b>	<b>472</b>

NOS: not otherwise specified.

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Subsite

<b>Surgical method</b>	<b>Nasal cavity</b>	<b>Ethmoid sinus</b>	<b>Frontal sinus</b>	<b>Sphenoid sinus</b>	<b>Paranasal sinus, NOS</b>	<b>Total</b>
No surgery	106	54	4	10	47	221
Maxillectomy, other type	52	6	0	0	9	67
Endoscopic skull base surgery	19	15	0	0	15	49
Skull base surgery	13	8	1	0	3	25
Partial maxillectomy	15	1	0	0	3	19
Total maxillectomy	5	1	0	0	2	8
Endoscopic resection	1	0	0	0	2	3
Others	48	8	0	0	12	68
<b>Total</b>	<b>259</b>	<b>93</b>	<b>5</b>	<b>10</b>	<b>93</b>	<b>460</b>

Surgical Methods for the Primary Lesion Subsite was not reported in 12 patients.

NOS: not otherwise specified.

## Reconstructive Surgery by Subsite

Reconstructive surgery	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
No reconstruction	212	74	4	10	68	368
Others	12	7	0	0	9	28
Mucosal flap	8	4	0	0	13	25
Local skin flap	13	3	0	0	1	17
Free ALT flap	5	2	1	0	1	9
Free RA MC flap	4	1	0	0	1	6
Free fibular OC flap	3	0	0	0	0	3
Free FA flap	1	0	0	0	0	1
PM MC flap	0	1	0	0	0	1
Skin graft	1	0	0	0	0	1
<b>Total</b>	<b>259</b>	<b>92</b>	<b>5</b>	<b>10</b>	<b>93</b>	<b>459</b>

Reconstructive Surgery Subsite was not reported in 13 patients.

NOS: not otherwise specified.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh. FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

### Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No N.D.	240	88	5	10	87	430
1) Total N.D.	3	1	0	0	3	7
2) Selective N.D.	14	1	0	0	1	16
8) Others	2	1	0	0	0	3
9) Unknown	0	0	0	0	1	1
<b>Total</b>	<b>259</b>	<b>91</b>	<b>5</b>	<b>10</b>	<b>92</b>	<b>457</b>

Neck Dissection on the Ipsilateral Side Subsite was not reported in 15 patients.

NOS: not otherwise specified.

N.D.: neck dissection.

### Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No N.D.	251	89	5	10	89	444
1) Total N.D.	0	1	0	0	0	1
2) Selective N.D.	5	0	0	0	2	7
8) Others	3	1	0	0	0	4
9) Unknown	0	0	0	0	1	1
<b>Total</b>	<b>259</b>	<b>91</b>	<b>5</b>	<b>10</b>	<b>92</b>	<b>457</b>

Neck Dissection on the Contralateral Side Subsite was not reported in 15 patients.

NOS: not otherwise specified.

N.D.: neck dissection.

### Radiotherapy by Subsite

Type of radiotherapy	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No radiotherapy	98	17	2	2	31	150
1) X-ray (and/or electron beam)	118	61	3	6	51	239
2) Particle beam	40	14	0	3	11	68
3) B.T.	1	0	0	0	0	1
5) X-ray + B.T.	1	0	0	0	0	1
8) Others	1	1	0	0	1	3
<b>Total</b>	<b>259</b>	<b>93</b>	<b>5</b>	<b>11</b>	<b>94</b>	<b>462</b>

Radiotherapy Subsite was not reported in 10 patients.

NOS: not otherwise specified.

B.T.: brachytherapy.

### Chemotherapy by Subsite

Route of administration	Nasal cavity	Ethmoid sinus	Frontal sinus	Sphenoid sinus	Paranasal sinus, NOS	Total
0) No chemotherapy	169	32	2	6	51	260
1) I.V.	86	56	3	4	41	190
2) I.A.	2	2	0	0	2	6
3) Oral	1	0	0	0	0	1
4) I.V.+I.A.	1	1	0	1	0	3
5) I.V.+Oral	0	2	0	0	0	2
9) Unknown	0	0	0	0	1	1
<b>Total</b>	<b>259</b>	<b>93</b>	<b>5</b>	<b>11</b>	<b>95</b>	<b>463</b>

Chemotherapy Subsite was not reported in 9 patients.

NOS: not otherwise specified.

I.V.: intravenous. I.A.: intraarterial.

# Maxillary Sinus(2022)

384 Cases

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	1	1	2
10 - 19	1	0	1
20 - 29	1	1	2
30 - 39	6	4	10
40 - 49	17	4	21
50 - 59	43	10	53
60 - 69	76	19	95
70 - 79	118	32	150
80 - 89	28	17	45
90 - 99	2	3	5
100 - 109	0	0	0
<b>Total</b>	<b>293</b>	<b>91</b>	<b>384</b>

## Histological Distribution

Histologic type	Total	(%)
S.C.C., NOS	279	(72.7)
Adenoid cystic ca.	17	(4.4)
Ca., NOS	13	(3.4)
S.C.C., kerat., NOS	13	(3.4)
Malig. melanoma, NOS	10	(2.6)
S.C.C., large cell, nonkerat., NOS	5	(1.3)
Neoplasm, malig.	4	(1)
Small cell ca., NOS	4	(1)
Spindle cell ca., NOS	4	(1)
Alveolar rhabdomyosarcoma	3	(0.8)
Extraskeletal Ewing's sarcoma	3	(0.8)
Osteosarcoma, NOS	3	(0.8)
S.C.C., spindle cell	3	(0.8)
Adenocarcinoma, NOS	2	(0.5)
Adenosquamous ca.	2	(0.5)
Hemangiosarcoma	2	(0.5)
Malig. lymphoma, NOS	2	(0.5)
Mucoepidermoid ca.	2	(0.5)
Ca., undiff., NOS	1	(0.3)
Carcinosarcoma, NOS	1	(0.3)
Chondrosarcoma, NOS	1	(0.3)
Fibromyxosarcoma	1	(0.3)
Liposarcoma, NOS	1	(0.3)
Malig. fibrous histiocytoma	1	(0.3)
Malig. tumor, spindle cell type	1	(0.3)
Myoepithelial ca.	1	(0.3)
Neurilemoma, malig.	1	(0.3)
Papillary S.C.C.	1	(0.3)
Spindle cell rhabdomyosarcoma	1	(0.3)
Synovial sarcoma, spindle cell	1	(0.3)
Verrucous ca., NOS	1	(0.3)
<b>Total</b>	<b>384</b>	<b>(100.0)</b>

Ca., ca.: carcinoma.  
 NOS: not otherwise specified.  
 S.C.C.: squamous cell carcinoma.  
 Malig., malig.: malignant.  
 undiff.: undifferentiated.  
 quest.: questionable.  
 kerat.: keratinizing.  
 nonkerat.: nonkeratinizing.

### T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	1	0	0	0	0	0	0	0	0	0	0	1
T1	2	0	0	0	0	0	0	0	0	0	0	2
T2	15	0	0	2	0	0	0	0	0	0	0	17
T3	58	5(2)	0	0	9	2(1)	0	0	0	2	0	76
T4	2	0	1	0	1	0	0	0	0	0	0	4
T4a	142(8)	18(2)	0	0	29(2)	13	0	0	2	1	0	205
T4b	43(2)	10(3)	0	0	10	8(1)	0	0	1	1(1)	0	73
Tis	1	0	0	0	0	0	0	0	0	0	0	1
TX	0	0	0	0	0	0	0	0	0	3	0	3
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>264(10)</b>	<b>33(7)</b>	<b>1</b>	<b>2</b>	<b>49(2)</b>	<b>23(2)</b>	<b>0</b>	<b>0</b>	<b>3</b>	<b>7(1)</b>	<b>0</b>	<b>382</b>

T and N Status was not reported in 2 patients.

M1:22 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Treatment Method for the Primary Lesion

<b>Treatment Method</b>	<b>Total</b>	<b>(%)</b>
<b>Surgery</b>		
without	264	(68.8)
with	116	(30.2)
unknown	4	(1)
<b>Radiotherapy</b>		
without	95	(24.7)
with	285	(74.2)
unknown	4	(1)
<b>Chemotherapy</b>		
without	138	(35.9)
with	242	(63)
unknown	4	(1)
<b>Total</b>	<b>384</b>	<b>(100.0)</b>

## Treatment Method for the Cervical Lymph Nodes

<b>Treatment Method</b>	<b>Total</b>	<b>(%)</b>
<b>Surgery</b>		
without	312	(81.2)
with	67	(17.4)
unknown	5	(1.3)
<b>Radiotherapy</b>		
without	250	(65.1)
with	129	(33.6)
unknown	5	(1.3)
<b>Chemotherapy</b>		
without	246	(64.1)
with	133	(34.6)
unknown	5	(1.3)
<b>Total</b>	<b>384</b>	<b>(100.0)</b>

## Sequence of Treatment Methods for the Primary Lesion

Sequence of treatment methods	Total	(%)
No treatment	21	(5.5)
F) (Rad.+Chem.)	124	(32.3)
B) Rad. alone	48	(12.5)
A) Surg. alone	35	(9.1)
A)B) Surg. -> Rad.	26	(6.8)
C)F) Chem. -> (Rad.+Chem.)	21	(5.5)
C) Chem. alone	20	(5.2)
A)F) Surg. -> (Rad.+Chem.)	15	(3.9)
C)A) Chem. -> Surg.	12	(3.1)
B)C) Rad. -> Chem.	8	(2.1)
C)B) Chem. -> Rad.	7	(1.8)
F)A) (Rad.+Chem.) -> Surg.	6	(1.6)
F)C) (Rad.+Chem.) -> Chem.	5	(1.3)
B)A) Rad. -> Surg.	3	(0.8)
C)A)F) Chem. -> Surg. -> (Rad.+Chem.)	3	(0.8)
C)F)C) Chem. -> (Rad.+Chem.) -> Chem.	3	(0.8)
C)A)B) Chem. -> Surg. -> Rad.	2	(0.5)
C)A)C) Chem. -> Surg. -> Chem.	2	(0.5)
C)C)C) Chem. -> Chem. -> Chem.	2	(0.5)
D) (Surg.+Rad.)	2	(0.5)
F)C)C) (Rad.+Chem.) -> Chem. -> Chem.	2	(0.5)
A)C) Surg. -> Chem.	1	(0.3)
A)F)A) Surg. -> (Rad.+Chem.) -> Surg.	1	(0.3)
A)F)C) Surg. -> (Rad.+Chem.) -> Chem.	1	(0.3)
A)F)H) Surg. -> (Rad.+Chem.) -> Nonspecific Immunotherapy	1	(0.3)
A)H) Surg. -> Nonspecific Immunotherapy	1	(0.3)
B)A)B) Rad. -> Surg. -> Rad.	1	(0.3)
C)B)C) Chem. -> Rad. -> Chem.	1	(0.3)
C)F)A) Chem. -> (Rad.+Chem.) -> Surg.	1	(0.3)
D)C) (Surg.+Rad.) -> Chem.	1	(0.3)
D)G) (Surg.+Rad.) -> Surg.+Rad.+Chem.	1	(0.3)
F)A)F) (Rad.+Chem.) -> Surg. -> (Rad.+Chem.)	1	(0.3)
F)H) (Rad.+Chem.) -> Nonspecific Immunotherapy	1	(0.3)
I)I)I) Other -> Other -> Other	1	(0.3)
Unknown	4	(1)
<b>Total</b>	<b>384</b>	<b>(100.0)</b>

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.  
Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion

Surgical method	Total	(%)
No surgery	263	(68.5)
Total maxillectomy	64	(16.7)
Partial maxillectomy	20	(5.2)
Extended maxillectomy	14	(3.6)
Maxillectomy, other type	12	(3.1)
Endoscopic resection	2	(0.5)
Endoscopic skull base surgery	2	(0.5)
Skull base surgery	1	(0.3)
Others	1	(0.3)
<b>Total</b>	<b>379</b>	<b>(100.0)</b>

Surgical Methods for the Primary Lesion was not reported in 5 patients.  
 NOS: not otherwise specified.

## Reconstructive Surgery

Reconstructive surgery	Total	(%)
No reconstruction	308	(80.2)
Free RA MC flap	39	(10.2)
Free ALT flap	14	(3.6)
Free fibular OC flap	7	(1.8)
Skin graft	4	(1)
Free scapular OC flap	2	(0.5)
Others	2	(0.5)
Free FA flap	1	(0.3)
Mucosal flap	1	(0.3)
<b>Total</b>	<b>378</b>	<b>(100.0)</b>

Reconstructive Surgery was not reported in 6 patients.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral

thigh. FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

## Neck Dissection on the Ipsilateral Side

Neck dissection	Total	(%)
0) No N.D.	308	(80.2)
1) Total N.D.	10	(2.6)
2) Selective N.D.	55	(14.3)
3) Lymph node excision	1	(0.3)
8) Others	1	(0.3)
<b>Total</b>	<b>375</b>	<b>(100.0)</b>

Neck Dissection on the Ipsilateral Side was not reported in 9 patients.  
N.D.: neck dissection.

## Neck Dissection on the Contralateral Side

Neck dissection	Total	(%)
0) No N.D.	364	(94.8)
1) Total N.D.	3	(0.8)
2) Selective N.D.	5	(1.3)
3) Lymph node excision	1	(0.3)
8) Others	2	(0.5)
<b>Total</b>	<b>375</b>	<b>(100.0)</b>

Neck Dissection on the Contralateral Side was not reported in 9 patients.  
N.D.: neck dissection.

## Radiotherapy

Type of radiotherapy	Total	(%)
0) No radiotherapy	85	(22.1)
1) X-ray (and/or electron beam)	261	(68)
2) Particle beam	31	(8.1)
8) Others	2	(0.5)
<b>Total</b>	<b>379</b>	<b>(100.0)</b>

Radiotherapy was not reported in 5 patients.

B.T.: brachytherapy.

## Chemotherapy

Route of administration	Total	(%)
0) No chemotherapy	135	(35.2)
1) I.V.	139	(36.2)
2) I.A.	97	(25.3)
3) Oral	2	(0.5)
4) I.V.+I.A.	4	(1)
5) I.V.+Oral	1	(0.3)
6) I.A.+Oral	1	(0.3)
9) Unknown	1	(0.3)
<b>Total</b>	<b>380</b>	<b>(100.0)</b>

Chemotherapy was not reported in 4 patients.

I.V.: intravenous. I.A.: intraarterial.

# Major Salivary Glands(2022)

833 Cases

## Primary Site

Site	Number of patients	(%)
Parotid gland	594	(71.3)
Submandibular gland	201	(24.1)
Sublingual gland	34	(4.1)
Major salivary gland, NOS	4	(0.5)
<b>Total</b>	<b>833</b>	<b>(100.0)</b>

NOS: not otherwise specified.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	1	0	1
10 - 19	7	8	15
20 - 29	9	16	25
30 - 39	25	29	54
40 - 49	41	32	73
50 - 59	71	61	132
60 - 69	121	55	176
70 - 79	170	77	247
80 - 89	61	37	98
90 - 99	6	6	12
100 - 109	0	0	0
<b>Total</b>	<b>512</b>	<b>321</b>	<b>833</b>

## Parotid gland Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	5	6	11
20 - 29	9	16	25
30 - 39	20	21	41
40 - 49	35	25	60
50 - 59	52	39	91
60 - 69	81	41	122
70 - 79	120	45	165
80 - 89	43	26	69
90 - 99	6	4	10
100 - 109	0	0	0
<b>Total</b>	<b>371</b>	<b>223</b>	<b>594</b>

## Submandibular gland Age Distribution by Gender

Age	Male	Female	Total
0 - 9	1	0	1
10 - 19	2	1	3
20 - 29	0	0	0
30 - 39	4	8	12
40 - 49	6	5	11
50 - 59	19	14	33
60 - 69	32	12	44
70 - 79	45	26	71
80 - 89	16	9	25
90 - 99	0	1	1
100 - 109	0	0	0
<b>Total</b>	<b>125</b>	<b>76</b>	<b>201</b>

## Sublingual gland Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	1	1
20 - 29	0	0	0
30 - 39	1	0	1
40 - 49	0	2	2
50 - 59	0	8	8
60 - 69	6	2	8
70 - 79	4	6	10
80 - 89	2	2	4
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>13</b>	<b>21</b>	<b>34</b>

## Major salivary gland, NOS Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	0	0	0
50 - 59	0	0	0
60 - 69	2	0	2
70 - 79	1	0	1
80 - 89	0	0	0
90 - 99	0	1	1
100 - 109	0	0	0
<b>Total</b>	<b>3</b>	<b>1</b>	<b>4</b>

NOS : Not Otherwise Specified

## Histological Distribution by Subsite

Histologic type	Parotid gland	Submandibular gland	Sublingual gland	Major salivary gland, NOS	Total
	(C07.9)	(C08.0)	(C08.1)	(C08.9)	
Salivary duct ca.	149	55	1	1	206
Adenoid cystic ca.	57	63	22	0	142
Mucoepidermoid ca.	113	9	6	1	129
S.C.C., NOS	43	23	1	0	67
Ca. ex pleomorphic adenoma	51	14	1	0	66
Ca., NOS	35	10	1	0	46
Acinar cell ca.	32	1	0	0	33
Adenocarcinoma, NOS	27	5	1	0	33
Epithelial-myoeplithelial ca.	22	3	1	0	26
Myoeplithelial ca.	16	6	0	2	24
Malig. lymphoma, NOS	5	3	0	0	8
Basal cell adenocarcinoma	7	0	0	0	7
Neoplasm, malig.	6	1	0	0	7
Secretory ca.	5	1	0	0	6
Cystadenocarcinoma	3	2	0	0	5
Lymphoepithelial ca.	3	2	0	0	5
Basal cell ca., NOS	3	0	0	0	3
Carcinosarcoma, NOS	2	1	0	0	3
Ca., undiff., NOS	2	0	0	0	2
Malig. melanoma, NOS	2	0	0	0	2
Adenosquamous ca.	1	0	0	0	1
Basaloid S.C.C.	0	1	0	0	1
Ewing sarcoma	1	0	0	0	1
Fibrosarcoma, NOS	1	0	0	0	1
Large cell ca., NOS	1	0	0	0	1

Major Salivary Glands -----833 Cases

Histologic type	Parotid gland	Submandibular gland	Sublingual gland	Major salivary gland, NOS	Total
	(C07.9)	(C08.0)	(C08.1)	(C08.9)	
Malig. lymphoma, large B-cell, diffuse, NOS	0	1	0	0	1
Marginal zone B-cell lymphoma, NOS	1	0	0	0	1
Oncocytic ca.	1	0	0	0	1
Polymorphous low grade adenocarcinoma	1	0	0	0	1
S.C.C., kerat., NOS	1	0	0	0	1
S.C.C., large cell, nonkerat., NOS	1	0	0	0	1
Sebaceous ca.	1	0	0	0	1
Transitional cell ca., NOS	1	0	0	0	1
<b>Total</b>	<b>594</b>	<b>201</b>	<b>34</b>	<b>4</b>	<b>833</b>

Ca., ca.: carcinoma.  
 NOS: not otherwise specified.  
 S.C.C.: squamous cell carcinoma.  
 Malig., malig.: malignant.  
 undiff.: undifferentiated.  
 quest.: questionable.  
 kerat.: keratinizing.  
 nonkerat.: nonkeratinizing.

## T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	7	0	0	0	2(1)	0	0	0	0	0	0	9
T1	99	6	0	1	4	1(1)	0	0	1	0	0	112
T2	185(6)	17(1)	2(2)	0	27(6)	2	0	0	3(2)	2	0	238
T3	114(6)	18(1)	1	1	41(8)	4(2)	0	0	3(2)	1	0	183
T4	5	0	1	0	2	0	0	0	0	0	0	8
T4a	103(11)	23(1)	0	1	49(11)	7(2)	1	0	15(5)	2	0	201
T4b	11(2)	2	0	0	9(1)	3(2)	0	0	2(1)	0	0	27
TX	10	0	0	0	2	0	0	0	0	31	0	43
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>534(25)</b>	<b>66(3)</b>	<b>4(2)</b>	<b>3</b>	<b>136(27)</b>	<b>17(7)</b>	<b>1</b>	<b>0</b>	<b>24(10)</b>	<b>36</b>	<b>0</b>	<b>821</b>

T and N Status was not reported in 12 patients.

M1:74 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

Parotid gland  
T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	7	0	0	0	1(1)	0	0	0	0	0	0	8
T1	77	2	0	1	3	1(1)	0	0	1	0	0	85
T2	133(2)	10	1(1)	0	11(3)	0	0	0	1(1)	1	0	157
T3	66(1)	10	1	1	20(3)	4(2)	0	0	1(1)	1	0	104
T4	3	0	0	0	2	0	0	0	0	0	0	5
T4a	86(9)	22(1)	0	1	42(8)	4(2)	0	0	11(4)	2	0	168
T4b	10(1)	2	0	0	7(1)	3(2)	0	0	1	0	0	23
TX	9	0	0	0	2	0	0	0	0	25	0	36
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>391(13)</b>	<b>46(1)</b>	<b>2(1)</b>	<b>3</b>	<b>88(16)</b>	<b>12(7)</b>	<b>0</b>	<b>0</b>	<b>15(6)</b>	<b>29</b>	<b>0</b>	<b>586</b>

T and N Status was not reported in 8 patients.

M1:34 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Submandibular gland T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	1	0	0	0	0	0	0	1
T1	18	4	0	0	1	0	0	0	0	0	0	23
T2	46(3)	5(1)	1(1)	0	15(2)	2	0	0	2(1)	1	0	72
T3	34(4)	7(1)	0	0	20(4)	0	0	0	2(1)	0	0	63
T4	2	0	1	0	0	0	0	0	0	0	0	3
T4a	13(2)	1	0	0	6(3)	2	1	0	3(1)	0	0	26
T4b	0	0	0	0	2	0	0	0	1(1)	0	0	3
TX	1	0	0	0	0	0	0	0	0	5	0	6
T-	0	0	0	0	0	0	0	0	0	0	0	0
Total	114(9)	17(2)	2(1)	0	45(9)	4	1	0	8(4)	6	0	197

T and N Status was not reported in 4 patients.

M1:25 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Sublingual gland T and N Status

T	N0	N1	N2	N2a	N2b	N2c	N3	N3a	N3b	NX	N-	Total
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	4	0	0	0	0	0	0	0	0	0	0	4
T2	6(1)	2	0	0	1(1)	0	0	0	0	0	0	9
T3	11(1)	1	0	0	1(1)	0	0	0	0	0	0	13
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	3	0	0	0	1	1	0	0	1	0	0	6
T4b	1(1)	0	0	0	0	0	0	0	0	0	0	1
TX	0	0	0	0	0	0	0	0	0	1	0	1
T-	0	0	0	0	0	0	0	0	0	0	0	0
Total	25(3)	3	0	0	3(2)	1	0	0	1	1	0	34

M1:5 cases. Number in parenthesis indicates number of M1 cases

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Major salivary gland, NOS T and N Status

<b>T</b>	<b>N0</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
T0	0	0	0	0	0	0	0	0	0	0	0	0
T1	0	0	0	0	0	0	0	0	0	0	0	0
T2	0	0	0	0	0	0	0	0	0	0	0	0
T3	3	0	0	0	0	0	0	0	0	0	0	3
T4	0	0	0	0	0	0	0	0	0	0	0	0
T4a	1	0	0	0	0	0	0	0	0	0	0	1
T4b	0	0	0	0	0	0	0	0	0	0	0	0
TX	0	0	0	0	0	0	0	0	0	0	0	0
T-	0	0	0	0	0	0	0	0	0	0	0	0
<b>Total</b>	<b>4</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>4</b>

NOS : Not Otherwise Specified

T-: not within defined T classification or without reported T classification.

N-: not within defined N classification or without reported N classification.

## Major Salivary Glands -----833 Cases

## Treatment Method for the Primary Lesion by Subsite

Treatment Method	Parotid gland (C07.9)	Submandibular gland (C08.0)	Sublingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
<b>Surgery</b>					
without	100	31	6	0	137
with	489	168	26	4	687
unknown	5	2	2	0	9
<b>Radiotherapy</b>					
without	318	105	19	2	444
with	271	94	13	2	380
unknown	5	2	2	0	9
<b>Chemotherapy</b>					
without	498	154	26	4	682
with	91	45	6	0	142
unknown	5	2	2	0	9
<b>Total</b>	<b>594</b>	<b>201</b>	<b>34</b>	<b>4</b>	<b>833</b>

NOS : Not Otherwise Specified

## Treatment Method for the Cervical Lymph Nodes by Subsite

Treatment Method	Parotid gland (C07.9)	Submandibular gland (C08.0)	Sublingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
<b>Surgery</b>					
without	327	62	13	1	403
with	262	137	19	3	421
unknown	5	2	2	0	9
<b>Radiotherapy</b>					
without	414	120	23	3	560
with	175	79	9	1	264
unknown	5	2	2	0	9
<b>Chemotherapy</b>					
without	517	161	27	4	709
with	72	38	5	0	115
unknown	5	2	2	0	9
<b>Total</b>	<b>594</b>	<b>201</b>	<b>34</b>	<b>4</b>	<b>833</b>

NOS : Not Otherwise Specified

## Sequence of Treatment Methods for the Primary Lesion by Subsite

Sequence of treatment methods	Parotid gland (C07.9)	Submandibular gland (C08.0)	Sublingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
No treatment	16	3	1	0	20
A) Surg. alone	260	77	16	2	355
A)B) Surg. -> Rad.	170	61	7	2	240
B) Rad. alone	42	9	2	0	53
A)F) Surg. -> (Rad.+Chem.)	29	11	3	0	43
C) Chem. alone	24	9	1	0	34
A)C) Surg. -> Chem.	9	8	0	0	17
F) (Rad.+Chem.)	7	6	1	0	14
A)A) Surg. -> Surg.	3	3	0	0	6
A)B)C) Surg. -> Rad. -> Chem.	4	2	0	0	6
Other	25	10	1	0	36
Unknown	5	2	2	0	9
<b>Total</b>	<b>594</b>	<b>201</b>	<b>34</b>	<b>4</b>	<b>833</b>

NOS : Not Otherwise Specified

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.

Treatment methods in parentheses were given concurrently.

## Surgical Methods for the Primary Lesion by Subsite

Surgical method	Parotid gland	Submandibular gland	Sublingual gland	Major salivary gland, NOS	Total
	(C07.9)	(C08.0)	(C08.1)	(C08.9)	
No surgery	99	31	6	0	136
Superficial parotidectomy	169	2	0	0	171
Total parotidectomy	164	0	0	1	165
Submandibulectomy	1	154	2	1	158
Extended total parotidectomy	62	0	0	2	64
Partial parotidectomy	51	0	0	0	51
Deep lobe resection of the parotid gland	36	0	0	0	36
Others	6	11	24	0	41
<b>Total</b>	<b>588</b>	<b>198</b>	<b>32</b>	<b>4</b>	<b>822</b>

Surgical Methods for the Primary Lesion Subsite was not reported in 11 patients.

NOS: not otherwise specified.

## Reconstructive Surgery by Subsite

Reconstructive surgery	Parotid gland (C07.9)	Submandibular gland (C08.0)	Sublingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
No reconstruction	447	176	15	3	641
Free ALT flap	51	9	7	1	68
Free nerve graft	42	0	0	0	42
Free RA MC flap	16	1	0	0	17
PM MC flap	12	2	1	0	15
Local skin flap	10	3	1	0	14
Free FA flap	3	3	3	0	9
Others	5	0	2	0	7
DP flap	1	2	0	0	3
Free fibular OC flap	0	1	2	0	3
Skin graft	1	1	0	0	2
Total	588	198	31	4	821

Reconstructive Surgery Subsite was not reported in 12 patients.

NOS: not otherwise specified.

RA: rectus abdominis.

MC: musculocutaneous.

ALT: anterolateral thigh. FA: forearm.

PM: pectoralis major.

OC: osteocutaneous.

DP: deltopectoral.

## Neck Dissection on the Ipsilateral Side by Subsite

Neck dissection	Parotid gland (C07.9)	Submandibular gland (C08.0)	Sublingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No N.D.	322	61	13	1	397
1) Total N.D.	67	34	2	0	103
2) Selective N.D.	186	103	17	3	309
3) Lymph node excision	8	1	0	0	9
8) Others	2	0	0	0	2
9) Unknown	3	0	0	0	3
<b>Total</b>	<b>588</b>	<b>199</b>	<b>32</b>	<b>4</b>	<b>823</b>

Neck Dissection on the Ipsilateral Side Subsite was not reported in 10 patients.

NOS: not otherwise specified.

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Subsite

Neck dissection	Parotid gland (C07.9)	Submandibular gland (C08.0)	Sublingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No N.D.	575	190	24	4	793
1) Total N.D.	2	2	1	0	5
2) Selective N.D.	6	5	7	0	18
3) Lymph node excision	1	0	0	0	1
8) Others	1	1	0	0	2
9) Unknown	3	1	0	0	4
<b>Total</b>	<b>588</b>	<b>199</b>	<b>32</b>	<b>4</b>	<b>823</b>

Neck Dissection on the Contralateral Side Subsite was not reported in 10 patients.

NOS: not otherwise specified.

N.D.: neck dissection.

### Radiotherapy by Subsite

Type of radiotherapy	Parotid gland (C07.9)	Submandibular gland (C08.0)	Sublingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No radiotherapy	301	99	19	2	421
1) X-ray (and/or electron beam)	231	86	12	2	331
2) Particle beam	51	14	1	0	66
4) X-ray + Particle beam	1	0	0	0	1
8) Others	3	0	0	0	3
<b>Total</b>	<b>587</b>	<b>199</b>	<b>32</b>	<b>4</b>	<b>822</b>

Radiotherapy Subsite was not reported in 11 patients.

NOS: not otherwise specified.

B.T.: brachytherapy.

### Chemotherapy by Subsite

Route of administration	Parotid gland (C07.9)	Submandibular gland (C08.0)	Sublingual gland (C08.1)	Major salivary gland, NOS (C08.9)	Total
0) No chemotherapy	485	152	26	4	667
1) I.V.	87	45	5	0	137
2) I.A.	1	1	0	0	2
3) Oral	10	0	1	0	11
9) Unknown	2	0	0	0	2
<b>Total</b>	<b>585</b>	<b>198</b>	<b>32</b>	<b>4</b>	<b>819</b>

Chemotherapy Subsite was not reported in 14 patients.

NOS: not otherwise specified.

I.V.: intravenous. I.A.: intraarterial.

# Primary Unknown(2022)

174 Cases

## Subtype

Subtype	Number of patients	(%)
EBV positive	5	(2.9)
p16 positive	51	(29.3)
Other	118	(67.8)
<b>Total</b>	<b>174</b>	<b>(100.0)</b>

Patients with both EBV-positive and p16-positive are classified as "EBV-positive" in all the tables.

## Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	2	0	2
40 - 49	8	1	9
50 - 59	28	4	32
60 - 69	42	5	47
70 - 79	47	12	59
80 - 89	21	3	24
90 - 99	1	0	1
100 - 109	0	0	0
<b>Total</b>	<b>149</b>	<b>25</b>	<b>174</b>

## EBV positive Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	0	0	0
50 - 59	2	1	3
60 - 69	1	0	1
70 - 79	0	0	0
80 - 89	1	0	1
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>4</b>	<b>1</b>	<b>5</b>

## p16 positive Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	2	0	2
40 - 49	5	0	5
50 - 59	10	1	11
60 - 69	10	2	12
70 - 79	15	3	18
80 - 89	3	0	3
90 - 99	0	0	0
100 - 109	0	0	0
<b>Total</b>	<b>45</b>	<b>6</b>	<b>51</b>

## Other Age Distribution by Gender

Age	Male	Female	Total
0 - 9	0	0	0
10 - 19	0	0	0
20 - 29	0	0	0
30 - 39	0	0	0
40 - 49	3	1	4
50 - 59	14	2	16
60 - 69	27	3	30
70 - 79	30	9	39
80 - 89	17	3	20
90 - 99	1	0	1
100 - 109	0	0	0
<b>Total</b>	<b>92</b>	<b>18</b>	<b>110</b>

## EBV positive N and M Status

M	N1	N2	N3	NX	N-	Total
M0	5	0	0	0	0	5
M1	0	0	0	0	0	0
MX	0	0	0	0	0	0
M-	0	0	0	0	0	0
<b>Total</b>	<b>5</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>5</b>

N-: not within defined N classification or without reported N classification.

M-: without reported M classification.

## p16 positive N and M Status

<b>M</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
M0	31	5	0	2	1	6	0	2	0	0	47
M1	1	0	0	0	0	1	0	0	0	0	2
MX	0	0	0	0	0	0	0	0	0	0	0
M-	0	0	0	0	0	0	0	0	0	2	2
<b>Total</b>	<b>32</b>	<b>5</b>	<b>0</b>	<b>2</b>	<b>1</b>	<b>7</b>	<b>0</b>	<b>2</b>	<b>0</b>	<b>2</b>	<b>51</b>

N-: not within defined N classification or without reported N classification.  
M-: without reported M classification.

## Other N and M Status

<b>M</b>	<b>N1</b>	<b>N2</b>	<b>N2a</b>	<b>N2b</b>	<b>N2c</b>	<b>N3</b>	<b>N3a</b>	<b>N3b</b>	<b>NX</b>	<b>N-</b>	<b>Total</b>
M0	14	0	9	31	2	1	2	44	3	1	107
M1	0	0	0	0	3	0	1	5	0	0	9
MX	0	0	0	0	0	0	0	0	0	0	0
M-	0	0	0	0	0	0	0	1	1	0	2
<b>Total</b>	<b>14</b>	<b>0</b>	<b>9</b>	<b>31</b>	<b>5</b>	<b>1</b>	<b>3</b>	<b>50</b>	<b>4</b>	<b>1</b>	<b>118</b>

N-: not within defined N classification or without reported N classification.  
M-: without reported M classification.

## Treatment Method for the Primary Lesion by Subtype

Treatment Method	EBV positive	p16 positive	Other	Total
<b>Surgery</b>				
without	5	39	99	143
with	0	12	19	31
<b>Radiotherapy</b>				
without	2	32	80	114
with	3	19	38	60
<b>Chemotherapy</b>				
without	3	36	88	127
with	2	15	30	47
<b>Total</b>	<b>5</b>	<b>51</b>	<b>118</b>	<b>174</b>

## Treatment Method for the Cervical Lymph Nodes by Subtype

Treatment Method	EBV positive	p16 positive	Other	Total
<b>Surgery</b>				
without	0	15	43	58
with	5	36	75	116
<b>Radiotherapy</b>				
without	1	16	43	60
with	4	35	75	114
<b>Chemotherapy</b>				
without	2	23	59	84
with	3	28	59	90
<b>Total</b>	<b>5</b>	<b>51</b>	<b>118</b>	<b>174</b>

## Sequence of Treatment Methods for the Cervical Lymph Nodes by Subtype

Sequence of treatment methods	EBV positive	p16 positive	Other	Total
No treatment	0	3	9	12
A)F) Surg. -> (Rad.+Chem.)	3	16	22	41
A) Surg. alone	1	10	25	36
A)B) Surg. -> Rad.	1	6	15	22
F) (Rad.+Chem.)	0	7	9	16
B) Rad. alone	0	3	5	8
C) Chem. alone	0	2	6	8
F)C) (Rad.+Chem.) -> Chem.	0	0	6	6
C)F) Chem. -> (Rad.+Chem.)	0	0	3	3
F)A) (Rad.+Chem.) -> Surg.	0	1	2	3
B)C) Rad. -> Chem.	0	0	2	2
C)A)F) Chem. -> Surg. -> (Rad.+Chem.)	0	1	1	2
D) (Surg.+Rad.)	0	0	2	2
G) Surg.+Rad.+Chem.	0	1	1	2
A)C) Surg. -> Chem.	0	0	1	1
A)C)F) Surg. -> Chem. -> (Rad.+Chem.)	0	0	1	1
A)D) Surg. -> (Surg.+Rad.)	0	0	1	1
A)H) Surg. -> Nonspecific Immunotherapy	0	1	0	1
B)A) Rad. -> Surg.	0	0	1	1
C)A) Chem. -> Surg.	0	0	1	1
C)A)B) Chem. -> Surg. -> Rad.	0	0	1	1
C)B) Chem. -> Rad.	0	0	1	1
C)F)C) Chem. -> (Rad.+Chem.) -> Chem.	0	0	1	1
G)C) Surg.+Rad.+Chem. -> Chem.	0	0	1	1
H) Nonspecific Immunotherapy	0	0	1	1
<b>Total</b>	<b>5</b>	<b>51</b>	<b>118</b>	<b>174</b>

Surg.: surgery. Rad.: radiotherapy. Chem.: chemotherapy.  
Treatment methods in parentheses were given concurrently.

## Neck Dissection on the Ipsilateral Side by Subtype

Neck dissection	EBV positive	p16 positive	Other	Total
0) No N.D.	0	15	43	58
1) Total N.D.	1	14	33	48
2) Selective N.D.	2	20	41	63
3) Lymph node excision	1	2	1	4
8) Others	1	0	0	1
<b>Total</b>	<b>5</b>	<b>51</b>	<b>118</b>	<b>174</b>

N.D.: neck dissection.

## Neck Dissection on the Contralateral Side by Subtype

Neck dissection	EBV positive	p16 positive	Other	Total
0) No N.D.	4	50	111	165
1) Total N.D.	0	0	3	3
2) Selective N.D.	0	1	4	5
8) Others	1	0	0	1
<b>Total</b>	<b>5</b>	<b>51</b>	<b>118</b>	<b>174</b>

N.D.: neck dissection.

## Radiotherapy by Subtype

Type of radiotherapy	EBV positive	p16 positive	Other	Total
0) No radiotherapy	1	15	38	54
1) X-ray (and/or electron beam)	4	36	78	118
Total	5	51	116	172

Reconstructive Surgery Subsite was not reported in 2 patients.

B.T.: brachytherapy.

## Chemotherapy by Subtype

Route of administration	EBV positive	p16 positive	Other	Total
0) No chemotherapy	2	20	56	78
1) I.V.	3	31	58	92
3) Oral	0	0	1	1
5) I.V.+Oral	0	0	1	1
Total	5	51	116	172

Chemotherapy Subsite was not reported in 2 patients.

I.V.: intravenous. I.A.: intraarterial.